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Adenosine triphosphate phosphoribosyltransferase (ATP-PRTase) catalyses the first 
committed step in histidine biosynthesis. This thesis discusses studies towards a better 
understanding of the enzyme structure, function and inhibition by both natural and non-
natural ligands, towards the goal of drug development. ATP-PRTase from Campylobacter 
jejuni and Mycobacterium tuberculosis, which both carry the long ATP-PRTase enzyme, and 
from Lactococcus lactis which carries the short form ATP-PRTase enzyme were studied using 
a range of approaches and techniques. 
The structural basis of inhibition of the C. jejuni ATP-PRTase was investigated. An altered 
model of inhibition is proposed, based on two crystal structures: an active ATP-bound 
structure, and an inactive histidine and adenosine monophosphate (AMP)-bound structure.  
Intrinsic kinetic isotope effect (KIE) values and transition state modelling was performed for 
all three ATP-PRTase enzymes. The reaction was studied in reverse, using phosphonoacetic 
acid as an alternative substrate to pyrophosphate to overcome the suppression of KIEs by 
commitment to catalysis. Radioactive labels were incorporated by coupled enzymatic 
syntheses at six positions, with the intrinsic KIEs measured using the internal competition 
method. A proposed dissociative reaction mechanism was supported by moderate primary 
14C isotope effects (1.028 to 1.031) and large α-secondary 3H isotope effects (1.147 to 
1.250). The transition state models were located with density functional theory at the 
B3LYP/6-31*G(d,p) level, and refined the reaction mechanism to a  DN*AN‡ type.  
Synthesis and inhibition studies were also performed, using transition state analogue 
synthesis, and preliminary work with a fragment based lead discovery technique. Three 
analogues were developed, with one based on the ring flattening effect predicted for the 
carbocation intermediate (a cyclopentene based analogue), and two based around the 
charge change of the cationic species (iminoribitol based analogues). The cyclopentene 
analogue was found have an IC 50 of 48 ± 4 µM for the M. tuberculosis ATP-PRTase enzyme 
and a Ki of 282 ± 66 µM for C. jejuni ATP-PRTase. 
The combined results contribute to the understanding of the reaction mechanisms and 
inhibition of ATP-PRTase enzymes. The results present the first crystallographic observation 
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of ATP bound to the ATP-PRTase enzyme. KIE and transition state modelling of the reaction 
of Type IV PRTases was successfully demonstrated. Competitive inhibition was observed for 
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The work presented in this thesis is focused on the first committed step in the histidine 
biosynthetic pathway. Efforts towards a better understanding of the enzyme structure, 
function and inhibition through both natural and non-natural ligands are presented. To build 
a foundation for understanding these processes, this chapter introduces the target 
organisms, followed by histidine biosynthesis, the family relationship of the target enzyme, 
and the structure and inhibition of the enzymes of interest. 
1.1 Enzymes 
Enzymes are biological catalysts that have the ability to specifically enhance reaction rates, 
impose stereochemical control, and provide means of regulation of complex metabolic 
processes.1 They catalyse an enormous diversity of chemical reactions, with each enzyme 
specifically binding a small number of substrates and generally catalysing only one reaction. 
Rate enhancements of up to 1015 times that of the uncatalysed reaction are achieved under 
dilute and mild conditions.1,2 Placed in sequence, enzymes form biosynthetic pathways that 
play vital roles in digestion, energy production and the biosynthesis of the complex 
metabolites essential to all living organisms. The step at the start of a specific biosynthetic 
pathway is usually referred to as the committed step, as from this point a metabolite is 
committed to be converted to the end product of the pathway. Regulation, another key 
function of enzymes, often occurs at this step, controlling the flux into the pathway. Direct 
regulation of enzyme activity can be achieved by the reaction product subsequently binding 
to the enzyme or by the end product of the pathway. The slowing down of the catalytic rate 
by enzyme inhibition allows an organism to control the production of metabolites based on 
the cellular needs. 
The ability to modulate the function of an enzyme through inhibition also forms the basis of 
many drugs.3,4 Enzyme inhibitors can be used to correct a metabolic imbalance or to block 
an essential metabolic pathway, which can kill a pathogen. In this, it is the specificity of an 
enzyme that allows for its selective targeting without impacting other vital processes. 
1.2 Target organisms 
1.2.1 Tuberculosis 
Tuberculosis (TB), which is estimated to affects 2 billion individuals worldwide, is 
predominately caused by an infection with Mycobacterium tuberculosis.5 The organism was 
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first discovered in 1882 by Robert Koch and is a rod shaped bacterium.6 M. tuberculosis has 
a unique lipid rich cell wall structure, which gives rise to the organism’s pathogenicity and 
resistance to treatments. TB infections are generally found in the respiratory system, but 
infections of other parts of the body such as the spine and lymph nodes can occur.7,8 In 
pulmonary TB, the infection triggers an immune response which leads to the formation of a 
macrophage-rich cell mass known as granuloma or tubercles, after which the disease is 
named.9,10 Formation of granuloma prevents the spreading of the disease to the remainder 
of the lung and other organs; however it does not effectively kill the bacteria. The 
encapsulated bacteria can survive in these granuloma for extended periods, which is 
referred to as a latent TB infection.11 TB is a widespread disease affecting around one third 
of the world’s population, of which most infections are latent.12–14 Individuals infected with 
a latent form of the disease do not show symptoms and are not at risk of spreading the 
disease, but they do have a 5% risk of developing the active form of TB at some point in 
their lives.12 Immune compromised individuals, such as those co-infected with human 
immunodeficiency virus (HIV), have an increased 50% risk of developing the active form of 
the disease.12 The World Health Organisation millennium development goal target to halt 
and begin to reverse tuberculosis spread globally was reached in 2004.14 However, the 
decline of the disease remains less than 1% per year, with over 9 million people still 
reported to fall ill to the disease each year.13,15,16 In 2013 alone, the total number of deaths 
caused by TB was estimated to be 1.5 million people, with a quarter of these individuals co-
infected by HIV.17 The burden of 80% of the world’s cases of the disease lies in only 22 
countries, which are often located in poorer and less developed regions.13 In these 
countries, the lack of appropriate diagnostics and limited treatment availability are the 
major causes of the prevalence of the disease. The standard treatment involves a 
combination of four frontline drugs isoniazid, a rifamycin, pyrazinamide and ethambutol, 




Figure  1.1. The four frontline drugs ethambutol, pyrazinamide, isoniazid and rifamycin (part of the 
ansamycins family) used for the treatment of TB-infected individuals. The general treatment regimen consists 
of a combination of these drugs over a 6-9 month period.  
Although the available treatment regimens can cure most patients and effectively reduce 
transmission, they are not without problems. The duration and complexity of the 
combination of drugs can lead to failure and relapse and the development of drug 
resistance. Side effects in response to the anti-TB drugs are common and are an additional 
contributing factor in the non-adherence of patients to their treatment regimen. Of 
particular concern is increasing prevalence of TB which is resistant to the available 
treatments. Based on this resistance, TB can be divided into two groups: multidrug resistant 
(MDR) strains and extensively drug resistant (XDR) strains. MDR-TB is non-responsive to at 
least isoniazid and rifampicin, whilst XDR-TB is unresponsive to rifampicin and isoniazid, as 
well as second line drugs such as fluoroquinolone, capreomycin, kanamycin, and 
amikacin.14,15,18  
1.2.1.1 New drugs and drug regimens to treat TB 
The emergence of MDR strains of M. tuberculosis and the lack of development of a new 
frontline drug over the last 50 years makes the discovery of new approaches for TB 
treatment based on new molecular scaffolds a priority.12 Ideally these new treatments 
would be effective against MDR and XDR strains, have shorter treatment times, require low 
dose frequency, simple administration and be co-administrable with HIV medication.12,19 
The growing awareness around TB in recent years has led to an increase in research into TB 
drugs, with considerable progress being made over the last ten years. There are six new 
drugs in preclinical development, and eight drugs in phase I, II or III of clinical trials for the 
treatment of both drug-resistant and susceptible TB in its active or latent forms.5 The new 
treatment regimen studies include the efficacy of existing firstline drugs applied in new 
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combinations, as well as increased doses to shorten treatment time. For example, high-dose 
daily rifapentine-containing regimens have been shown to reduce the intensive phase of 
treatment to less than six months. Fluoroquinolone-based antibiotics have also been 
studied, however a recent four month phase III clinical trial gave disappointing results in 
which the substitution of ethambutol or isoniazid was associated with a higher risk of 
relapse of TB.5  
A new class of compounds are the nitroimidazole-containing compounds such as TBA-354, 
delamanid and pretomanid (Figure 1.2).5 These are pro-drugs, and require bioreduction of 
the nitrogroup for activation, catalysed by a deazaflavin-dependent nitroreductase.20,21 
Bioreduction leads to the release of reactive nitrogen species, which include nitric oxide, 
and is partly responsible for the anti-TB activity. TBA-354, which has just entered phase I 
clinical trials, was developed to further optimise potency of delamanid and pretomanid.21 
Delamanid is in phase III clinical trials and works by blocking the synthesis of mycolic acid, an 
important part of the M. tuberculosis cell wall.22,23 Delamanid was granted accelerated 
approval by the European Medicines Agency (EMA) in 2013 for the treatment of XDR-TB.5 
This is the second drug receiving accelerated approval following bedaquiline in 2012, which 
was approved by the United States Food and Drug Administration (FDA) for the treatment of 
XDR-TB as a last resort drug (Figure 1.2).24 Bedaquiline affects the proton pump of ATP 
synthase which is a critical enzyme in the synthesis of ATP for M. tuberculosis.24 The drug 
binds 20,000 times more strongly to the Mycobacterium variant of this enzyme than to the 
human equivalent. This drug however gave rise to health concerns as it was shown to cause 
arrhythmia by prolonging the hearts QT time, which can lead to cardiac arrest.24  
 
Figure  1.2. New TB drugs currently in clinical trials.  Bedaquiline is part of diarylquinolines, a novel group 
of compounds for the treatment of TB. Delamanid, pretomanid and TBA-354 are all nitroimidazole-containing 
compounds and are in various stages of clinical trials. 
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1.2.2 Campylobacter jejuni 
Campylobacter jejuni is a Gram-negative, spiral-shaped, non-spore forming bacterium. C. 
jejuni is motile through the presence of unipolar or bipolar flagella and is relatively slow 
growing.25 The bacteria are one of the most common cause of gastroenteritis, and 
symptoms range from diarrhoea and abdominal cramps and pain to joint pain and fever in 
some cases.25 Ingestion through contaminated food or water, uncooked poultry, and raw 
dairy products are the main causes of a Campylobacter infection. An infection normally 
shows symptoms 3–5 days after consumption and can take somewhere from 1 hours to 7 
days to clear in most cases. The infection has been linked to a form of neuromuscular 
paralysis known as Guillain-Barre syndrome, an autoimmune disease affecting the nervous 
system. This syndrome develops after the infection, but cases are rare.26 A Campylobacter 
infection can be severely debilitating, but generally does not require treatment with 
antibiotics. Treatment through liquid and electrolyte replacement is commonly sufficient to 
clear the disease.27 However, in cases involving prolonged illness, high fever, bloody stools, 
pregnancy, or co-infection with HIV, treatment of the infection with antibiotics can become 
necessary.25,27,28 When antibiotic treatment is required, macrolides such as clarithromycin 
or azithromycin are the main form of treatment for confirmed Campylobacter cases. 
Fluoroquinolones are also commonly used, as C. jejuni infections cannot be distinguished 
from diarrhoeal illnesses, caused by Salmonella and Shigella, based on symptoms alone 
(Figure 1.3).25 Alternative drugs that can be used to treat a C. jejuni infection are the 
tetracycline doxycycline, and chloramphenicol (Figure 1.3). However, the use of antibiotics 
in the food industry has led to the development of significant resistance with resistance 
observed up to 57%  for tetracycline based antibiotics in some cases.25,29 Campylobacter 
remains a significant cause of food borne illnesses and continues to be a burden on public 
health. 
 
Figure  1.3. Common antibiotics used for the treatment of a C. jejuni infection; doxycycline, 
chloramphenicol and the essential structure for fluoroquinolones. 
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1.3 Amino acid biosynthesis as a drug target 
There are 22 proteinogenic α-amino acids from which proteins are synthesised. Thirteen of 
these can be synthesised by humans, making the remaining nine, which include L-histidine, 
essential to our diet to ensure optimal growth and development.1 Bacteria, fungi and plants, 
on the other hand, do have the biosynthetic pathways for these amino acids. The absence of 
these pathways in humans makes enzymes of these biosynthetic pathways potentially 
interesting for the design of antimicrobial drugs and fungicides which are non-toxic to 
humans.4,30 For example, inhibition of histidinol dehydrogenase, involved in histidine 
biosynthesis, showed growth inhibition for Brucella suis in minimal media and human 
macrophages.31 Also, M. tuberculosis was shown to be auxotrophic for L-histidine or L-
tryptophan when enzymes involved in the biosynthesis of these amino acids were deleted.32 
This study further showed that these L-tryptophan or L-histidine auxotrophs did not survive 
single amino acid starvation experiments, which is similar to the environment encountered 
in the compartment of macrophages where the TB bacteria reside.33,34 This supports the 
theory that enzymes of this pathway are potential drug targets for the treatment of TB and 
other infectious diseases.32  
1.4 Histidine biosynthesis 
The biosynthesis of L-Histidine, referred to as histidine from here on, comprises ten linear 
steps (Figure 1.4).35 This pathway is energetically expensive and to control production the 
pathway is regulated both at the enzyme level and the transcription level.36 The first 
committed step involves the condensation reaction between adenosine triphosphate (ATP) 
and phosphoribosyl pyrophosphate (PRPP) to form phosphoribosyl-ATP (PRATP) and 
inorganic pyrophosphate (PPi), catalysed by adenosine triphosphate 
phosphoribosyltransferase (ATP-PRTase) (Figure 1.4).37 As is commonly observed for 
enzymes involving the first committed step of a biosynthetic pathway, the activity is subject 
to feedback inhibition. The PRATP product then undergoes another four steps to form 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR) and D-erythro-imidazole-glycerol-
phosphate (IGP). This is where the pathway branches. AICAR feeds into the purine 






Figure  1.4. Schematic overview of histidine biosynthesis. 
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1.5 Adenosine triphosphate phosphoribosyltransferase 
Adenosine triphosphate phosphoribosyltransferase is the enzyme responsible for the first 
committed step in histidine biosynthesis and the focus of this thesis. ATP-PRTase catalyses 
the reversible, magnesium-dependent, substitution reaction between ATP and PRPP (Figure 
1.5).37 ATP-PRTase controls the flux of metabolites into the histidine biosynthetic pathway 
through an allosteric feedback mechanism by the product of the pathway, histidine, 
providing control of the enzyme as a function of the available histidine. Adenosine 
monophosphate (AMP) and adenosine diphosphate (ADP) act as competitive inhibitors and 
therefore reflect on the energy state of the cell. In some cases higher concentrations of the 
PRATP product also inhibits activity.37 
 
Figure  1.5. The ATP-PRTase enzyme catalyses the condensation reaction between PRPP and ATP to form 
PRATP and PPi. 
 
1.6 Classification of the PRTase enzyme family 
ATP-PRTase belongs to the phosphoribosyltransferase (PRTase) enzyme family. This group of 
enzymes generally catalyse the transfer of the ribose 5-phosphate part of PRPP to a 
nitrogenous, and generally aromatic, base.38 However, not all PRTase proteins perform 
biosynthetic roles. In some bacteria PRTase enzymes are also involved in regulation of the 
expression of purine and pyrimidine synthetic genes. The proteins of this family play diverse 
metabolic roles such as purine and pyrimidine biosynthesis, as well as in the nucleotide 
salvage pathway.39–42  
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Some of the best-studied types of PRTase enzymes are the Type I PRTases and these were 
first identified at the sequence level.38 Crystal structures later confirmed the family 
relationship of the Type I PRTases.38 The Type I PRTase enzymes share a common core 
responsible for PRPP binding; additional decorations, and in some cases an additional 
domain is responsible for binding the nucleophile. The common core consists of a five 
stranded parallel β sheet (β2-β1-β3-β4-β5) decorated by three α helices. α1 and α2 are 
found on one face of the β sheet and α3 is found on the other side (Figure 1.6, A). There is a 
thirteen amino acid sequence motif characterised by four hydrophobic amino acids, two 
acidic amino acids of either glutamate or aspartate and seven amino acids of variable 
character, usually including glycine and threonine.38 This motif makes up the PRPP binding 
site which in itself is made up of three loops, a PPi loop; a flexible loop and a phosphate 
loop. The phosphate loop constitutes nine residues and is responsible for binding the ribose 
5-phosphate parts of PRPP. The two acidic amino acids, which are generally found adjacent 
to each other at the start of the phosphate loop, are responsible for binding the hydroxyl 
groups of the ribose ring. The PPi binding loop is a small loop that accommodates the 
pyrophosphate part of PRPP and binding of this ligand is between the phosphate and PP i 
binding loops. The flexible loop acts as a gate and sits over the active site. PRPP binds to this 
signature sequence in association with magnesium. 
The classification of a second type of PRTase enzymes was proposed based on the novel fold 
found for quinolinic acid phosphoribosyltransferase (Figure 1.6, B).43,44 The Type II PRTases 
lack the signature sequence and the classification of this enzyme as part of the PRTase 
family was based on the reaction chemistry. Nicotinic acid phosphoribosyltransferase shares 
this unique fold and together with quinolinic acid phophoribosyltransferase these two 
enzymes form the Type II subgroup. The active site architecture is conserved among 
bacteria and eukaryotes for this Type. Differences are found in the quaternary structure 
with dimeric and hexameric species reported.43,44 The novel fold consists of a mixed α/β N-
terminal domain and a unique seven-stranded α/β barrel-like domain.45 The PRPP binding 
site is formed at the interface of two chains with residues contributing from both chains. 
Given the vastly different active site architecture between Type I and Type II PRTases a 
remarkable similarity between the binding mode of PRPP is observed, with differences only 
found around the pyrophosphate part which is rotated approximately 60° compared to Type 
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I enzymes. Interestingly, two acidic amino acids shown to interact with the hydroxyl group 
of the ribose ring are also present in Type II enzymes. Because of its unique fold, Type II 
PRTase has most likely evolved independently of Type I PRTases. 
Type III PRTase enzymes are exemplified by anthranilate PRTase (An-PRTase), which 
catalyses the second step in tryptophan biosynthesis (Figure 1.6, C).46 An-PRTase is a 
homodimer, with the active site found in the hinge region of the two domains that make up 
the monomeric unit. A large C-terminal domain formed by eight α-helices surround a central 
seven-stranded β-sheet. The N-terminal domain, which is significantly smaller, is made up of 
six α-helices. PRPP binding is mostly accommodated by the C-terminal domain. The binding 
mode of PRPP resembles that of the other types of PRTase enzymes with again differences 
mainly found around the pyrophosphate part. Again binding of PRPP is associated with a 
divalent metal ion essential for catalysis.  
The ATP-PRTase enzyme belongs to Type IV subgroup of PRTases and like An-PRTase solely 
makes up this subgroup in the PRTase enzyme family (Figure 1.6, D).47 ATP-PRTase is found 
as two structurally diverse enzymes which differ in their allosteric machinery. The long form 
is a homohexamer with the subunit comprised of a mixed α/β bilobal domain containing the 
active site, and a C-terminal ACT domain where the allosteric binding site for histidine is 
found. The short form is a heterooctamer, containing a similar mixed α/β bilobal catalytic 
core but instead of a regulatory domain, the short form enzyme associates with a second 
enzyme, structurally related to histidyl-tRNA-synthatases, to achieve allosteric regulation.48 
The active site is found in the cleft of domains I and II that make up the catalytic core. 
Domain I, a mixed α/β domain, makes up the ATP binding site and domain II shares parts of 
the signature amino acid sequence found for Type I PRTase enzymes and accommodates 
PRPP binding. Domain II has structural similarities to the shared core of the Type I PRTase 
subgroup, with a five stranded parallel β sheet decorated by three α helices. The PRPP 
binding site including the conserved acidic amino acids found in Type I PRTases including the 
phosphate and pyrophosphate binding loop. Type IV PRTases lack the flexible hood domain 
which sits over the PRPP binding site in Type I enzymes.  
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Figure  1.6. The PRTase family  can be divided into four types based on their structural architecture. Type 
I A Hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi PDB:1TC2. Type II B Quinolinate 
phosphoribosyltransferase from M. tuberculosis PDB: 1QPR.Type III C anthranilate phosphoribosyltransferase 
from M. tuberculosis PDB:1ZX1. Type IV D, the shared catalytic core of ATP-PRTase is shown from Lactococcus 
lactis PDB: 1Z7N. α-helices are displayed in red, β-sheets in yellow, flexible loops in green, and active site 
regions involved in PRPP binding in blue. 
 
1.7 The structure of ATP-PRTase long form 
The structure of ATP-PRTase long form comprises around 300 amino acids. Crystal 
structures for Escherichia coli (PDB: 1Q1K, 1H3D), M. tuberculosis (PDB: 1NH7, 1NH8) and 






and ligand bound forms have been reported. The crystal structures revealed an elongated 
molecule consisting of 10 α-helices and 15 β-sheets (Figure 1.7). Each monomeric unit of the 
protein is formed by three domains: domain I consisting of a six stranded β-sheet (β1-β5, 
β11) wrapped by four α-helices (α1-α3, and α8); domain II is topographically inserted into 
domain I and comprises five stranded β-sheets (β6-β10) and four α-helices; and domain III 
features an antiparallel β-sheet topology with a pair of antiparallel alpha helices on one 
face.47,49,50 Domain III is where the allosteric histidine binding site is found, approximately 40 
Å away from the active site, and resembles an ACT regulatory domain found in a variety of 
proteins including enzymes involved purine and amino acid metabolism.50 Work done by 
Kryvi et al. on the E. coli ATP-PRTase suggests it exists in a dynamic equilibrium between an 




Figure  1.7. The monomeric unit of ATP-PRTase long form M. tuberculosis with histidine bound (PDB: 
1NH8) displayed here with α-helices in cyan, β-sheets in purple and flexible loops in pink.  
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1.7.1 Natural allostery and inhibition  
ATP-PRTase activity is controlled through different mechanisms, allosterically through a 
feedback mechanism by the end product histidine, synergistically with AMP and histidine, 
and inhibition by AMP or ADP to reflect the overall energy state of the cell.37,52 High 
concentrations of ATP and high concentrations of the product PRATP sometimes also result 
in reduced activity.51  
M. tuberculosis ATP-PRTase was the first long form of this enzyme successfully crystallised 
as the apo structure (PDB: 1NH7) and the synergistically inhibited, histidine and AMP bound, 
structure (PDB: 1NH8). Both structures were crystallised in the hexameric form, which was 
attributed to the high protein concentration required in the crystal conditions. The apo 
structure displayed a more open and loose hexamer then the inhibited enzyme. Crystal 
structures with AMP, E. coli ATP-PRTase (PDB: 1H3D), and histidine, M. 
thermoautotrophicum (PDB: 2VD3), have since also been reported. The AMP bound 
structure resembled the apo structure, where the histidine bound structure displayed the 
more closed conformation, suggesting that histidine alone is responsible for the observed 
structural change. 
1.7.1.1 Histidine binding site and the regulatory response 
The histidine binding site is found approximately 40 Å away from the active site and 
regulation is thus achieved allosterically. Histidine binding stabilises the closed 
conformation, which has an altered orientation of the regulatory domain relative to the 
catalytic core as compared to the monomer of the apo structure. The histidine binding site 
is found at the interface of two domains and involves residues from a flexible loop (α9–β13) 
and Leu253 on β-sheet 14 from one monomer, and of residues Ala273′ (β15) and Asp218′ 
(β12) of the adjacent monomer (Figure 1.8, A). The interaction of histidine across the 
interface of two domains brings the regulatory domains closer together. the cross interface 
interaction is believed to be the basis of stabilisation of the hexameric form of the enzyme 






Figure  1.8. Histidine binding site of M. tuberculosis  (PDB: 1NH8). A Histidine (white) makes interactions 
across the interface of two regulatory domains with the main chain (green) and the adjacent monomer (pink). 
Upon binding of the allosteric ligand the protein undergoes a conformation change bringing the regulatory 
domains closer together. Heteroatoms are coloured according to element: oxygen (red), nitrogen (blue), 
phosphorous (orange). B Histidine stabilises the inhibited hexameric form of the ATP-PRTase long form enzyme 
(PDB: 1NH8). A single chain is coloured with the catalytic core (domain I and II) in red and the regulatory 
domain in yellow. 
 
1.7.1.2 Synergistic inhibition of ATP-PRTase by histidine and AMP 
The mode of action for AMP inhibition was initially believed to be through competitive 
binding at the ATP site.49 The crystal structures of M. tuberculosis and E. coli ATP-PRTase, 
however, reveal that binding of AMP occurs across the PRPP and ATP binding site (Figures 
1.9 and 1.10).47,49 Looking at the binding mode of AMP, insight into how AMP can act as a 
competitor for both ATP and PRPP, and how AMP provides a synergistic inhibitory response 
with histidine, can be elucidated.  
In the AMP bound M. tuberculosis ATP-PRTase structure the 5-phosphate of AMP binds in 
the phosphate binding loop (Asp154 -Thr161) of the PRPP binding site (Figure 1.9). Here, a 
hydrogen bonding (H-bonding) network is formed between the phosphate group and 
Gly157–Thr161. The adenine ring sits over a hydrophobic part of the active site towards 




three ordered water molecules present in the ATP binding site. The 2′ and 3′ hydroxyl 
groups of ribose form interactions with Asp30′ across the dimer interface to the adjacent 
monomer. Formation of these interactions could explain further stabilisation of the 
inhibited form in the presence of AMP and histidine.47 It should be noted that for the M. 
tuberculosis structure, the electron density for the 2′ and 3′ hydroxyl group and the CH2 at 
the 5′ position of the ribose ring of AMP is of poor quality, with no density observed at these 
positions.47  
 
Figure  1.9. The binding mode of AMP to M. tuberculosis ATP-PRTase. AMP binds at the interface of two 
monomeric units forming interactions across the interface. The main chain residues are in green and residues 
from the adjacent monomer are in purple. Heteroatoms are coloured according to element: oxygen (red), 
nitrogen (blue), phosphorous (orange). 
 
In the E. coli ATP-PRTase structure with AMP bound to the active site, a different binding 
mode is modelled for AMP (Figure 1.10). The ribose ring is 180o rotated compared to its 
position in the M. tuberculosis structure and only interacts with a single chain. The 
difference in binding may be a result of the absence of Arg16 in the M. tuberculosis ATP-
PRTase enzyme, providing extra stabilisation of the adenine part of AMP in the E. coli 
structure. The ribose 2′ and 3′ hydroxyls form additional interactions with the two acidic 
residues Asp169 and Glu156 placing this part of AMP in a similar position as PRPP.49   
The ability of AMP to bind across both the PRPP and ATP binding sites explains the basis of 





Figure  1.10.  AMP (white) binding mode for E. coli ATP-PRTase forming most binding interactions with the 
PRPP binding site and additional stabilisation of a non-conserved Arg16 positioned over the active site. The 
main chain is coloured in brown. Heteroatoms are coloured according to element: oxygen (red), nitrogen (blue), 
phosphorous (orange).  
 
1.8 The structure of ATP-PRTase short form 
The short form ATP-PRTase comprises 205-220 residues and is structurally similar to domain 
I and II of the long form enzyme (Figure 1.11, A).53,54 The ATP-PRTase short form lacks the 
65–105 residues long C-terminal regulatory domain and instead associates with a second 
enzyme for regulation.48 Sequence comparison revealed distant similarities between the 
additional unit and an aminoacyl-tRNA synthetase enzyme.48 The ATP-PRTase short form 
enzyme comes together with the aminoacyl-tRNA synthetase-like domain to form a hetero-
octamer containing four chains of each (Figure 1.11, B). The overall architecture features an 
X-shaped complex made up of the aminoacyl-tRNA synthetase units. The ATP-PRTase 
catalytic core is found as a dimer on each end. Crystal structures of the full complex have 
been obtained for Thermotoga maritima in complex with histidine and L. lactis with 
phosphate bound (PDB: 1Z7M) and PRPP bound (PDB: 1Z7N). Eight histidine binding sites 
were identified from T. maritima ATP-PRTase complex. However, these were not at the 
histidine binding site which would be expected considering the relationship to the 
aminoacyl-tRNA synthetase-like and its domains function. The identified histidine binding 
sites were not conserved for the L. lactis ATP-PRTase enzyme. Here, through single point 
mutations, the aminoacyl-tRNA synthetase active site was identified to be responsible for 
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the regulatory response.55 Overall the mode of inhibition is less well understood for this 
group of enzymes.  
 
Figure  1.11. The quaternary structure of ATP-PRTase short form enzyme, from L. lactis (1H7N). A The 
catalytic domain of ATP-PRTase short form comes together as a dimer, domain I (red) and domain II (blue) of 
one monomer are indicated and the other dimer is represented in green. B The aminoacyl-tRNA synthetase-like 
regulatory domain (single chain in yellow, remaining chains are in grey) come together in an X shaped complex 
with two catalytic dimers (green) at each end of the complex.  
 
1.9 The active site of ATP-PRTase 
ATP-PRTases have a large solvent exposed active site found in the cleft between domain I 
and II, and the active site encompasses residues from both domains. The active site can be 
divided into two sites based on where these ligands bind. Residues expected to make up the 
ATP binding site are mostly found on domain I whereas residues involved in PRPP binding 
are primarily found on domain II.  
A crystal structure with PRPP bound at the active site of all four chains of L. lactis ATP-
PRTase has been reported (PDB: 1H7N).55 In the crystal conditions ATP and N-1-methyl-ATP 
were also present; however, these ligands were not observed crystallographically. Like for 
Type I PRTase enzymes the 5-phosphate of PRPP is accommodated by the phosphate 
binding loop (Figure 1.12, A). This signature fold (β9–α7) varies slightly from Type I PRTase 
enzymes and consists of an acidic residue of either aspartic acid or glutamic acid followed by 
two hydrophobic residues with the remaining residues including at least one glycine and 




Asp155 is found at the start of the phosphate binding loop and Glu142 is functionally 
conserved for the reported structures of both the long and short form enzymes.47,49,54,55 
Variations are observed around the pyrophosphate part of PRPP across the four active sites, 
potentially as a result of the lower resolution of 3.0 Å. Residue Ser140, which is highly 
conserved, and Lys8′ from the adjacent monomer, are expected to play an important role in 
binding this part of the ligand.55 Additionally, the catalytically essential Mg2+ cation is not 
observed. 
The crystal structure with the PRATP product bound to the active site of E. coli ATP-PRTase 
is reported (PDB: 1Q1K), however only the PRA part of the full length structure is observed 
crystallographically and the remaining part of the molecule was modelled into the active site 
(Figure 1.12, B).49 PRA part binds at the active site with the 5′-phosphate interacting with 
the phosphate binding loop. The ribose hydroxyl groups interact with the two conserved 
acidic residues Asp169 and Glu156, of which Asp169 is found at the start of the phosphate 
binding loop. Overall the binding mode is similar to what is observed for PRPP for this part 
of the molecule. The adenine ring forms hydrophobic interactions with Leu170 and Cys104 
on one side and a π-π sandwich stacking interaction with the guanidine group from Arg16 
on the other side. Interestingly Arg16 is not conserved across species; for example in M. 









Figure  1.12. ATP-PRTase active site. A crystal structure of L. lactis ATP-PRTase with PRPP bound. The main 
chain residues are in blue and residues for an adjacent monomer are in pale yellow (1H7N), B E. coli ATP-
PRTase in brown with PRA (white) bound at the active site (1Q1K). In both structures oxygens are in red, 
nitrogen in blue and phosphate in orange. 
 
1.10 The reaction mechanism  
The reaction of ATP-PRTase follows an ordered sequential reaction mechanism with ATP 
binding first followed by PRPP.56 After product formation PPi is released first, followed by 
the product PRATP with overall inversion of the stereochemistry at the site of the reaction.56 
The order of binding brings both substrates together before catalysis, resulting in a possible 
reaction mechanism being ANDN or SN2-like, where nucleophilic attack and PPi departure 
take place in the same reaction step. However, a general reaction mechanism has been 





involving product formation through ribose migration.38 This mechanism was based on 
crystal structures of nine different PRTases involved in nucleotide synthesis.38,57 Crystal 
structures provide information on states relevant to catalysis, in a way providing snapshots 
along the reaction pathway. Smith et al. found the position of the ribose ring varied whether 
C1 is bonded to PPi or the nucleophile, with little change in position of the nitrogenous base 
or PPi observed in the different structures. From this, movement of the ribose ring as a 
carbocation intermediate was proposed, consistent with a DN+AN or SN1 reaction 
mechanism.38,58 
A powerful approach to characterise reaction mechanisms in enzyme catalysed reaction is 
through kinetic isotope effect (KIE) studies.59 One of the challenges however, can be that 
events other then the chemical step of interest along the reaction pathway can mask the 
observation of an isotope effect. KIE studies on a number of PRTase enzymes from various 
host organisms including ATP-PRTase from Salmonella typhimurium have been reported.58 
In the case of ATP-PRTase suppression of KIEs was observed in both the forward and reverse 
directions, leading to inconclusive results. 
KIE studies and transition state analysis on orotate phosphoribosyltransferases (OPRTases), 
a Type I PRTase enzyme, from a number of host organisms have been investigated.60–62 
These studies showed that the reaction catalysed by OPRTase passes through a dissociative 
reaction mechanism. OPRTase belongs to the Type I PRTase subfamily and supports the 
proposed reaction mechanism based on crystal structures for this group. Given the level of 
conservation around the PRPP binding site in this group of enzymes and ATP-PRTase, these 
findings support a dissociative reaction mechanism as a likely mechanism for the ATP-
PRTase enzyme. The lack of the flexible loop and small changes around the two acidic 
residues at the PRPP binding site, in addition with the observation that ATP binds in the 
active site first, means that a direct role of the ATP participating as a nucleophile at the 
transition state cannot be ruled out.  
1.11 Known non-natural active site inhibitors of ATP-PRTase 
To date a number of non-natural inhibitors for the ATP-PRTase enzyme have been 
identified. A study by Dall-Larsen et al. has shown that pentachlorophenol, dicoumarol, and 
2,4-dinitrophenol have a moderately inhibitory effect with competitive inhibition constants 
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(Ki) values ranging 50–400 µM for the E. coli enzyme.63 Gohda et al. performed a three 
dimensional pharmacophore search technique to find inhibitors based on the product of the 
reaction (PRATP) for ATP-PRTase from Arabidopsis thaliana.64 This led to the discovery of 
biaryl containing inhibitors, with the most potent inhibitors containing a disulphide-bond 
between the two rings (Figure 1.13, 1.1 and 1.2). Inhibition by this class of compounds can 
be explained through covalent binding to cysteine residues present in the enzyme, making 
them non-specific and for that reason these compounds were not ideal for further drug 
development. In 2008 Cho et al. used a virtual screening approach to try and find inhibitors 
for M. tuberculosis ATP-PRTase.65 In this study, over 500,000 lead and drug-like compounds 
were docked into the active site of M. tuberculosis ATP-PRTase, which led to the discovery 
of several 1–10 µM inhibitors in the initial screen. One of the strongest inhibitors contained 
a nitrobenzothiazole core (Figure 1.13, 1.3) which has similarities to the dinitrophenol 
compound found for the E. coli enzyme. Additional structure activity relationship (SAR) 
studies by virtual screening were used to find additional sets of compounds based around 
this nitrobenzothiazole core group, with two compounds demonstrating inhibition of 
bacterial growth in a whole cell assay on Mycobacterium smegmatis. 
 
Figure  1.13. Examples of non-natural inhibitors for ATP-PRTase enzymes. Compounds 1.1 and 1.2 
exemplify biaryl containing compounds. 64 1.3 the nitrothiazole core found in a virtual screening afford by Cho 
et al. 65   
 
1.12 Outline of thesis 
ATP-PRTase is responsible for the first step in the biosynthesis of histidine, where it controls 
the flux into the pathway. The absence of this enzyme in humans and the essential nature of 
this pathway to pathogenic organism makes this enzyme an interesting drug target. The 
kinetic properties of the two distinct forms of the ATP-PRTase enzyme have been 
investigated on the substrate level; however, the current knowledge regarding substrate 
binding and details of the species involved during catalysis are limited. 
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This project aims to gain a better understanding of substrate binding at the active site of 
ATP-PRTase, the reaction mechanism and transition state of ATP-PRTase enzymes, and the 
inhibition of ATP-PRTase through non-natural inhibitors.  
Chapter 2 reports the crystallisation of C. jejuni ATP-PRTase in the active ATP-bound form, 
and the inactive closed form, in complex with histidine and AMP. A crystal structure of ATP 
bound to the active site of M. tuberculosis ATP-PRTase was obtained and the differences in 
binding modes are discussed. 
Chapter 3 encompasses the work towards measuring kinetic isotope effects for ATP-PRTase 
to examine the reaction mechanism. This work includes the chemical synthesis of 15N 
labelled adenine, coupled enzymatic synthesis of 15N labelled ATP, coupled enzymatic 
synthesis of unlabelled and 3H, 14C and 15N labelled PRATP, the investigation of an 
alternative PPi substrate for ATP-PRTase enzymes, conditions for kinetic isotope effect 
measurement, and the measurement of kinetic isotope effects for M. tuberculosis, C. jejuni 
and L. lactis ATP-PRTase enzymes. 
Chapter 4 discusses the generation of ground state and transition state models through 
density functional theory (DFT) calculation with the experimental KIEs as boundary 
conditions to the generated structure. A potential reaction mechanism based on the 
modelled transition state has also been proposed. 
Chapter 5 presents the design, synthesis and characterisation of potential transition state 
analogues. The inhibitory properties of the designed ligands will also be discussed. 
Chapter 6 covers a fragment based lead discovery effort in an attempt to find non-natural 
inhibitors for the ATP-PRTase enzyme from M. tuberculosis. 
Chapter 7 provides the overall conclusion and future direction of the research. 
This work was carried out on three different ATP-PRTase enzymes: two of these were from 
pathogenic host organisms, namely M. tuberculosis and C. jejuni, which both express the 
long form ATP-PRTase enzyme. ATP-PRTase from L. lactis was also included to investigate 
how the presence of an alternative regulatory domain may affect the reaction mechanism. 
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The L. lactis ATP-PRTase enzyme was chosen as it has been studied in some detail. The 






Chapter 2  









2.1 Introduction  
This chapter discusses the structural basis for regulation of the Campylobacter jejuni ATP-
PRTase enzyme. Two crystal structures, one with the substrate ATP bound to the enzyme, 
and the other with histidine and AMP, were obtained as part of this study. Prior to 
commencing the studies reported in this chapter, the quaternary structure of C. jejuni ATP-
PRTase in solution was examined by Dr G. H. Mittlestädt.66 The enzyme was studied by 
analytical ultracentrifugation (AUC), as well as analytical size exclusion (SEC) and SEC-
coupled static light scattering techniques. This confirmed C. jejuni ATP-PRTase to mainly 
exists as a hexamer even at low enzyme concentration. 
Furthermore, a crystal structure with ATP-bound at the active site of M. tuberculosis ATP-
PRTase was also obtained, enabling comparison of the binding mode of ATP to the C. jejuni 
ATP-PRTase enzyme. 
2.2 Protein crystallisation and structure determination of C. jejuni ATP-
PRTase 
2.2.1 Crystal conditions 
Suitable crystal conditions for the co-crystallisation of ATP, and histidine and AMP were 
identified from Clear Strategy I and II screens (Section 8.2.4.4) using a Mosquito® crystal 
robot. Suitable conditions were further optimised using the hanging drop vapour diffusion 
method to give single crystals of uniform shape and larger size. In this it was important to 
ensure freshly purified C. jejuni ATP-PRTase enzyme was used, stored no longer then 1-2 
days at 4 °C, to grow single uniform crystals. Typically crystals were fully formed after 1-3 
days and generally grew as cuboid-shaped crystal (Figure 2.1). Cryo-protection required 
particular care and the best method was found by using a 40 % glycerol, 60 % reservoir 
solution, slowly added directly to the crystal drop before looping. Datasets were collected 
with ligand density observed for ATP, and histidine and AMP (Table 2.1). This is the first 
reported ATP-PRTase enzyme with full ligand density observed for the ATP ligand. Data 




Figure  2.1. C. jejuni ATP-PRTase protein crystals. A Co-crystallisation of ATP was achieved in 0.1 M 
sodium acetate, 0.1 M MgCl2, 13–15 % w/v PEG 4000, at pH 5.5 and 10 mM ATP. B Co-crystallisation of the 
synergistically inhibited structure was achieved in 0.1 M Tris, 0.1 M MgCl2, 13–15 % w/v PEG 4000, pH 7.5 with 
1 mM histidine and 5 mM AMP.  
 
2.2.2 Molecular replacement  
The crystal structure with the allosteric ligand histidine bound, had been previously solved 
for C. jejuni ATP-PRTase and was used in the molecular replacement strategy for the ATP, 
and the histidine and AMP structure.67 A molecular replacement strategy using the full 
hexameric arrangement from the histidine bound structure provided a good model for the 
synergistically inhibited crystal structure. This initial solution was further refined with clear 
density for both histidine and AMP. 
Molecular replacement of the ATP-bound crystal structure proved more challenging. No 
solution was found when the monomeric unit of the histidine bound structure was used. 
The final molecular replacement strategy involved several steps, initial searches involved 
only the catalytic core (domain I and II) to find a suitable dimeric arrangement. This 
structure was then used in a subsequent search to find two hexameric assemblies. This was 
consistent with the expected number of chains based on the unit cell dimensions. Domain III 
was then built back into the chains through several rounds of refinement.  
In both structures ligands bound to the enzymes were added last in the refinement process 
to avoid introduction of model bias. Information on data collection and refinement 





Table 2.1. Crystal parameters, data collection and refinement statistics for C. jejuni ATP-PRTase 
 ATP Histidine and AMP 
Data collection   
Crystal system, space group Triclinic, P 1 Monoclinic, P 1 21 1 
Unit cell parameters  
a, b, c (Å)  
α, β, γ (°) 
 
91.67, 91.83, 154.90 
101.11, 95.21, 118.14 
 
91.87, 124.91, 92.81 
90.00, 115.86, 90.00 
Resolution range (Å) 50.00-2.20 (2.24-2.20) 50.00-1.98 (2.01-1.98) 
Measurements 839825 493057 
Unique reflections 212958 127994 
Redundancy 3.9 (4.0) 3.9 (3.9) 
Completeness (%) 98.1 (97.3) 98.1 (96.9) 













   
Refinement   
Resolution (Å) 48.06-2.20 41.34-1.98 
Rcryst 0.236 0.203 
Rfree 0.259 0.220 
Chain length 300 300 
Observed number of residues 2x292, 2x293, 3x294, 1x295, 
4x296 
1x289, 1x290, 1x293, 2x295, 1x296 
Water molecules 365 714 
Other 12 ATP, 12 Mg2+, 
6 PO43- , 1 acetate 
6 His, 6 AMP, 
9 Mg2+, 6 PEG 
Mean B (Å2)   
 Protein 47.13 24.58 
 Water 35.20 26.94 
 Other 





RMSD from target values   
 Bond lengths (Å) 0.009 0.009 
 Bond angles (°) 1.470 1.372 
 Dihedral angles (°) 0.073 0.077 
Ramachandran   
 Preferred (%) 98.22 98.36 
 Allowed (%) 1.78 1.64 
 Outliers (%) 0.00 0.00 
PDB entry 4YB7 4YB6 
 
2.3 The structure of Campylobacter jejuni ATP-PRTase  
The ATP-bound C. jejuni ATP-PRTase crystallised in space group P1 and the unit cell contains 
a total of twelve chains forming two complete hexamers (Root mean square deviation 
(RMSD) between hexamers 0.50 Å). A single Mg2+-bound ATP molecule is found in the active 
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site of each chain. The second crystal structure with AMP and histidine bound at the active 
site and allosteric site was solved in space group P1211 and contains six chains, arranged in a 
single hexamer. The structure features six well-defined histidine molecules bound to the 
regulatory domain of the hexamer and one AMP molecule per active site. There were 4-11 
residues per chain that were not resolved.These residues are located at the N-terminus, as 
well as external loops (α1-β2, β6-α4, and β13-β14 loops). 
Each individual C. jejuni ATP-PRTase chain is composed of 10 α helices, 16 β strands and the 
connecting loops (Figure 2.2). Each chain is arranged in three domains, domains I, II, and III, 
adopting the same overall architecture as the M. tuberculosis ATP-PRTase and E. coli ATP-
PRTase.47,49 C. jejuni ATP-PRTase domain I is composed of residues 0-103 and 191-225, 
which form a Rossmann fold, commonly found for nucleotide binding proteins.68 Residues 
104–190 form domain II, which is inserted into domain I between the two β-strands β5 and 
β11. Together the two domains form a bilobal core unit that contains the catalytic site in the 
cleft between them, where the binding of ATP and AMP is observed. The last 74 C-terminal 
residues form domain III. In the structure with AMP and histidine, the allosteric inhibitor 
histidine is bound at the interface of domain III of two different chains and is referred to as 
the regulatory domain. 
 
Figure  2.2. The C. jejuni ATP-PRase chain structure. Architecture of a single chain of the histidine and 
AMP bound C. jejuni ATP-PRTase structure is given in a three-dimensional cartoon representation. The 




Figure 2.2  (continued) The same single chain with secondary structure elements labelled according α-
helices in cyan, β-sheets in violet, and flexible loops in salmon. 
 
The individual chains of both C. jejuni ATP-PRTase structures form homo-hexamers via 
interaction at two main interfaces. The first of these, the “dimer interface”, is created by the 
catalytic domains of two chains with an approximate 180˚ rotational symmetry (Figure 2.3). 
The interface is mainly formed by interactions from β2 and β3 and the end of the α1-β2 loop 
on domain I to the α-helices α6 and α7 and the loops at either end of α6 (β8-α6 and α6-β9) 
on domain II of the adjacent monomer. In addition a small number of interactions are made 
between α2 to the β8-α6 loop as well. The two fold symmetry means that these interactions 
are repeated at the other end of the monomer. The dimer interface buries an area of 950 ± 
21 Å2 and 990 ± 77 Å2 of each subunit in histidine and AMP, and ATP-bound forms, 
respectively.  
The second interface, the “trimer interface” is formed around the three fold symmetry axis 
and pays large contributions to the overall hexameric structure. The interface is formed by 
interactions between the regulatory domain from different dimers: the regulatory domains 
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from three dimeric units come together to form two trimeric arrangements at either end 
thereby forming a hexamer, placing all active sites on the inside of the hollow-centred 
complex. Accordingly the trimer interface occurs six times per hexamer and is generated 
between the two different faces of neighbouring regulatory domains, so that each chain 
contributes to two trimer interfaces. The main point of interaction is the C-terminal β-strand 
β16 (residues K296-L298), which is donated into the β-sheet of the adjacent regulatory 
domain. The buried surface area of the trimer interface ranges from 822 ± 70 Å2 (ATP-
bound, PDB: 4YB7) to 1224 ± 21 Å2 (Histidine and AMP, PDB: 4YB6).  
The PISA complexation significance score (CSS) was calculated for both structures. The PISA 
CSS allows for comparison of the contribution of the interfaces relative to each other.69 The 
score is defined as a maximal fraction of the total free energy of binding that belongs to the 
interface in a stable assembly. The dimer interface gave a CSS of 0.33 for both structures 
where for the trimer interface a CSS of 0.53 (ATP bound) and 0.66 (histidine and AMP 
bound) was found. Overall the trimer interface was classified as more significant than the 
dimer interface in both structures which is consistent with the observation of the hexameric 
assembly in solution.66  
      
Figure  2.3. C. jejuni ATP-PRTase comes together in a hexameric arrangement with a two fold symmetry 
between two catalytic cores (domain I (red) and II (blue)). The trimer interface forms the three fold symmetry 
Axis around the regulatory domain (yellow) making the overall structure hexameric. The structure shown is 
from the synergistically inhibited enzyme (4YB6). 
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2.4 ATP binding is consistent with a sequential mechanism 
In the ATP bound structure, ATP was observed for the first time in any ATP-PRTase structure 
to be present at full occupancy and was present in all 12 chains. In the observed binding 
mode ATP occupies the majority of the active site, but does not involve the conserved 14 
amino acid PRTase signature motif found on domain II.38 This fold is characteristic to type I 
and IV PRTase enzymes and includes the PRPP loop that is known to specifically bind 
phosphate-groups, or chemically similar compounds, and therefore plays a key role in 
substrate binding. This finding is in line with a sequential binding mechanism, in which ATP 
can bind first, leaving the active site open for interaction with PRPP. 
ATP is accommodated by a groove, part of domain I, involving interactions with a number of 
residues that are in part conserved. The triphosphate moiety of ATP interacts with the side 
chains of Arg54 and Arg16, which form H-bonds with the γ and α-phosphate respectively 
(Figure 2.4). Additionally the Gln12 side chain is placed in an optimal position to interact 
with several of the triphosphate oxygen atoms. A determining feature of the ATP binding 
site is the presence of a Mg2+ ion in complex with the bound ATP. It is coordinated in an 
octahedral arrangement created by the side chains of residues Asp55 and Asp56, the β and 
γ-phosphate of ATP, and two water molecules. This coordination embeds the Mg2+ into the 
binding site of C. jejuni ATP-PRTase, providing a strong interaction with the ATP 
triphosphate. 
The ATP ribose ring is positioned in a small cavity created by the backbone and short 
sidechains of Leu17, Gly73, Gly102, Ser191, Arg192 and Ala193 and the 2′ and 3′ hydroxyls 
form H-bonding interactions with the functionally conserved residue Asn75. The adenine is 
held in place by hydrophobic interactions with the side chain of Arg16 on one side and 
Leu170 and Cys104 on the other side. Interaction of Arg16 is through a π-π sandwich 
stacking interaction with the adenine base. The hydrophobic pocket allows the adenine to 
adopt two different orientations. Adenine was observed in either a catalytic relevant 
position, placing the N1 nitrogen close to the expected PRPP binding site, or flipped by an 





Figure  2.4. The ATP binding site. ATP was observed to adopt two binding modes in structure 4YB7. Stick 
representation of the ATP molecule (white) surrounded by the active site residues (pink). Water molecules and 
the Mg2+ ion are represented as spheres. The Omit map (Fo-Fc) is displayed in grey. Mg2+ is shown as a sphere 
(lime). Heteroatoms are coloured according to element: oxygen (red), nitrogen (blue), phosphorous (orange). 
 
2.5 AMP-binding mode confirms competitive characteristic towards ATP 
AMP was found to interact almost entirely with residues of the PRPP-binding loop, Asp169-
Thr176 (Figure 2.5). Residues Ser172–Thr176 tightly coordinate the phosphate group of 
AMP by H-bonding interactions with their backbone nitrogen atoms and the side chain 
oxygen atoms of Ser173 and Thr176. H-bonding interactions also occur between the ribose 
hydroxyl groups and the side chain of the conserved residue Asp169. The AMP adenine is 
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positioned over Leu170, as described for ATP, but with an inverted orientation. A close to 
identical binding mode was reported for the AMP-bound crystal structure of E. coli ATP-
PRTase (Section 1.8.1.2).49 Evidently AMP-binding occurs in both the ATP and the PRPP-
binding regions of the active site, which strongly supports the competitive inhibition of AMP 
towards both substrates observed in the kinetic analysis (Figure 2.6).  
 
Figure  2.5. AMP binding at the active site. AMP (pink) as presented in crystal structures 4YB6 is displayed 
as sticks (cyan) with the omit map (Fo-Fc) displayed in grey. Mg2+ is shown as a sphere (lime). Heteroatoms are 
coloured according to element: oxygen (red), nitrogen (blue), phosphorous (orange). 
 
 
Figure  2.6. Overlap of AMP and ATP-binding at the active site. AMP (pink) and ATP (white) as presented 
in crystal structures 4YB6 and 4YB7 respectively are displayed as sticks in the active site of C. jejuni ATP-PRTase 
(grey) in surface representation. Mg2+ is shown as sphere (lime). Heteroatoms are coloured according to 
element: oxygen (red), nitrogen (blue), phosphorous (orange). 
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2.6 The histidine binding site of C. jejuni ATP-PRTase 
Histidine-binding occurs at the interface between two adjacent regulatory domains in their 
trimeric arrangement. Consequently one histidine is bound per chain, but each chain 
provides two different faces for the interaction with histidine. The histidine carboxyl and 
amino groups are coordinated via backbone interactions with a highly conserved binding 
loop between α9 and β13 of one regulatory domain (consensus sequence: PGXXXPT, C. 
jejuni ATP-PRTase residues Pro246–Thr252), while the imidazole side chain is inserted into a 
small cavity created by the side chains on the β-sheets of the other regulatory domain, 
involving interactions with His232′, Ser288′, Leu290′, and a conserved water molecule. A 
very similar binding mode for histidine was found in the of M. tuberculosis ATP-PRTase 
structure (PDB: 1NH8)(Section 1.8.1.1).47  
 
Figure  2.7. Histidine-binding site. Binding mode of the allosteric inhibitor histidine as presented in the 
histidine and AMP bound C. jejuni ATP-PRTase crystal structures. The omit map (Fo-Fc) is displayed in grey. 
Heteroatoms are coloured according to element: oxygen (red), nitrogen (blue), phosphorous (orange). The main 
chain is in part omitted for display purposes. Residues from the main chain are in cyan and residues from the 
adjacent monomer are in purple.  
 
2.7 C. jejuni ATP-PRTase exists in two distinct conformational states 
The ATP-bound structure (4YB7) differs considerably from the histidine bound structures 
(4YB6) in its overall hexamer-conformation. This is apparent from the differences in the 
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orientation of the individual chains towards each other and the consequential 
reorganisation of their corresponding interfaces.  
The two hexamers found in the ATP-bound structure have an overall wider and more 
rounded appearance when compared to the inhibitor-bound structures (Figure 2.8. A and 
B). The change in diameter reflects this change which is decreased by an average of 77.4 ± 
0.7 Å for the ATP-bound (Figure 2.8, C) structure to 71.7 ± 0.1 Å for the histidine and AMP 
bound structure (Figure 2.8. D). Overall the histidine bound structures appear longer and 
more ellipsoid. The change from the active to the inactive conformation is visible by the 
rotational twist of the regulatory domain relative to the catalytic core by approximately 30˚. 
This change is driven by the binding of histidine at the interface of neighbouring regulatory 
domains, which pulls the monomers closer together, significantly increasing the buried 
surface area of the trimer interface from 822 ± 70 (ATP-bound, PDB: 4YB7) to 1224 ± 21 Å2 
(Histidine and AMP, PDB: 4YB6).  
                     
Figure  2.8. Comparison of C. jejuni ATP-PRTase hexamer conformations. A shows the open ATP (white) 
bound structure(chains in purple) and B shows the histidine (yellow) and AMP (pink) inhibited structure(chains 
in cyan). Histidine binding induces a conformational change that results in a more narrow structure making it 





      
Figure 2.8. (continued) C and D are cross sections looking down the trimer interface. The conformational 
change going from an open more round structure (C) to a more narrow inhibited structure (D). The distance, 
yellow dashed line, between active sites is shown to further visualise this change. 
 
Comparison of the occupied allosteric site, with histidine bound, to the unoccupied 
allosteric site of the ATP-bound structure reveals clear differences between the two 
conformations. This shows in the distance and orientation of the two faces of the binding 
site relative to each other. Although the conserved histidine binding loop does not change 
its conformation, it is significantly displaced from the adjacent monomer’s binding face 
(Figure 2.9, A). Moreover in the presence of histidine a tight hydrogen-bonding network is 
formed between all three neighbouring regulatory domains via the residues Thr252, Tyr228 
and His266, a water molecule and the bound histidine molecules, strengthening the 
interface (PDB: 4YB6) (Figure 2.9, B).  
While histidine binding directly and prominently affects the trimer interface, the catalytic 
domains also contribute to the overall changes in the hexamer. The large conformational 
change of the regulatory domains does not affect the conformation of the regulatory 
domains (I and II) (1.02 ± 0.05 Å RMSD between residues 4–225 of AMP and histidine bound, 
and ATP-bound C. jejuni ATP-PRTase). However, changes in the dimer interface are evident 
when comparing the AMP and histidine bound with the ATP-bound structures (Figure 2.9, 
C). The two chains of a dimeric unit undergo a rotational flex with respect to each other. The 
majority of the central dimer interface contacts, involving residues Thr152–Leu163 (α6 and 




of the second chain, stay intact upon histidine-binding, but close contacts between residues 
Thr176–Asn180 (α7) and Glu37′–Ile40′ (α1-β2 loop) are lost as the α7 helices are shifted 
towards the outside of the hexamer. Additional interactions are formed on the opposite 
side of the dimer interface, as Asn148–Leu151 (β8) and Glu57′–Glu64′ (α2) and the C-
terminal ends of the α3 helices (Leu87 and Leu87′) are now in close proximity to each other. 
This movement increases the distance between the two sites by approximately 3 Å and 
thereby alters the geometry of the dual-active site cavity. 
 
          
Figure  2.9. Conformational change upon histidine binding. A, An alignment of the catalytic domain of the 
monomeric units (residues 5–225) of the active, ATP-bound form, to the inactive, histidine bound forms (4YB5 
and 4YB6) reveals the large conformational change of the regulatory domain of 13.6 Å upon histidine binding. 
B, Visualisation of the formed H-bonding network associated with the binding of histidine(yellow).C Close up of 
the dimer interface, overlay of a single catalytic core (domain I and II) of the ATP bound structure (cyan), with 






2.8 M. tuberculosis ATP-PRTase structure with ATP-bound 
2.8.1 Cloning, expression and purification of M. tuberculosis ATP-PRTase 
The kinetic and structural features of M. tuberculosis ATP-PRTase have been studied in 
detail previously.47,70 A small modification was made to the previously published sequence 
around the thrombin cleavage site to include a tobacco etch virus (TEV) cleavage site more 
commonly used within the Parker laboratory. Amplification of the gene of interest was 
successfully achieved from genomic DNA as determined by agarose gel electrophoresis 
(Figure 2.10). Both the linearized vector and PCR product were then purified by agarose gel 
electrophoresis.  
Cloning of M. tuberculosis ATP-PRTase was achieved through the use of the in-fusion® 
cloning system outlined in Section 8.1.13. The linear product was cloned into the donor 
vector pET-28a. The product was transformed into StellaTM cells for DNA propagation and 
positive clones were determined by colony PCR and the gene encoding M. tuberculosis ATP-
PRTase was successfully sequence verified in the donor vector. 
 
Figure  2.10. Agarose gel showing the amplified gene had the right size ~950 Da. 
 
The plasmid was transformed into two different expression cell lines to test for soluble 
expression (Figure 2.11). The M. tuberculosis gene was transformed into E. coli BL21(DE3) 
Star cells, and E. coli BL21(DE3) Star pLysS cells. Both cell lines gave soluble expression and 
expression of the protein of interest was indicated by retention on an immobilised metal-
affinity column (IMAC) and later confirmed by mass spectrometry. The E. coli BL21(DE3) Star 







up-scaled growth. Further details on expression and purification of the protein can be found 
in Section 8.2.3. 
. 
Figure  2.11. Expression test of M. tuberculosis ATP-PRTase in E. coli BL21(DE3) Star cells: 1 cell pellet, 2 
supernatant, 3 flow through spin Hitrap column, 4 elution spin Hitrap column and E. coli BL21(DE3) Star pLysS 
cells: 5 cell pellet, 6 supernatant, 7 flow through spin Hitrap column, 8 elution spin Hitrap column. 
 
2.8.2 M. tuberculosis ATP-PRTase crystal conditions 
It was found that an improvement on the crystal shape and diffraction quality could be 
obtained by cleaving the N-terminal histidine tag. M. tuberculosis ATP-PRTase enzyme 
crystals in the apo form were grown according to published conditions using the hanging 
drop vapour diffusion method (Section 8.2.4.2).47 Suitable conditions for the co-
crystallisation of ATP required the addition of 10 mM ATP and a slight dilution (by 1-10%) of 
the condition reported for the apo form. Crystals formed after 12 to 48 hours and grew as 
uniform triangular prisms of various size (Figure 2.12). This resulted in clear density for ATP 
bound at the active site M. tuberculosis ATP-PRTase not previously observed. Information 
on the collection and refinement parameters can be found in Table 2.2. 
 
Figure  2.12. Image of M. tuberculosis ATP-PRTase crystals. 
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Table 2.2. Crystal parameters, data collection and refinement statistics for ATP bound M. tuberculosis 
ATP-PRTase crystal structure.  
 ATP 
Data collection  
Crystal system, space group Trigonal, H32 
Unit cell parameters  
a, b, c (Å)  
α, β, γ (°) 
 
134.76, 134.76, 111.00  
90, 90, 120 
Resolution range (Å) 40.99–2.40 
Measurements 303991 
Unique reflections 15289 
Redundancy 20.0 (20.0) 
Completeness (%) 100 (100) 











Resolution (Å) 40.99–2.40 
Rcryst 0.222 
Rfree 0.256 
Chain length 287 
Observed number of residues 281 
Water molecules 48 
Other 9 
Mean B (Å2)  
 Protein 53.79 
 Water 51.39 
 Other (SO43-, Mg2+) 
   Ligand (ATP) 
96.39 
38.72 
RMSD from target values  
 Bond lengths (Å) 0.0194 
 Bond angles (°) 1.8505 
 Dihedral angles (°) 0.1067 
Ramachandran  
 Preferred (%) 98 
 Allowed (%) 1 
 Outliers (%) 1 
 
2.8.3 The binding mode of ATP  
Binding of ATP to the active site of M. tuberculosis ATP-PRTase did not significantly alter the 
conformation of the monomeric unit of M. tuberculosis ATP-PRTase in the apo form (1NH7). 
An overlay of the apo-crystal structure (PDB: 1NH7) and the ATP bound crystal structure 
gave a RMSD of 0.528 unit with only small changes observed around the active site. In 
addition to ATP, three sulphate ions were also observed in the PRPP binding site consistent 
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with the previously reported apo structure. The close resemblance in quaternary structure 
further supports that the ATP bound structure represent the active form of the enzyme.  
ATP binding is accommodated by domain I, involving interaction with a number of residues 
that are in part conserved (Figure 2.13). The adenine ring is positioned over Val155, which 
forms the main interaction with the adenine ring and the active site. The adenine group is 
bound in what is considered the catalytically relevant position with the N1 position towards 
the PRPP binding site. The ribose ring is accommodated by a small cavity formed by Ala11, 
Leu12, Asp70 and Ser90, the ribose 2′ and 3′ hydroxyl groups form H-bonding interactions 
with the strictly conserved Asp70, a H-bond is also made to the side chain of Ser90. There 
are two Mg2+ ions found at the active site which both interact with the triphosphate group 
of ATP. One Mg2+ ion is positioned towards the centre of the active site with the α, β and γ 
phosphates coordinated around the metal ion and a further three water molecules in a 
octahedral configuration. The second Mg2+ ion is found at the dimer interface and 
interactions are made to the γ phosphate of ATP. This interaction is mirrored on the other 
side by the adjacent active site effectively sharing this Mg2+ ion between two ATP ligands. 
The γ phosphate further interacts with the conserved Arg49. Furthermore, Lys 9′ from the 
adjacent monomer also interacts with this position. 
 
Figure  2.13. The binding mode of ATP for M. tuberculosis ATP-PRTase. Stick representation of the ATP 
molecule (White) surrounded by the active site residues (Cyan). Water molecules and the Mg2+ ion (Lime) are 
represented as spheres and the Omit (Fo-Fc) is displaced in grey. Heteroatoms are coloured according to 




Comparison of the active site of M. tuberculosis and C. jejuni ATP-PRTase displays 
considerable differences in amino acid composition, in particular around the ATP binding 
site. For example, Arg16 which was shown to be directly involved in adenine binding in the 
C. jejuni enzyme is not present in the M. tuberbulosis enzyme where an alanine (Ala12) is 
found. Additionally the double Asp55–Asp56 motif responsible for coordinating magnesium 
in C. jejuni ATP-PRTase is not found for the M. tuberculosis enzyme. Given these changes 
remarkable similar binding modes for ATP were found between the two structures. In 
particular around the adenosine part of ATP (Figure 2.14). Small differences are observed 
around the triphosphate part of the molecule. In C. jejuni ATP-PRTase the triphosphate part 
is held in place through coordination to a single Mg2+, which in turn is held in place by the 
double aspartate motif, where in the M. tuberculosis enzyme a proline is found and overall 
fewer direct interactions with the active site are made.  
 
Figure  2.14. Overlay of domain I and II of ATP bound to M. tuberculosis (ATP in pink and Mg2+ in cyan) and 




ATP-PRTase acts as the gateway into histidine biosynthesis and as such plays an important 
metabolic role. C. jejuni ATP-PRTase shares many biochemical and structural properties with 
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the long form ATP-PRTase enzymes that have been studied from other sources. A 
competitive behaviour of AMP towards both substrates has been observed for C. jejuni ATP-
PRTase which has also been shown for other ATP-PRTase enzymes.56,68,71 This is consistent 
with the active site binding of AMP where it is observed to be present in both the ATP and 
PRPP binding site.   
The clear observation of ATP at full occupancy for the first time in the active site gave 
further insight into the ATP binding site. The binding site of PRPP can be clearly inferred 
from this structure and from the positioning of AMP in the active site in the AMP and 
histidine bound structure. Additionally Mg2+ was observed bound to a double aspartate 
motif (Asp55–Asp56) underlining the importance of Mg2+ for the ATP-PRTase reaction. 
Although clearly functional, this metal-binding site along with other identified interactions is 
not conserved. In the active site of M. tuberculosis ATP-PRTase a proline (Pro48) is found in 
place of the double aspartate motif. Triphosphate binding is still associated with Mg2+ but 
no strong interactions are made to the active site such as what is seen in the C. jejuni ATP-
PRTase structure. 
Solution studies had shown that C. jejuni ATP-PRTase exists as an active hexamer in solution. 
Analysis of the interfaces of the crystal structures gives further support for the existence of 
the ATP-PRTase enzyme as a hexameric species. Two main interfaces make up the hexamer, 
the dimer interface and the more extensive trimer interface. Based on PISA complexation 
significance score the trimer interface was found to be more significant for both the open, 
ATP bound, and closed, histidine and AMP bound, forms of the enzyme.  
In the ATP-PRTase hexamer all active sites are positioned on the inside. This poses the 
question of how the charged substrate and product molecules then enter or leave the 
enzyme with the C. jejuni ATP-PRTase identified as a functional hexamer. The hexameric 
structures of all structurally characterised ATP-PRTase long form enzymes possess the same 
large openings between neighbouring domains, which would likely permit access to the 
interior of the complex (Figure 2.15, A). Another possible entrance for substrate molecules 
is present in form of a small opening in the dimer interface, observed in the ATP-bound 
structure (4YB7) obtained as part of this study, which leads directly to the active site and 
thus may function as a substrate channel. It should also be noted that all chains observed in 
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the hexameric structures of C. jejuni ATP-PRTase differ marginally from each other, but 
more so in the ATP-bound crystal resulting in the loss of symmetry. 
The structures of the hexameric C. jejuni ATP-PRTase provide insight into the changes that 
are associated with histidine binding and how histidine binding can contribute to the low 
activity. Histidine binds at the interfaces of the regulatory trimers, found at either end of the 
core and clearly constricts movement of this part of the protein (Figure 2.15, B). Upon 
binding, these regulatory trimers appear to rotate relative to the catalytic hexameric core 
and come closer together stabilising the hexamer. Some limited evidence of the stabilisation 
of the protein comes from thermal stability experiments performed on C. jejuni ATP-PRTase, 
which showed a significantly increased (5 ˚C) melting temperature for the inhibitor-bound 
enzyme.66 The large active site of this protein is located at the hinge between domains I and 
II, the conformation and conformational flexibility at this position of the protein is likely to 
impact on catalysis and this may be restricted or altered by the structural changes 
associated with histidine binding. Furthermore, the rotation of the regulatory domain 
relative to the catalytic core reduces the size of the entrance into the hexamer described 
earlier. The ability of AMP to bind in presence of histidine suggests that access to the active 
site is not completely closed off even in the inhibited hexameric state and may account for 
the observed residual activity observed.  
            
Figure  2.15. Active site access. A A surface representation of the active ATP bound form of C. jejuni ATP-
PRTase (4YB7). A large cavity can be found between the regulatory domain, 1, and the catalytic core. 
Furthermore there is a small opening visible at the dimer interface, 2, potentially providing an alternative 
entrance to the active site. B. A surface representation of the inhibited C. jejuni ATP-PRTase (4YB6) enzyme, 






In conclusion, the ATP-PRTase enzyme from C. jejuni has been shown to exist as an active 
hexamer and a new mode of the allosteric inhibition can be proposed based on the 
presented crystal structures. The ATP-PRTase enzyme has been shown to exist in two states 
the open “active” state and the closed “inactive” state. The active state has a more open 
hexameric structure to allow for access of substrates and products in and out of the 
hexameric core. Upon histidine binding the regulatory domains come closer together with 
mediation of the regulatory signal through a rotational movement relative to the catalytic 
core. This rigidification reduces the access to the interior of the hexamer limiting substrate 
access. This “twisting the tail” does not result in obvious changes around the active site of 
ATP-PRTase, however, changes are observed around the dimer interface increasing the 
distance between the two catalytic sites. The lower catalytic rate may be a result of the 
reduced access into the interior and the reduced dynamics by restricting motion of the 





Chapter 3  





3.1 Kinetic isotope effects and reaction mechanisms for enzymes 
3.1.1 Transition state theory 
The theory of absolute reaction rates, or transition state theory (TST), was developed in 
1935 simultaneously by Eyring and by Evans, and Polanyi.72 The theory assumes that the 
reactants are in equilibrium with an activated complex or transition state, and the 
decomposition of the complex is the rate controlling step for the overall process.72–74 
Although TST is not perfect, it describes many aspects of the process well, including reaction 
rates, transition states (TSs), and the energy needed to achieve the TS. TST also provides a 
framework to explain the observation of kinetic isotope effects.75 TST fails for some high 
temperatures reactions, and reactions involving small particles. Alternative theories to 
describe these types of reactions have been proposed.76,77 During the work presented in this 
thesis quantum mechanical tunnelling through the reaction potential energy barrier was 
ignored because it was considered unlikely to be involved in the reaction catalysed by ATP-
PRTase.78,79 Quantum mechanical tunnelling is usually only important at very low 
temperatures and for reactions involving very light atoms and is therefore not required.78,79 
3.1.2 Potential energy surface maps  
A potential energy surface (PES) describes the relationship between the energy of a 
molecule and its geometry.80 This is a mathematical description of the potential energy, 
which is a function of the bond motion (bond stretching, bond bending and bond torsion) 
and van der Waals interactions of the system. A potential energy surface map can be used 
to describe the internal energy of a molecule undergoing a reaction. In this energy 
landscape, the wells represent relatively low energy structures such as reactants, products, 
and intermediates. The peaks represent extremely high energy structures seldom achieved 
during a typical reaction. The lowest point between two peaks, the saddle point, represents 
the lowest high-energy state which must be overcome for the transformation of one 
structure to another. The saddle point in this case encompasses the activation energy 
needed for the reaction to proceed and the structure associated with that point is called the 
transition state. The valleys on either side represent the lowest energy path to or from the 
starting material and product.  
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3.1.3 Reaction coordinate diagrams 
A reaction coordinate diagram is a cross section of a PES map along a low energy pathway, 
showing a single reaction coordinate (x axis) against energy (y axis). As with a PES map, 
depressions represent stable structures, shallow wells represent reactive intermediates, and 
peaks represent transition states (TS) (Figure 3.1). Any chemical structure lasting longer than 
a typical bond vibration (10-13 to 10-14 s) can be considered an intermediate.80 In these 
diagrams, the highest energy barrier is associated with the rate-determining step of the 
reaction, and needs to be overcome for the reaction to proceed.  
 
 
Figure  3.1. Example of a reaction coordinate diagram and the states involved to go from one stable 
structure to another.  
 
3.1.4 The origin of a kinetic isotope effect 
Kinetic isotope effects refer to the change in rate of a chemical reaction when one of the 
atoms is substituted with one of its isotopes. Isotopic molecules traverse the same potential 
energy surface as each other. The observation of a KIE arises from a difference in zero-point 
energy (ZPE) for the isotopic molecules. In the case where a bond is broken, the stretching 
vibration of that bond defines the reaction coordinate. A Morse potential can be used to 
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show the relationship between bond strength and bond length (Figure 3.2). A Morse 
potential diagram is a plot of the potential energy as a function of the distance between two 
atoms. The shape of this curve is indicative of an anharmonic oscillator. 
A chemical bond vibrates in a manner constrained by the Morse potential in that a system 
displaced from equilibrium responds with a restoring force which is proportional to the 
displacement.80 The energies of these vibrations are not continuous but are instead 
quantised. The energy associated with n=0 is referred to as the ZPE and is the lowest 
vibrational state of a molecule. At room temperature, most bonds of a molecule are in this 
lowest energy state. At low energy the harmonic oscillator approximation can be used to 
explain this vibration (Equation 1). In this equation, h is Planck’s constant, 𝑣 is the 
vibrational frequency of the bond, n is an integer representing the vibrational mode and En 
is the quantised energy of that mode. 
 
 
Figure  3.2. A Morse plot can be used to show the effect of different vibrational modes. n shows the 
quantised state of the bond. 
 
The fundamental frequency 𝑣 of a bond can then be found by Equation 2. In this equation, 𝑐 
is the force constant of the bond, which is the same for isotopic atoms, and µ is the reduced 







mass. Reduced mass is the effective inertial mass in equations of motion for a many-particle 
system.81 The value for the reduced mass itself can be found by Equation 3 where m1 
represents the weight of the anchoring atom(s) and m2 gives the mass of the atom of 
interest.  
This shows that the frequency is directly proportional to the square root of the force 
constant for the bond, and inversely proportional to the square root of the reduced mass. 
For instance, when a C–H bond is replaced by a C–D bond, the stretching frequency is lower 
because of the increased mass. The ZPE for that bond is therefore also lower. This is 
depicted in a potential energy well by a lower energy rung for the C–D bond (Figure 3.3). If 
the energy needed to break the C–H compared to the C–D bond is considered, then the 











𝑚1 +  𝑚2
 Equation 3 
 
Figure  3.3. A Morse potential plot to illustrate the difference in activation energy needed for breaking a 




To understand how this affects the rate, the Arrhenius equation is very important.80 The 
Arrhenius equation for rate constants (Equation 4) allows for direct comparison of the rate 
of bond breaking for a C–H bond compared to that of a C–D bond. In this equation, k is the 
reaction rate, Ea is the activation energy, kb is the Boltzmann constant, and T is the absolute 
temperature. Using the same example of exchanging a protium for a deuterium, kH and kD 
are the rates of reaction associated with C–H and the isotope substituted C–D. It is assumed 
that the pre-exponential factor 𝐴 is equal for both isotopes, which is reasonable given that 
the isotopes follow the same reaction coordinates. The ratio of the rates of reaction then 















With bonds featuring different isotopes, but following the same reaction path, it follows 
that the increase in activation energy arises only from the difference in ZPE of the chemical 






Equations 2 and 3 show that the fundamental frequency of the bond is directly affected by 
the increase in mass of the atoms. The modified Arrhenius equation (Equation 6) thus gives 
the theoretical maximum isotope effect expected for bond breaking at this step.72,74 Using 
the Eyring equation, in the case of breaking a C–H bond compared to a C–D bond, a 
theoretical kH/kD of ~6.7 is predicted. Isotope effects of this magnitude, however, are rarely 
observed. Heavy-atom isotope effects are much smaller with isotope effects <1.10 for 
substitutions of carbon, oxygen, nitrogen, sulphur, chloride and bromide. The difference in 
magnitude is directly related to the percentage mass change, as going from 12C to 13C is a 
much smaller relative weight increase than going from 1H to 2H.  
In the C–H to C–D example it was assumed that the bond of interest would be fully broken 
and the observed isotope effect would arise only from the difference in ZPE of the reactant, 
however the effect can be more complex. Transition states are often reached with partial 
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bond character between multiple atoms, due to bond making and/or breaking. The bonds at 
these transition states, just like any other bonds, have vibrational modes and associated 
ZPEs. This means there is also a ZPE difference for the isotopically substituted bond. To 
understand how this affects the observed isotope effect, the vibrational mode undergoing a 
change along the reaction coordinate needs to be considered (Figure 3.4). The difference in 
activation energy no longer arises only from the variation in ZPE of the reactant but from 
the differential ZPE variation between the reactant state and the transition state: 
ΔZPEreaction = ΔZPETS - ΔZPEreactant  Equation 7 
 
 
Figure  3.4. Reaction coordinate diagram with the difference in ZPE for a C–H and C–D bond shown. 
Arrows indicate the activation energy needed to go from the reactant to the transition state. If a bond is not 
fully broken at the transition state these bonds have vibrational modes and therefore ZPE as well. The observed 
isotope effect arises from the differential ZPE difference. The ZPE for the C–D bond is shown in red. 
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3.1.5 Secondary isotope effects 
The effects discussed above have all been relating to the primary isotope effect, where an 
isotopically substituted atom participates directly in the bond change. When an isotopic 
substitution is instead made close to the atom directly involved in the reaction this gives rise 
to secondary isotope effects.80 The substitution position relative to the primary position is 
denoted as α, β,γ, etc. Secondary isotope effects typically arise from hybridisation changes 
that occur during reactions, or when the electrons of a sigma bond are involved in 
hyperconjugation.82 As for primary isotope effects, the change in vibrational frequencies, 
and therefore the change in ZPE, is responsible for the observed effect.  
During a hybridisation change there are a limited number of vibrational modes that undergo 
a large change. Those that do undergo a large change include the stretching modes, as well 
as the in- and out-of-plane bending vibrational modes.80 The bond strength changes 
according to the change in hybridisation state of the bond, with a decrease in bondstrength 
according to sp > sp2 > sp3. The force constant of the bond follows the same trend. The 
expected kinetic isotope effect is generally smaller for this type of isotope effect compared 
to bond breaking as the difference in force constant is smaller. 
In transitioning from an sp3 to an sp2 centre it is the out of plane bending, which arises from 
reduced steric constraints around the sp2 centre, that is mostly responsible for the observed 
isotope effect. The out-of-plane bending vibration observed in an infrared (IR) spectrum for 
a C–H bond on an sp3 carbon is ~1350 cm-1, while for a C–H bond on an sp2 carbon is ~800 
cm-1.  This leads to a theoretical secondary isotope effect for a C–H and a C–D bond of 
approximately 1.4. Typically, however, isotope effects of 1.1–1.2 are observed because the 
full conversion between sp3 and sp2 geometry is not present at the transition state. Clearly, 
such changes in hybridisation can also lead to inverse isotope effects, or isotope effects <1. 
When a reaction centre changes from sp2 to a more sp3-like state the difference in ZPE 
energy is greater at the transition state, leading to an inverse isotope effect.  
β-secondary isotope effects arise from the electrons of a sigma bond which are involved in 
changes in hyperconjugation at the rate-determining step. An example is stabilisation of a 
cation through hyperconjugation, where the electrons of a sigma bond interact with the 
adjacent empty non-bonding p-orbital of the cation, this leads to weakening of the sigma 
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bond and results in a normal (>1) isotope effect. Inverse KIEs are possible through decrease 
in hyperconjugation (<1). 
3.1.6 Techniques to measure kinetic isotope effects 
There are three main methods used to determine the isotope effect of an enzyme-catalysed 
reaction. The first method is through the comparison of the reaction rates of isotopically 
labelled and unlabelled reactants while the other substrates are kept at a fixed 
concentration. This method is the only method that provides information on both catalytic 
turnover (kcat) and catalytic efficiency (kcat/Km), but is limited to larger isotope effects of at 
least 1.05.59 A second, more sensitive, method to determine kinetic isotope effects is 
through isotopic perturbation of an equilibrium. This technique can be applied to systems 
with near degenerate equilibria and generates what is sometimes referred to as an 
equilibrium isotope effect (EIE). Kinetic isotope effects are measured as the rate of re-
establishing chemical and isotopic equilibrium. This information is obtained by montoring 
the perturbation continuously.83 The third method is an internal competition experiment. 
This is the most sensitive of the three methods. Here a reaction-sensitive position is 
measured against an internal control.84,85 More specifically, the substrate of interest is 
isotopically substituted at, or directly adjacent to, the site of the reaction to report on the 
reaction mechanism. The labelled substrate is then either mixed with the naturally 
abundand isotopologue, when detection is by mass spectrometry, or with a second labelled 
substrate at a position remote from the reaction centre (typically at least two bonds away), 
when detection by radiation is used. The remote or unlabelled substrate act as an internal 
control for the unimpeded rate. The reaction is allowed to proceed to 20-70% conversion 
and the ratio of the isotopically labelled substrates is compared to the initial standard. The 
apparent isotope effect can then be found by comparing the ratio between the isotopically 
sensitive position and the internal control in the substrate (Equation 8) or in the product 
(Equation 9).59,83 These equations hold for work with microscopic amounts of stable isotopic 
substrates, as well as for investigations where one of the competing species is present in 
radioactive tracer amounts only. In Equations 8 and 9,  Rs and Rp are the isotopic ratio of 
substrate and product, respectively, at the observed fractional conversion, f. x(kcat/Km) gives 
the observed KIE, with x giving the mass of the heavier isotope. R0 gives the isotopic ratio at 
the start of the reaction or at 100% completion. Examples of when this method is used is for 
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measuring 3H- or 14C-isotope effects, or when looking at natural abundance with an isotope-
ratio mass spectrometer to determine changes in 13C, 15N, or 18O mass ratio in CO2 or N2. 
 
 𝑥(𝑘𝑐𝑎𝑡 𝐾𝑚⁄ ) = log(1 − 𝑓)/log(1 − 𝑓) (𝑅𝑠 𝑅0⁄ ) 
 
Equation 8 
 𝑥(𝑘𝑐𝑎𝑡 𝐾𝑚⁄ ) = log(1 − 𝑓)/log(1 − 𝑓 𝑅𝑝 𝑅0⁄ ) Equation 9 
 
3.1.7 Commitment to catalysis 
A major challenge when measuring KIEs for enzyme catalysed reactions can be forward 
and/or reverse commitment to catalysis (Figure 3.5).2,86,87 When measuring isotope effects 
by internal competition, the measured or “apparent” KIE includes all steps from the enzyme 
and substrate(s) free in solution to the first irreversible step of the reaction coordinate. This 
includes non-chemical steps such as substrate binding and product release.2 Commitment to 
catalysis can arise from any step whose rate constant appears in the expression for kcat/Km. 
Commitment to catalysis can lead to suppression or completely masking of the KIE on the 
reaction step. To overcome high commitment to catalysis a number of methods have been 
developed including measuring KIEs at pH values away from the optimum, through the use 
of alternative weakly binding substrates for forward commitment to catalysis (Cf) or 
alternative substrates that form unstable products for reverse commitment to catalysis 
(Cr).60,61,85,88–91 Alternative weakly binding substrates overcome forward commitment by the 
increased dissociation constant.92 This makes the concentration of enzyme bound species 
very low, leading to substrates only rarely undergoing transformation to the next enzyme 
bound species. The increased ligand dissociation rate reduces commitment to catalysis and 
the expression of the kinetic isotope effect on the reaction can be observed.59,85,93 
alternative substrates that form unstable products overcome reverse commitment by 
making the reaction the first irreversible step as the formed product rapidly decomposes 




Figure  3.5. Hypothetical reaction coordinate diagram of a two substrate reactions.85  Dashed lines show 
a potential situation that could give rise to forward commitment, if after substrate binding the reaction is 
destined to go to product, or reverse commitment when product release is associated with a high energy step. 
When there is high commitment to catalysis (Cf or Cr) partly or completely suppressing the KIEs is observed. 
 
Intrinsic isotope effects can be obtained from the apparent isotope effect by correcting for 
the forward and reverse commitment using the expression derived by Northrop:94 
𝑘 + 𝐶𝑓 + 𝐶𝑟𝐾𝑒𝑞







In this equation, kcat/Km is the observed isotope effect, Cf is the forward commitment to 
catalysis, Cr is the reverse commitment to catalysis, Keq is the equilibrium isotope effect and 
k the intrinsic isotope effect. The expression can be reduced if the kinetic isotope effects are 
measured on a reaction that is irreversible. If one of the reaction products is effectively 
coupled off or the reaction is measured under initial velocity conditions this equation may 










3.2 Kinetic isotope effect measurements on ATP-PRTase 
Goitein et al. studied a number of PRTase enzymes through kinetic isotope effect studies 
including ATP-PRTase from Salmonella typhimurium. However, in their work inconclusive 
results were obtained for the ATP-PRTase enzyme, with 14C primary isotope effect of 1.01, 
an α-secondary isotope effect of 1.11 in the forward direction and isotope effects at unity in 
reverse. These results were attributed to commitment factors suppressing the observed 
isotope effect.58 Based on these observations similar challenges were expected for the M. 
tuberculosis, C. jejuni, and L. Lactis ATP-PRTase enzymes. As previously discussed, 
commitment to catalysis can be overcome through the use of alternative substrates which 
are able to reduce or even fully suppress commitment.  
In this chapter, the work towards the chemoenzymatic synthesis of isotopically labelled 
substrates, reaction conditions for measuring KIEs, measuring of commitment factors, 
measuring KIEs by internal competition, and the measurement of KIEs for M. tuberculosis, C. 
jejuni and L. lactis ATP-PRTase are discussed. 
3.2.1 Selection of isotopic labels in KIE study 
To study the reaction mechanisms by KIEs the most valuable information on the reaction is 
obtained from the primary and α-secondary isotope effects. It is these positions that 
undergo the biggest change going from reactants to the transition state. ATP-PRTase 
catalyses the condensation reaction between PRPP and ATP, whereby a new bond is formed 
between the anomeric carbon of PRPP and N1 of ATP, with inversion of stereochemistry at 




Figure  3.6. The reaction catalysed by ATP-PRTase. Highlighted in red are the atoms expected to undergo 
bond changes during catalysis. 
 
In this work, studying the reverse reaction was preferred, as alternative substrates for 
pyrophosphate had been reported previously.60,61 In addition the PRATP product was 
expected to be more stable than PRPP or PRPP analogues. The work from here on will be 
discussed in relation to the reverse direction unless stated otherwise. 
The primary isotope effect at the anomeric carbon (1′-C), will report on the bonding 
characteristics to the leaving group and incoming nucleophile of the activated species. As 
discussed in Section 3.1.5, the α-secondary position (1′-H) reports on hybridisation changes 
and will be important to support the findings for the primary carbon isotope effect. During 
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catalysis the bonding characteristics around the adenine ring of ATP are changed as well. 
The sigma bond is broken between the 1-N adenine nitrogen and the anomeric carbon 
affecting the conjugation of the aromatic ring. It is likely that the adenine 6-N will undergo a 
change in protonation state either before, during or after the reaction to allow for this 
change. These positions were thus expected to provide information on the change in 
conjugation and charge of the adenine ring. In addition, the 1-15N KIE would give insight to 
the involvement of the adenine base at the transition state, information which is not 
necessarily clear from the primary and α-secondary isotope effects alone. The KIEs 2′-3H or 
β-secondary and ribose ring oxygen, 18O, provide additional information on the ribose ring 
conformation and the reaction mechanism; however, enough information was expected 
from the primary and α-secondary isotope effects and these sites were therefore not 
included in the study. Together this gave four sites of interest: 1′-C, 1′-H, 1-N, and 6-N. To 
establish the KIE of these sites the internal competition method was used (Section 3.1.6), 
with use of radioactive isotopes and detection by liquid scintillation counting. The isotopic 
substitutions are then 3H, 14C and 15N for the relevant position. To measure the 15N isotope 
effects a double isotopically labelled substrate was synthesised with the second label distal 
to the reaction site. In addition to the four sites of interest two internal standards were also 
included. To allow for the same method of separation during the KIE experiments the label 
was placed in the ribose 5-phosphate part of the molecule. The 5′ position was chosen as it 
is at least two bonds away from the reaction site and thus expected to be unaffected by the 
reaction. This gave six isotopically labelled substrates that needed to be synthesised [1′-3H]-, 
[1′-14C]-, [1-15N, 5′-14C]-, [6-15N, 5′-14C]-, [5-3H]- and [5-14C]PRATP. The preparation of 
compounds containing these isotopic labels is discussed below. 
3.2.2 Coupled enzymatic synthesis of phosphoribosyl adenosine triphosphate 
Bearing in mind the synthesis of isotopically labelled substrates needed later in the project, 
and the amount of phosphoribosyl adenosine triphosphate (PRATP) needed in general, a 
coupled enzymatic synthetic route was considered for synthesising the unlabelled product. 
A method for the coupled enzymatic synthesis of PRATP has been reported.58 This allows 
PRATP to be made in three enzymatic steps, starting from D-ribose (Scheme 3.1). Recycling 
of ATP prevents build-up of ADP and AMP in the reaction mixture, which are known 
inhibitors of the ATP-PRTase enzyme. It also limits the amount of ATP needed for the 
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reaction, which makes purification of the PRATP product after synthesis easier as well. The 
required adenylate kinase (AK) and pyruvate kinase (PK) were commercially available, 
whereas the ribose kinase (RK) and phosphoribosyl pyrophosphate synthase (PRPPase) 
needed to be expressed and purified. Plasmids bearing genes encoding for these two 
enzymes were kindly provided by Prof. V. L. Schramm (Albert Einstein College of Medicine, 
AECOM) along with the procedures for the expression and purification of the enzymes 
(Sections 8.3.1 and 8.3.2).95,96 
 
Scheme 3.1 R5P: ribose 5-phosphate, Reactions were carried out in a phosphate buffer, in presence of 
NaCl and MgCl2 pH 8.5. Substrates were added from stock solutions, pH adjusted to pH ~7.5.   
 
Nuclear magnetic resonance (NMR) was used to obtain a more detailed picture of the 
reaction progress and the species present in the reaction mixture. This allowed for 
identification of problems, more challenging by other techniques such as UV analysis. The 
reactions were set up on a 1 mL scale and monitored by NMR employing  PRESAT water 
suppression pulse sequence in presence of 15% D2O (Figure 3.7).97 After optimisation of 
buffer conditions, pH, enzyme concentration and metal concentration, good conversion 
(>70% by integration of the NMR peaks) of starting materials to product was achieved. After 
longer incubation times, the formation of the 6-N-PRATP side product (Dimroth 
rearrangement) was also observed.  Formation of this side product can be prevented by 
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lowering the pH and keeping reaction times below 2 hours. Sufficient pure PRATP product 
can then be obtained by Biorad® P2 size exclusion gel filtration. 
 
Figure  3.7. The coupled enzymatic synthesis of PRATP monitored by 1H-NMR. With the reaction time in 
minutes, adenine protons of ATP are indicated. The change on the adenine ring is shown as two new peaks 
further downfield as well as the formation of two new anomeric protons. Characteristic peaks around the 
aromatic region of the rearranged side product are also shown. 
 
3.2.2.1 Dimroth rearrangement  
The first step of a Dimroth rearrangement is the addition of water to give the hemiiminal 3.2 
followed by ring opening to give the aminoaldehyde product 3.3 (Scheme 3.2).58,98,99 The 
ring opened product then allows rotation around the acetamidine and subsequent ring 
closure with release of water, restoring aromaticity to the adenine base leading to the  6-N 
substituted product 3.4.  
H-2 and H-8, PRATP 
6-N-PRATP 
H-1′ and H-1′′ PRATP 




 Scheme 3.2. The reaction mechanism of the Dimroth rearrangement leading to the 6-N substituted ATP 
side product. Blue arrow indicates rotation step leading to the rearranged side product. 
 
3.2.3 Alternative substrates  
The study by Goitein et al. showed high commitment to catalysis for Salmonella 
typhimurium ATP-PRTase, and so this was therefore also expected for the M. tuberculosis, C. 
jejuni and L. lactis ATP-PRTase enzymes.58 An important aspect of this study was therefore 
to find conditions that would allow the measurement of KIEs. Previously, for the 
measurement of KIEs for orotate phosphoribosyltransferase (OPRTase), which catalyses 
similar chemistry to the ATP-PRTase enzyme, phosphonoacetic acid was successfully used to 
overcome commitment to catalysis.60,61  
Phosphonoacetic acid was therefore tested for activity with the ATP-PRTase enzymes. 
Methyl bisphosphonate and fluoromethyl bisphosphonate were also tested based on their 
structural similarity to the substrate pyrophosphate (PPi). The abilities of these PPi 
analogues to act as substrates were tested spectroscopically and the relative rates of 
conversion compared to that of the natural substrate PPi. Methyl bisphosphonate and 
fluoromethyl bisphosphonate gave similar rates to pyrophosphate under the conditions 
tested and thus expected to be unsuitable. A significant reduction in rate was observed for 
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the phosphonoacetic acid analogue (Tables 3.1). The catalytic efficiency was reduced 370 
times for C. jejuni ATP-PRTase, and 500 times for L. lactis, compared to the natural substrate 
PPi. The strong product inhibition for the M. tuberculosis enzyme made determining binding 
constants for this enzyme challenging. In addition, it was found that pyrophosphate started 
precipitating out before saturating conditions could be achieved (>2mM). Phosphonoacetic 
acid significantly reduced the rate of catalysis and, based on the findings of the other two 
enzymes, considered sufficient to continue. 
It is important to note that a change in the transition state by the use of an alternative 
substrate cannot be ruled out, and examples of small alterations to the transition state by 
the use of alternative substrates have been reported.61,62 However, high levels of detail on 
the transition state can still be obtained using this method and transition-state structures 
generated through the use of non-natural ligands have led to development of some of the 
most potent inhibitors known to date.84 With transition-state guided inhibitor design being 
one of the goals of this research project, phosphonoacetic acid was considered to be a good 
candidate for KIE measurements and transition state analysis of ATP-PRTase. 
Table 3.1. Kinetic parameters for ATP-PRTase from C. jejuni and L. lactis with pyrophosphate (PPi) and 
the alternative substrate phosphonoacetic acid (PA). 
Enzyme  Substrate  Km (µM) kcat (s-1)  Catalytic efficiency 
kcat/ Km (s-1M-1) 
C. jejuni 
ATP-PRTase 
 PPi  96 ± 15 1.1 ± 0.05  11.5 
 PA  157 ± 48 0.008 ± 0.001  0.051 
L. lactis 
ATP-PRTase 
 PPi  10 ± 3 0.84 ± 0.05  84 
 PA  530 ± 145 0.089 ± 0.007  0.17 
 
3.2.4 Isotopically labelled substrate synthesis 
3.2.4.1 Synthesis of [1-15N]adenine 
The required 15N-labelled substrates were not commercially available and therefore needed 
to be synthesised. Based on a modified literature procedure [1-15N]adenine was expected to 
be accessible in a one-step synthesis from commercially available 5-aminoimidazole-4-
carbonitrile (3.5) and 15N labelled formamide (as in Scheme 3.3).100,101 The challenge in this 
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synthesis was the small scale (<200µL total volume) and elevated reaction temperatures 
(180 °C) needed to drive the reaction. The higher temperatures led to partial evaporation of 
the formamide, concentrating the reaction and causing the starting material to precipitate 
out. After optimisation it was found that the best yield was obtained by performing the 
reaction in a closed off mass spectrometry vial and heating in an oil bath to ensure even 
heating under inert atmosphere. Following this procedure sufficient [1-15N]adenine (3.6) 
was obtained for the isotope effect studies albeit in a modest 52% yield. 
 
Scheme  3.3. Synthesis of [1-15N]adenine with isotopically labelled formamide and 5-aminoimidazole-4-
carbonitrile. 
 
3.2.4.2 Synthesis of [6-15N]adenine:  
It was envisioned that [6-15N]adenine would be accessible in one step through aromatic 
substitution of 6-chloropurine 3.7 and ammonia (Scheme 3.4). The preferred method was 
by McCann and Berti who used sodium carbonate and ammonium chloride in dimethyl 
sulfoxide (DMSO).102 In this reaction, sodium carbonate reacts with ammonium chloride 
with the release of ammonia. It was found that the best yield could be obtained by 
performing the reaction in a sealed bomb for five days. The desired [6-15N]adenine (3.8), 
was characterised by the splitting pattern of ~90 Hz of the amine proton. Side products 
were also formed. The major side product was identified as the dimerised product by Mass 
spectrometry. The similar nature of the side products to adenine made purification 
challenging and after several attempts by recrystallization, extraction and reverse phase 
chromatography this method was considered unpractical for the synthesis of [6-15N]adenine 




Scheme  3.4. One step synthesis of [6-15N]adenine by nucleophilic aromatic substitution. 
 
A three step synthesis of [6-15N]adenine starting with 6-chloropurine and the incorporation 
of the tetrahydropyranyl ether (THP) protecting group has been successfully demonstrated 
by Milecky et al. (Scheme 3.5).103 To this end, 6-chloropurine was subjected to 2,3-dihydro-
2H-pyran and catalytic p-toluenesulphonic acid (p-TsOH) in ethyl acetate (EtOAc) to give 
protected purine (3.9) in 93% yield. In addition to masking the N-9 position the introduction 
of the THP protecting group also aids solubility in organic solvents which made purification 
of the intermediates easier. Nucleophilic aromatic substitution of protected purine (3.9) 
with 15N labelled ammonium chloride and sodium carbonate in a sealed bomb then gave 
protected adenine (3.10) in an 84% yield.  Acid hydrolysis followed by purification by 
DOWEX© H+ exchange resin gave the desired [6-15N]adenine (3.8)(95% yield).  
 
Scheme 3.5. Total synthesis of [6-15N]adenine using the THP protecting group. 
 
3.2.4.3 Synthesis of [1-15N] and [6-15N]ATP  
Preparation of 15N labelled ATP was readily achieved using a coupled enzymatic synthesis 
starting from PRPP and the appropriately 15N labelled adenine (Scheme 3.6).104 A small 
amount (<1%) of unlabelled ATP needed to be added to initiate the reaction. The reaction 
was then followed by HPLC (50 mM KH2PO4 Bu4NHSO4 pH 5.0, Section 8.3.7) and left at 37 
°C until complete conversion of starting material to product was observed. Purification by 
semi-preparative HPLC using the same ion-pairing method, followed by desalting with 0.1% 
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trifluoroacetic acid in acetonitrile, gave the desired 15N labelled ATPs. The products were 
concentrated by freeze drying, taken up in water and stored at -80 °C until further use. 
 
Scheme  3.6. Enzymatic synthesis of isotopically labelled ATP, example given for the synthesis of [6-
15N]ATP. APRTase: adenosine phosphoribosyl transferase, PRPP: phosphoribosyl pyrophosphate, PP i: 
pyrophosphate, AMP: adenosine monophosphate, ADP: adenosine diphosphate, ATP: adenosine triphosphate, 
PEP: phosphoenol pyruvate.  Reactions were carried out in a 50 mM phosphate buffer, in presence of NaCl 100 
mM, MgCl2 10 mM, pH 8.5. Substrates were added from stock solutions pH adjusted to pH ~7.5. 
 
3.2.4.4 Synthesis of isotopically labelled PRATP starting from ribose 
The synthesis of [1′-3H]PRATP and [1′-14C]PRATP was achieved starting from the 
appropriately  isotopically labelled D-ribose precursor. The synthesis of isotopically labelled 
PRATP starting from D-ribose was achieved following the conditions established for the 
synthesis of unlabelled PRATP (Scheme 3.7). Reactions were carried out using 20–50 µCi of 
isotopically labelled D-ribose. The reaction for the 3H-labelled substrate was incubated for 
30 min before additional unlabelled D-ribose was added. Unlabelled D-ribose was added to 
aid in manipulations following the reaction of this label. Reactions were followed by HPLC 
(reverse phase (C18), 50 mM KH2PO4 8mM Bu4NHSO4 pH 5.0, Section 8.3.7) and acidified 
after reaction completion or after two hours to prevent excessive formation of side 
products (Section 3.2.2.1). Isotopically labelled PRATP was then purified by HPLC (reverse 
phase (C18), 50 mM KH2PO4 8mM Bu4NHSO4 pH 5.0, Section 8.3.7), followed by drying using 
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speed vacuum evaporation. Samples were desalted shortly (at most one day) before KIE 
measurements were made using HPLC (reverse phase (C18), 50mM AcONH4 pH 6.0 and 
acetonitrile, Section 8.3.7). Extreme care was taken to prevent even small amounts of 
degradation at this point, as this was found to greatly affect the KIE measurements. It was 
found that drying the samples for no longer than 10–15 min in small volumes (<200 µL) by 
speed vacuum evaporation gave the best results. After concentration the product was taken 
up in a small amount of water, divided into small aliquots, the radioactivity level was tested, 
and then the samples were frozen at -80 °C until further use. Each aliquot was used once 
and any remaining label was repurified before further use. 
 
Scheme  3.7. RK: ribose kinase, PK: pyruvate kinase, R5P: ribose 5-phosphate, PRPPase: phosphoribosyl 
pyrophosphate synthase, AK: adenylate kinase; PRPP phosphoribosyl pyrophosphate, ATP-PRTase: ATP-
phosphoribosyl transferase. Reactions were carried out in a phosphate buffer, in presence of NaCl, MgCl2, Tris 
pH 8.5. Substrates were added form stock solutions, pH adjusted to pH ~7.5. Radiolabels were added, achieving 
radioactivity levels of 20–50 µCi.   
3.2.4.5 Synthesis of isotopically labelled PRATP starting from glucose: 
The synthesis of isotopically labelled PRATP starting from D-glucose comprises of six linear 
enzymatic conversions and three recycling steps and is a modified procedure for the 
synthesis of ATP published by Parkin et al. (Scheme 3.8).96 The adenine PRTase (APRTase) 
enzyme was substituted for ATP-PRTase from C. jejuni. In addition, pyrophosphatase (PPase) 
was added, favouring the production of the PRATP product. Reactions were carried out on a 
20–50 µCi scale. Unlabelled D-glucose was added to [6-3H]-D-glucose after a 30 minute 
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incubation period because of the high specific activity (60 Ci/mmol) of this substrate. The 
double isotopically labelled PRATP reactions were carried out by exchanging ATP for the 
appropriately isotopically labelled counterpart. Again reactions were monitored by HPLC 
(Section 8.3.7) and left until no further conversion was observed or for two hours, 
whichever came first. The reaction was then purified by HPLC (Section 8.3.7). Overall the six 
isotopically labelled substrates required for this study were obtained starting either from D-
ribose (Section 3.2.4.4) or D-glucose. 
 
Scheme  3.8. Coupled enzymatic synthesis of isotopically labelled PRATP starting from d-glucose. HK, Hexo 
kinase; G6PDH, glucose 6-phosphate dehydrogenase; PGDH, Phosphogluconic acid dehydrogenase; PRI, Ribose 
5-phosphate isomerase; PRPPase, phosphoribosyl pyrophosphate synthetase; PK, pyruvate kinase;  GDH, l-
glutamic dehydrogenase; AK, adenylate kinase; PEP, phosphoenolpyruvate; PYR, pyruvate; G6P, glucose 6-
phosphate; 6PG, 6-phosphogluconate; Ru5P, ribulose 5-phosphate; R5P, ribose 5-phosphate; αKG, α-
ketoglutarate; Glu, glutamic acid; NADP+/H, nicotinamide adenine dinucleotide phosphate. Reactions were 
carried out in a phosphate buffer, in presence of NaCl, MgCl2, Tris pH 8.5. Substrates were added form stock 
solutions. Radiolabels were added, achieving  radioactivity levels of  20-50 µCi. 
3.3 Kinetic isotope effects for ATP-PRTases 
3.3.1 Separation of substrate and product by charcoal/cellulose column 
Isotopically labelled substrates and/or product are commonly separated either by HPLC or 
by solid phase extraction (SPE) using charcoal/cellulose columns.86,104 The SPE columns have 
successfully been used for separating adenosine based substrates from ribose-like products. 
Separation of PRATP from the ribose reaction products ribose 5-phosphate (R5P) and/or 
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phosphoribosyl phosphonoacetic acid (PRPA) was therefore expected to be possible through 
this method. The advantage of using SPE columns is that it allows for faster processing of 
the samples and makes including multiple replicates easier. For these reasons separation by 
SPE was the preferred method and explored first.  
To assess separation of the isotopically labelled starting material and product, conditions 
needed to be found which would retain the isotopically labelled PRATP but would also elute 
reaction products. For this, 0% and 100% conversion were chosen as the positive and 
negative controls. To favour the reaction equilibrium towards the PRPA and ATP products, a 
large access of phosphonoacetic acid was added. An excess of the nucleophile was expected 
to push the equilibrium towards the PRPA and ATP product. To allow for a direct 
comparison, a master mix containing isotopically labelled PRATP and phosphonoacetic acid 
in Tris buffer (50 mM Tris, 100 mM NaCl, 50 mM KCl, 10 mM MgCl2, pH 8.5) was divided into 
two. To achieve 100% conversion an excess of C. jejuni enzyme was added to one part and 
buffer to the other part. These were split another time, one to act as a reference count and 
one to test retention of the label onto a charcoal column.  
After optimisation it was found that addition of ammonium carbonate (pH 6.0) facilitated 
the separation of the PRATP substrate from the ribose products. In addition, the reaction 
was confirmed to go to completion under the used reaction conditions described above 
with the small discrepancy ascribed to pipetting errors (Table 3.3). 
Table 3.2. The results from the charcoal retention experiment and selective elution of isotopically 
labelled ribose recovery after 100% conversion. Results are from a 50 mM ammonium carbonate pH 6.0 elution 
buffer. 
  No enzyme  100% Completion 
Charcoal  240 cpm  21900 cpm 
Reference   22000 cpm  21600 cpm 
 
3.3.2 Commitment to catalysis by isotope trapping 
The forward commitment to catalysis, or the partitioning of the Michaelis complex to 
product relative to substrate release, was measured by the isotope trapping method.85 The 
experiment determines the fraction of enzyme-bound isotopically labelled PRATP that 
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converts to product after a large excess of unlabelled PRATP and the second substrate PA is 
added. Fractions are taken after one and several turnovers and extrapolated back to find 
the initial amount of substrate released. The commitment factor can be found through 
Equations 12 - 14.85 Et represents the concentration of enzyme active sites, 14CPRATP gives 
the concentration of substrate, Km is the michaelis constant for PRATP and [EA] gives the 
concentration of enzyme-bound isotopically labelled PRATP. [PRPA] represents the initial 
amount of product formed of a large excess of unlabelled PRATP and phosphonoacetic acid 
is added.Y gives the fraction of product over the concentration of enzyme-bound 14C-PRATP.  
Cf is the forward commitment factor. An example calculation can be found  in Section 8.3.9.  
[𝐸𝑡][ C 
14 PRATP]













The C. jejuni enzyme showed low commitment to catalysis with a commitment factor of 
0.030 ± 0.004 (Table 3.4). A similar commitment factor was obtained for the L. lactis ATP-
PRTase enzyme complex with a commitment to catalysis of 0.028 ± 0.004. Commitment 
factors of similar magnitude were also observed for H. sapiens and P. falciparum OPRTase at 
0.042± 0.006 and 0.035 ± 0.003.61 This suggests that commitment to catalysis should not 
affect the KIE measurements for these enzymes. 
No commitment to catalysis could be observed for M. tuberculosis ATP-PRTase; however, in 
addition no reaction was observed under the conditions used. The isotope trapping 
experiment relies on the addition of a large excess of unlabelled PRATP (500 µM) to 
outcompete the isotopically labelled substrate for binding back to the enzyme after the 
initial incubation period. The M. tuberculosis ATP-PRTase enzyme shows strong inhibition by 
PRATP significantly reducing the observed rate. How product inhibition affects the 
experiment is unknown. However, based on the reduced rate by phosphonoacetic acid, 
similarly to the other two enzymes studied, and the observation of low commitment to 
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catalysis for the C. jejuni and L. lactis ATP-PRTase enzyme, suppression of KIEs for M. 
tuberculosis ATP-PRTase was not expected. 
Table 3.3. Forward commitment factors for C. jejuni and L. lactis ATP-PRTase. 
Enzyme  Forward commitment (Cf) 
C. jejuni ATP-PRTase  0.030 ± 0.004 
L. lactis ATP-PRTase  0.028 ± 0.004 
M. tuberculosis ATP-PRTase  - 
Error given as standard deviation in measured PRPA concentration. 
 
3.3.3 Measuring kinetic isotope effects for ATP-PRTase 
In all the KIE experiments performed, a master mix containing all components except for the 
enzyme was made (Section 8.3.8). The master mix was then divided into seven equal 
volumes to give four reactions for partial conversions (20% to 40%), two reactions for 100% 
conversions and a negative control. The reactions were incubated at 25 °C for 10 to 25 min 
depending on the enzyme. The reaction was acidified with sulphuric acid to pH 6.0 to stop 
the reaction and then directly loaded onto pre-equilibrated charcoal columns and the 
column washed with elution buffer. The eluent was collected in scintillation vials, and dried 
by speed vacuum evaporation for at least 12 hours. The resulting solids were taken up in 
500 µL of water and 10 mL scintillation fluid was added. The samples were then counted on 
a scintillation counter for 10 cycles of 10 min per sample. Channel A was set for 3H (0.0–25.0 
keV and channel B for the remaining 14C signal (25.0–400.0 keV). In each sample set, a 14C 
standard was included to correct for channel overlap between the two isotopes. The isotope 
effects were then calculated from the average cpm/isotope by Equation 9 (Section 3.1.6). 
For a more detailed description see Section 8.3.8, which includes an example calculation. 
Each position was measured for at least two independent experiments with a minimum of 
eight replicates in total. Reliability of the results is reported as standard error of the mean 
(SEM). 
3.3.3.1 KIE results for Mycobacterium tuberculosis ATP-PRTase 
The primary isotope effect 1′-14C reports directly on the nature of the nucleophilic 
substitution at the transition state. This isotope effect provides information on the 
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interaction of the anomeric carbon and is sensitive to the motion along the reaction 
coordinate of this position during catalysis. KIEs between 1.01–1.08 suggest weak 
interactions with partial involvement of the nucleophile and/or leaving group at the 
transition state.60,104 If an isotope effect of around unity is found, that indicates a fully 
dissociated transition state with a carbocation intermediate. Values above 1.08 indicate an 
ANDN or SN2 type reaction mechanism.62,105,106 Large isotope effects (>1.25) for the α-
secondary KIE 1′-3H are characteristic of a dissociative reaction mechanism with limited 
participation of the nucleophile and leaving group at the transition state.102  
The M. tuberculosis ATP-PRTase enzyme gave a primary isotope effect of 1.028 ± 0.001 1′-
14C which suggests weak bonding interactions at the transition state to the nucleophile 
and/or leaving group (Table 3.5). This is supported by the large 1′-3H isotope effect of 1.250 
± 0.008 which suggest a well-developed ribocation with double bond characteristics 
between the ribose ring oxygen and the anomeric carbon. An α-secondary isotope effect of 
1.250 ± 0.008 is close to the maximum isotope effect reported for dAMP hydrolysis in water 
further supporting that commitment to catalysis is not affecting the isotope effect values 
and the measured isotope effects are intrinsic.102 The dissociative mechanism is further 
supported by the large 1-15N isotope effect of 1.024 ± 0.001 which approaches the 
theoretical maximum of 1.04 for this isotope label.87 The 1.012 ± 0.001 6-15N isotope effect 




Table 3.4. KIE results for Mycobacterium tuberculosis ATP-PRTase. 
Position  KIE SEM n 
1′-3H  1.250 0.008 8 
1′-14C  1.028 0.001 8 
1-15N, 5′-14C  1.024 0.001 12 
6-15N, 5′-14C  1.012 0.001 8 
5-3H  1.017 0.001 8 
 
3.3.3.2 KIE results for Campylobacter jejuni ATP-PRTase 
The intrinsic KIEs for ATP-PRTase from C. jejuni suggest that the reaction goes through a 
dissociative DN*AN reaction mechanism based on the primary isotope effect of 1.029 ± 0.002 
(Table 3.6). The large α-secondary isotope effect of 1.212 ± 0.002 further supports these 
findings. The isotope effect of near unity for the primary 1-N was surprising given the large 
isotope effects found for the other two ATP-PRTase enzymes.   
Table 3.5. KIE results for Campylobacter jejuni ATP-PRTase. 
Position  KIE SEM n 
1′-3H  1.212 0.002 10 
1′-14C  1.029 0.002 8 
1-15N, 5′-14C  0.995 0.003 8 
6-15N, 5′-14C  1.005 0.001 8 
5-3H  1.009 0.001 8 
 
3.3.3.3 KIE results for Lactococcus lactis ATP-PRTase 
The 1′-14C intrinsic KIE for L. lactis suggests that this short form of the ATP-PRTase enzyme 
also goes through a DN*AN reaction mechanism with an unstable carbocation intermediate 
(Table 3.7). The α-secondary of 1.147 ± 0.006 supports these findings, although given the 
small primary 1′-14C and large 1-15N isotope effect, a larger 1′-3H isotope effect was 
expected. 3H isotope effects are also sensitive to other interactions at the transition state, 
such as H-bonding and van der Waals interactions, potentially reducing the conformational 
freedom and partly suppressing the α-secondary isotope effect. The 1-15N isotope effect at 
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the theoretical maximum suggests a fully dissociated adenine base with only interactions 
between the phopshonoacetic acid and the ribose ring remaining at the transition state. The 
isotope effect at unity for 6-15N suggests changes at this position are not involved at the 
transition state. 
Table 3.6. KIE results for Lactococcus lactis ATP-PRTase. 
Position  KIE SEM n 
1′-3H  1.147 0.006 10 
1′-14C  1.031 0.001 8 
1-15N, 5′-14C  1.028 0.001 8 
6-15N, 5′-14C  0.996 0.003 8 






Chapter 4  




4.1 Introduction  
The modelling of transition states through density functional theory (DFT) calculations, 
coupled with experimental kinetic isotope effects, can provide a detailed representation of 
the reactive specie involved at the rate determining step. To this end, the transition states 
of the reaction catalysed by ATP-PRTase were investigated by DFT with the experimental 
KIEs forming the boundary conditions for the transition state model. All optimisations were 
carried out in vacuo. A structure was considered optimised when a calculation successfully 
converged and only one imaginary frequency corresponding to the reaction coordinate was 
found. The calculated isotope effects were generated by comparing the ground state (GS) to 
the transition state with the ISOEFF98 program.107 ISOEFF98 is a program that uses the force 
constants from the GS and the TS to calculate the corresponding isotope effect.107,108 The 
program includes a scaling factor optimisation, which allows correction of the vibrational 
frequencies for the used functional and basis set.107,109–111  The refinement process of the GS 
and TS will be discussed below.  
4.2 IUPAC nomenclature to describe enzymatic nucleophilic 
displacement and substitution reactions 
In this work the International Union of Pure and Applied Chemistry (IUPAC) nomenclature 
will be used to describe enzymatic nucleophilic displacement and substitution reactions.105 
Enzyme catalysed reactions differ from reactions in solution, in that enzyme active sites can 
introduce additional geometric restrictions upon a reaction. In an ANDN, or an “SN2”, 
reaction the first step involves association of a nucleophile to the reaction centre. This leads 
to a degree of symmetry at the transition state, with bond lengths to both the association 
nucleophile (AN) and the dissociation nucleophile (DN) smaller than 2.0 Å and overall 
inversion of the stereochemistry in the product (Figure 4.1). For DN*AN or “SN1-like” 
reactions dissociation of the leaving group occurs first, followed by association of the 
nucleophile. The reaction may go through an unstable intermediate (*) or a transition state 
(‡) depending on its lifetime, the short lifetime precludes chemical detection or isolation. 
Reactions with a stable intermediate (+)  is a DN+AN reaction.112 When the nucleophile 
commences its approach (~ 3.0 Å) prior to full dissociation of the leaving group (<2.0 Å), this 
is referred to as a DNAN reaction. 
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As per Chapter 3, when discussing the ATP-PRTase catalysed reaction throughout this 
chapter the reaction steps are discussed in reverse order. When the physiological direction 
is discussed this will be specified. 
 
Figure  4.1. Different types of nucleophilic displacement and substitution reactions for enzyme catalysed 
reaction following the IUPAC nomenclature. Nuc, Nucleophile; Lg, leaving group; DN, dissociation nucleophile; 
AN, association nucleophile; *, unstable intermediate; ‡, transition state; TS, transition state. Distances in 
transition states represent the physical separation that needs to occur for this type of transition state to form. 
Image is a modified figure taken from Schramm and Shi.112  
  
4.3 The ground state model 
Experimental KIEs represent the isotope effect from free in solution to the highest energy 
barrier of the reaction pathway, the transition state. A ground state model used in 
calculating the kinetic isotope effect should therefore best represent the lowest energy 
state of the substrate in solution. As the input model, crystal structures can provide a good 
starting point for the geometry optimisations. To ensure that the full conformational space 
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will be sampled, different starting points are generated. Refinement of these structures was 
employed using Gaussian 09, Gaussian, Inc.113 
PRATP bound to C. jejuni ATP-PRTase core mutant was used as the input structure.67 Large 
structures such as PRATP can make optimisation computationally time consuming; the 
model was therefore simplified to include the ribose-5-phosphate adenine in the ground 
state structure (Figure 4.2). Generally atoms greater than two bonds away from the reaction 
centre are unlikely to contribute significantly to the kinetic isotope effect.114,115 Therefore, 
truncation of the model was not expected to affect the calculated isotope values around the 
reaction centre. The 5′-phosphate was considered deprotonated based on the experimental 
conditions (pH 8.5) and reported pKa for related structures.116 
 
Figure  4.2. The truncated ground state structure generated from the PRATP bound C. jejuni ATP-PRTase 
core mutant crystal structure.67 
 
Seven different starting conformations were generated by changing the dihedral angle of 
bonds that could rotate freely. These input structures were optimised using the B3LYP and 
M06-2X functionals and the 6-31G(d) basis set.117–119 The Becke three parameter exchange 
functional in combination with the Lee-Yang-Parr correlation functional (B3LYP) has 
successfully been used for the generation of a number of transition states for reactions 
involving D-ribose.61,62,84,85 B3LYP offers a high level of accuracy across different systems at 
reasonable computational cost. The M06-2X functional is designed for a number of 
applications, including excited states such as transition states and was therefore also 
employed.107,118 A structure was considered optimised when the calculation successfully 
met the convergence criteria and there were no imaginary frequencies for the optimised 
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structure. The energy (kcal/mol) of the structure was then compared for each functional to 
find the lowest energy state (Table 4.1).  
Table  4.1. Energy of the three lowest energy ground state structures after geometry  
optimisation by DFT. 
Functional  Structure  
Overall energy 
(kcal/mol) 
 Δ (kcal/mol) 
B3LYP 
 1  -960085.0  0 
 2  -960077.9  7 
 3  -960072.2  13 
M06-2X 
 1  -959800.8  0 
 2  -959794.0  7 
 3  -959790.5  10 
 
An interesting trend was observed for the optimised ground states. The position of the 
imine proton (6-NH) greatly affected the conformation of the adenine base. When the 
proton points towards the ribose ring, an interaction was formed with the 5′-O and the 2-H 
or 6-NH proton (Figure 4.3, A and B) whereas for structures with the 6-NH proton pointing 
away from the ribose ring a structure with a hydrogen bond (H-bonds) between 6-N and 2′-
H was usually found (Figure 4.3, C). 
The lowest energy structures were the same for both the B3LYP and M06-2X functionals 
(Figure 4.3, A and B). Structure A and B both form four H-bonds, two of which are conserved 
in both structures. These are the H-bond between 3′-H and O-phosphate and the H-bond 
between 3′-OH and 2′-O. In structure A there is a H-bonding interaction between the 2′-H 
and the oxygen of the phosphate group at an angle of 175°. Another interaction is made 
with the same phosphate oxygen and the 2-H of the adenine ring at an angle of 172°, which 
is close to the optimum of 180° for H-bonds.120 The ribose ring adopts the slightly less 
favourable 3-exo ring pucker, potentially resulting from interactions between the phosphate 
oxygen and the 2-H proton. In structure B, the adenine ring position allows for a H-bond to 
form between the imine proton and the 5′-oxygen at an angle of 168°. In addition, an 
interaction is made between 2′-OH and the phosphate group at an angle of 145°. The ribose 
ring pucker adopts the favourable 2-endo conformation in this structure. Overall, for 
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structure A having the H-bond closer to the optimum bond angle of 180° outweighs the 
slightly less favourable ribose ring pucker and leads to the lowest energy ground state 
structure. Structure A was thus used for comparison to the transition state models in the 





Figure  4.3. GS models A the lowest energy structure for both functional, this GS model was used to 
generate calculated KIEs. B the ground state structure that ranked second lowest overall, which was also the 







Figure  4.3. (continued). C is an example of the effect of the change in proton position on the imine group 
resulting almost exclusively in structures with the adenine base in this position. 
 
4.4 Molecular electrostatic potential surface 
The molecular electrostatic potential surface (MEPS) is a means to visualise the 
characteristic molecular electrostatic potential, displayed on a van der Waals surface. 121,122 
The MEPS provides a template for inhibitor design by highlighting where charges are built 
up.  
The MEPS of the ground state structure is represented in Figure 4.4 and shows a generally 
neutral ribose part with the more electron rich ribose ring oxygen. On the adenine there is 
charge build up around the 1-N, 3-N and 7-N nitrogen’s and overall a neutral aromatic ring 
system. The electron rich nature of the phosphate group is highlighted by the negative 














Figure  4.4. Molecular electrostatic potential surface (MEPS) of the ground state structure used in this 
study. The MEPS are shown on the right hand side at two different orientations, with the images on the left 
showing the corresponding stick representation. In the MEPS, red indicates electron rich or a relative negative 
charge, green refers to a neutral position and relatively positive atoms are shown in blue.  
 
 4.5 The transition state model 
The experimental primary 1′-14C KIE of 1.028-1.031 and α-secondary 1′-3H isotope effects 
between 1.147–1.250 suggest a dissociative reaction mechanism for the ATP-PRTase 
enzymes with low bonding order to the leaving group and/or the incoming nucleophile.105 
The 1-15N nitrogen isotope effect further supports this mechanism. Work towards the 
generation of the transition state model and matching to the experimental values 
introduced in Section 3.3.3, will be discussed below. 
4.5.1 Adenine model to match the nitrogen isotope effect  
The 1-15N and 6-15N KIEs arise from the extent of C1′-N1 bond dissociation as well as leaving 
group interaction at the transition state (Section 3.2.1). A positive KIE indicates more 
conformational freedom at the transition state and an inverse KIE suggests a more 
constrained environment. The theoretical magnitude of the 15N isotope effect is 1.04 with 
values ranging from 1.010 to 1.037 reported for reactions involving aromatic nitrogenous 
bases.123,124 In most purine N-ribosyl transferases, protonation of the purine at N7 is 
proposed as part of the transition state structure.104,125 Protonation at this position makes 
84 
 
the adenine electron deficient, weakening the N-ribosidic bond and facilitating the reaction 
by forming a neutral leaving group. Overall the transition state was generally matched to 
the primary 14C isotope effect and small differences in the primary 15N were accepted as 
being within experimental uncertainties. In some cases the difference was ascribed to not 
considering the environment around the leaving group in the model, such as  π-stacking, H-
bonding and hydrophobic interactions.85,104 
M. tuberculosis and L. lactis ATP-PRTase gave large primary nitrogen isotope effects within 
the range of a fully dissociated purine ring, when compared to previously reported 
transition state structures. A nitrogen isotope effect at unity was found for C. jejuni ATP-
PRTase. The kinetic isotope effect of a fully dissociated adenine was thus investigated first. 
The effects of charge, tautomer state and the position of imine proton in either the E or Z 
configuration were also examined. This work was carried out at the B3LYP/6-31+G(d,p) and 
M06-2X/6-31+G(d,p) level. Different functionals were chosen to investigate their 
performance in modelling the transition state. The B3LYP functional is most widely used in 
transition state model calculations and therefore included.61,85,126 The M06-2X is upcoming 
and has been used successful for other systems.127,128 The results of the two functionals can 
be found in Table 4.2 and Figure 4.5. 
Table  4.2. The effect of protonation and tautomeric state of the adenine ring on the calculated 1-15N 
isotope effect. 
 B3LYP  M06-2X 
State  1-15N 6-15N  1-15N 6-15N 
Neutral  1.016 0.989  1.022 0.994 
Anionic E  1.023 1.004  1.026 1.007 
Anionic Z  1.025 1.004  1.027 1.007 
Neutral N3 tautomer E  1.019 1.000  1.020 1.005 
Neutral N3 tautomer Z  1.022 0.999  1.023 1.006 
Neutral N7 tautomer E  1.022 1.007  1.022 1.010 
Neutral N7 tautomer Z  1.023 1.009  1.023 1.013 
Protonated at N3  1.014 0.988  1.018 0.988 
Protonated at N7  1.017 0.996  1.021 0.991 
- not calculated for this functional 
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Anionic E Neutral Neutral N3 tautomer E 
   
Neutral N7 tautomer E Protonated at N3 Protonated at N7 
Figure  4.5. Different adenine charge and tautomeric states. Bond lengths are given in Å next to individual 
bonds. 
 
The charge, imine proton position and tautomer state of the adenine ring had a profound 
effect on the calculated isotope effects for both functionals. Also between the two 
functionals, differences in the calculated KIEs were found. Generally M06-2X suggested 
larger isotope effects then B3LYP for the different models. Discrepancies between 
functionals and basis sets used to generate the models has been reported previously by 
Singh and Schramm for Streptococcus pneumonia 5′-methylthioadenosine nucleosidase 
(MTAN) where a variety of methods (ab initio, HF, and DFT), and basis sets (3-21G, 6-31G(d), 
and 6-31G(d,p)) were used to calculate KIEs of the transition state.124 The 1′-14C primary 
isotope effect was predicted well by most method and basis set combinations; however, the 
predicted 9-15N primary nitrogen isotope effect ranged from 1.035 (HF/3-21G and B1LYP/6-
31G(d)) to 1.024 (HF/6-31G(d,p)).  
Initially the PRATP structure was truncated to include only the adenine ring of ATP, with the 
ribose part replaced by a hydrogen. This was done under the assumption that atoms more 
than two bonds away would not affect the KIE. However, the results from the different 
charge and tautomer states suggest that electronic effects further away do affect the result 
through the conjugated ring system. The N9 proton was thus replaced by the ribose ring 
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part in both the ground state and the dissociated adenine base. The lowest energy ground 
state was again found by starting from several conformations, generated by rotating the N-
ribosidic bond. This gave back a single resultant conformation for all structures tested. In 
the dissociated base, the dihedral angle to the ribose ring was fixed to represent the angle 
observed in the ATP bound crystal structure of M. tuberculosis ATP-PRTase (Section 2.8.3). 
The different charge and tautomeric states were generated and the structures optimised at 
the B3LYP/6-31+G(d,p) level (Figure 4.6). The B3LYP functional was chosen based on results 
discussed in Section 4.5.3. The corresponding calculated KIE results can be found in Table 
4.3.  
Table  4.3. The calculated KIEs for a dissociated adenine base including the ATP Ribose and the effects 
of charge and tautomer state on the kinetic isotope effect. Experimental KIEs included for comparison. 
  B3LYP    Experimental KIE 
State  1-15N 6-15N  ATP-PRTase  1-15N 6-15N 
Neutral  1.018 0.992  M. tuberculosis  1.024 ± 
0.001 
1.012 ± 
0.001 Anionic  1.024 1.005  
Neutral N3 tautomer  1.019 1.000  C. jejuni  0.995 ± 
0.003 
1.005 ± 
0.001 Neutral N7 tautomer  1.023 1.007  
Protonated at N3  1.013 0.981  L. lactis  1.028 ± 
0.001 
0.996 ± 
0.003 Protonated at N7  1.017 0.988  
 
       
Figure  4.6. Adenine with ribose expansion. A The extended ground state model. B The extended neutral 





Inclusion of the ribose ring did not give rise to large changes in the calculated nitrogen KIEs. 
This suggests that the simplified model was sufficient to capture the features of the 
transition state of the dissociation of the adenine ring and the results in Table 4.2 will 
therefore be used to discuss the nitrogen isotope effect. 
Matching the experimental and calculated KIEs indicates that an anionic or neutral (as one 
of its tautomers) were possible states for the adenine ring at the transition state of M. 
tuberculosis and L. lactis ATP-PRTase. The formation of altered tautomers or an anionic 
adenine requires residues which can protonate or deprotonate the adenine, especially 
considering the physiological direction (PRPP + ATP  PRATP + PPi). Crystal structures with 
ATP bound had been obtained for M. tuberculosis ATP-PRTase and C. jejuni ATP-PRTase 
(discussed in Chapter 2) and were examined for such residues.  
M. tuberculosis ATP-PRTase has a hydrophobic pocket where the adenine part binds. A 
hydrogen bond is made to a water molecule at the N3 position; this same water molecule 
also coordinates to Mg2+ (Figure 4.7, A). No further polar interactions occur and no other 
active site residues that could aid in deprotonation of the adenine or stabilise the anion are 
in close proximity.  
A slightly different binding mode and different interactions were observed for the ATP 
bound C. jejuni ATP-PRTase structure. The adenine is further stabilised by Arg16 which 
forms a sandwich π-π stacking interaction enclosing the adenine ring between Leu170 and 
Arg16. In addition the adenine amine binds in close proximity to Ser172 (Figure 4.7, B).  
The ATP binding site of L. lactis ATP-PRTase contains features from both C. jejuni and M. 
tuberculosis ATP-PRTase. An arginine is situated close to the adenine binding envelope, 
similar to Arg16 in the C. jejuni ATP-PRTase structure; however this does not greatly alter 
the binding position of the adenine part of ATP between the two structures. The 
triphosphate binding site is structurally more similar to M. tuberculosis ATP-PRTase and 
gives rise to a different binding mode around the triphosphate part. The M. tuberculosis 
ATP-PRTase crystal structure with ATP bound was thus used to generate an overlay of the 
catalytic core (domain I and II, residues 1–200) of the M. tuberculosis structure and the 
active site of L. lactis ATP-PRTase (residues 1–204). This resulted in an RMSD of 1.601 Å over 
141 atoms. (Figure 4.7, C and D). The overlay revealed that in addition to a hydrogen bond 
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to water at N3 and a π-π stacking interaction from Arg10, Glu158 was in close proximity to 






Figure  4.7. ATP binding. A Active site of M. tuberculosis ATP-PRTase (main chain green, second chain 
yellow) with ATP bound. H-bonds as yellow dashed lines. B Active site C. jejuni ATP-PRTase (magenta) with ATP 
bound at the active site. C Active site alignment of M. tuberculosis ATP-PRTase (green) with ATP bound and L. 
lactis ATP-PRTase (blue) (PDB: 1Z7N, PRPP not shown). D The L. lactis ATP-PRTase active site (main chain blue, 
adjacent active site orange) with ATP displayed from the alignment with M. tuberculosis ATP-PRTase.  
 
The nitrogen isotope effects for M. tuberculosis were 1.024 ± 0.001 for 1-15N and 1.012 ± 
0.001 for 6-15N (Section 3.3.3.1). The anionic and neutral N3 and N7 tautomers agree best 
with these values, with large primary nitrogen isotope effects and smaller positive 6-15N 





unlikely state, with no residues in close proximity able to deprotonate the adenine. 
Furthermore, stabilisation through a hydrogen bonding network was ruled out, with few of 
these interactions made to the adenine part. Of the neutral tautomeric states the N3 
tautomer was considered the most likely state based on the close proximity of a resolved 
water molecule in the crystal structure of M. tuberculosis ATP-PRTase, held in place by Mg2+. 
The detail in the crystal structure was not considered sufficient to distinguish between the E 
or Z conformationof the imine proton. The small discrepancy between the calculated and 
measured isotope effect could arise from factors such as the used functional and/or basis 
set, or the unmodelled active site interactions. Although the N3 tautomer was the more 
likely state the N7 tautomer cannot be ruled out based on these results. Overall the results 
support a fully dissociated adenine at the transition state for all charged and tautomeric 
states and the transition state was modelled accordingly. 
L. lactis ATP-PRTase gave a slightly larger primary 1-15N isotope effect of 1.028 ± 0.001 and 
suggests a substantial increase in vibrational freedom following dissociation of the N-
glycosidic bond (Section 3.3.3.3). The 6-15N isotope effect near unity at 0.996 ± 0.003 
suggests no significant change in vibrational freedom upon dissociation. The best match 
between calculated and experimental KIE was for an anionic adenine or N7 tautomer. At the 
active site of L. lactis ATP-PRTase Arg10 is likely to interact with the adenine through 
sandwich π-π stacking, similar to what is observed for C. jejuni ATP-PRTase. These types of 
interactions have been shown to play a role lowering the pKa tyrosine as well as purine 
bases.129,130 Glu158 is part of the phosphate binding loop, and is in close proximity to the 
adenine base. It is therefore potentially able to interact and stabilise an anionic ring system 
or alternate tautomeric state. However, given the pKa of ~16 for the adenine amine, the 
anionic adenine was considered less likely to occur even if multiple interactions would 
facilitate this step.131,132 Overall, the small differences between the model and experimental 
KIE could arise from the discussed un-modelled interactions or the functional and/or basis 
set used. The results support a fully dissociated adenine base at the transition state of L. 
lactis ATP-PRTase.85 
C. jejuni ATP-PRTase gave a primary isotope effect near unity of 0.995 ± 0.003 (Section 
3.3.3.2).  An isotope effect near unity suggests there is no change in vibrational freedom at 
the transition state through bond breaking and/or that several bonding changes fortuitously 
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compensate for each other in the conjugated purine ring.85,104 Given the similarities of the 
active site of L. lactis and C. jejuni ATP-PRTase around the adenine binding pocket, this 
result is surprising and cannot be explained through compensation by several bonding 
changes alone. Another explanation would be that N-glycosidic bond cleavage does not 
occur close to the rate determining step and is thus suppressed. Given the similarities of the 
primary 14C and α-secondary 3H isotope effects to the other two ATP-PRTases studied, a fully 
dissociated adenine ring was also assumed for this enzyme. 
4.5.2 The transition state model generation 
The Hammond postulate suggests that the transition state resembles the species closest in 
free energy.133 With the nitrogen isotope effect suggesting a dissociated nitrogenous base 
the transition state was expected to resemble the ribose 5-phosphate-phosphonoacetic acid 
(PRPA) species. 
It is important to consider during model generation that the enzyme active site can 
introduce conformational constraints to the substrate or product during catalysis. A crystal 
structure can provide insight into such constraints as well as any other factors playing a role 
during catalysis such as metals, active site residues, and conserved water molecules. 
However, no crystal structure with PRPA bound at the active was available. There is a PRPP 
bound crystal structure of ATP-PRTase from L. lactis available, which is expected to closely 
resemble the PRPA species, although at lower resolution (3.0 Å PDB:1Z7N). Low resolution 
can make accurate modelling of ligands challenging and information from such structures 
was used with caution. The ligand binding modes across the four chains were compared, 
with differences in geometries observed for the four ligands in particular around the 
pyrophosphate part (Figure 4.8). The omit map (Fo-Fc) further emphasises the poor fit of 
these ligands and the PRPP conformation from these structure were therefore considered a 






Figure  4.8. The different binding modes for PRPP modelled at the active site of L. Lactis. The omit map 
(Fo-Fc) is displaced in grey (1Z7N). 
 
Type I and Type IV PRTase enzymes share a signature fold responsible for PRPP binding 
(Section 1.10). Because of this high level of conservation a similar binding mode for PRPP 
was expected. To test this hypothesis the PDB database was searched for crystal structures 
of Type I phosphoribosyl transferase enzymes with PRPP bound. Structures with resolutions 
greater than 2.50 Å were excluded from this search. A total of 10 structures meeting these 
criteria were found and an overlay of the phosphate binding loop, which is part of this 
signature fold, was generated (Figure 4.9). From the overlay it can be seen that PRPP adopts 
a very similar binding mode across the various species examined. In addition, for most 
structures the catalytically essential Mg2+ cation was present situated under the ribose ring 
coordinated to the pyrophosphate, the 2- and 3-OH, and water. Magnesium is required for 
activity and the observed binding mode make it likely to play an important role at the 
transition state. The metal ion was therefore also included in the model. The binding mode 
of PRPP bound to adenine phosphoribosyltransferase from Giardia lamblia (PDB: 1L1R) 




Figure  4.9. Overlay of the phosphate binding loop of some Type I PRTase enzymes with the PRPP product 
bound. PDB: 1TC2, 1FSG, 1L1R, 1P18 and 1ZN7 shown. 
The pyrophosphate group was replaced by the alternative substrate phosphonoacetic acid 
and the structure optimised without constraints using B3LYP and the 6-31G(d) basis set. This 
model was unstable with the ligands around the magnesium reorganising, the 5-phosphate 
formed unrealistic interactions to other parts of the model and in some cases the model did 
not converge (Figure 4.10, A). A crystal structure has been obtained for human 
hypoxanthine-guanine phosphoribosyl-transferase (HGPRTase) with a transition state 
analogue bound at the active site including pyrophosphate.134 The pyrophosphate is bound 
in the same orientation around magnesium as observed for PRPP. The observation of the 
ligands rearranging around the magnesium in the transition state model were thus 
considered unrealistic.  
To reduce unrealistic interactions the ribose was truncated by removing the ribose 5-
phosphate part. Optimisation of the ribose ring and divalent magnesium cation separately 
prevented the rearrangement. After the ligands around the magnesium were optimised the 
ribose 5-phosphate could be reincluded.  
This iteration was an improvement from the first model, however when the C1-OPA bond 
was further extended this still resulted in unrealistic and unstable models. More specifically, 
interactions of the phosphate with ligands around the magnesium would result in unrealistic 
rearrangements around the magnesium ion (Figure 4.10, B, C and D) or the abstraction of 
the 2-OH proton (Figure 4.10, C).  
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At the active site the charged ribose 5-phosphate is accommodated by the phosphate 
binding loop, anchoring PRPP in place for catalysis.38 To resemble these constraints imposed 
by the active site, additional constraints by fixing the dihedral angle to the ribose 5-
phosphate, have been reported.61 The dihedral angles to this group were fixed and the 
phosphate protonated to resemble the charged interaction formed upon binding at the 
active site. The structure optimisation calculation was then repeated. This gave a stable 
transition state model that could be extended without becoming unstable. The absence of 
any additional imaginary frequencies suggests that fixing the dihedral angle to the 5-
position did not introduce substantial unrealistic constraints to the system.  
A  B  
C  D  
Figure  4.10. PRPA after the 5-phosphate is reincluded. Yellow dotted lines indicate interactions between 
atoms, the red dashed line shows the scissile bond. A The PRPA model after optimisation with a dianionic PA 
and deprotonated phosphate input structure. B Deprotonation by the phosphate group and magnesium has 
lost the more favourable octahedral configuration. C PRPA partially protonated, Mg has lost the octahedral 
coordination configuration. D  PRPA fully protonated, the ligands around magnesium have rearranged upon 
elongation of the C1ʹ-OPA bond.  
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4.5.3 Different functionals for the transition state structure calculations 
In the calculations of the nitrogen KIEs differences where seen between the B3LYP and M06-
2X functionals. A similar affect was expected for the optimisation of the transition state with 
these two functionals. To establish how well the two functionals could model the change in 
bonding interactions, the C1′-OPA bond (Figure 4.11) was iteratively extended by 0.1 Å until 
loss of the bond was observed (no or small imaginary frequency). A gradual change in the 
force constants (Section 3.1.4), in particular for C1′, are expected upon extension of the C1′-
OPA bond and the sigma bond is broken (Figure 4.12).   
 
Figure  4.11. PRPA input model. the red arrow indicates the C1ʹ-OPA bond was iteratively extended. 
 
B3LYP and M06-2X gave a similar response for the α-secondary 1′-3H KIE with B3LYP 
predicting a more gradual increase in conformational freedom then M06-2X. A stronger 
difference was predicted for the primary 1′-14C KIE. The M06-2X functional showed little 
change in the primary KIE for bond lengths of up to 2.10 Å after which a rapid change was 
predicted with full loss of interactions past 2.3 Å. A bond distance of 2.1 Å corresponded to 
a natural bond order of ~0.33 or loss of over 67% of the original bonding interactions. It was 
considered unlikely for this to not have an effect on the primary isotope effect. Furthermore 
the full loss of bonding interaction over 0.2 Å is unrealistic. A possible explanation for the 
underperformance of the M06-2X functional compared to B3LYP is that it was 
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parameterised for non-metals.107,118 Magnesium has a central role in the transition state 
model and potentially the incorrect modelling of the electron density around the 
magnesium may have caused the observed effect.   
 
 
Figure  4.12. Relationship between bond length (Å) and calculated KIE for the primary 14C and the α-
secondary 3H isotope effect for the two functionals tested. 
 
B3LYP was considered to perform well; but starts to fail in some cases to predict long range 
interactions. To test if an improvement on the B3LYP functional could be achieved by 
including a long range correction, the CAM-B3LYP functional was also included. The CAM-
B3LYP combines the hybrid quality of B3LYP and the long range correction presented by 
Tawada et al., who suggested the treatment of short range exchange interaction by means 
of an appropriate pure density functional and the long-range interaction by Hartree-Fock 
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(HF) exchange.135,136 To explore the trend in the calculated KIE the TS model calculations 
were repeated with the CAM-B3LYP functional and the 6-31G(d) basis set (Figure 4.13). 
 
 
Figure  4.13. Results of the grid search with B3LYP and CAM-B3LYP functionals with the 6-31G(d) basis set 
for both 14C and 3H. 
The predicted primary 14C KIE  at shorter bond lengths was increased relative to the isotope 
effects predicted for B3LYP reflecting on this difference in functionals. The longer range 
interaction up to 2.5 Å gave a similar performance, with a gradual loss of the predicted 
primary 14C kinetic isotope effect upon the formation of a greater carbocation being 
characteristic for both functionals. Beyond this bond length the B3LYP functional started to 
fail with complete loss of the interaction between the C1′-OPA bond. The CAM-B3LYP 
functional gave a slight increase in the primary isotope effect but still modelled this 
interaction reasonably well based on the observed trend. Overall both functionals predicted 
primary isotope effects higher than expected for near full bond loss, with primary isotope 
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effects expected near unity for a carbocation intermediate.124 The limited basis set may 
have been responsible for this result. To increase modelling accuracy for the atomic orbitals 
more distant from the nuclei a diffuse function can be added to the basis set. The basis set 
was thus extended to include a diffuse function on the heavy atoms. A polarization function 
was also added to the hydrogen atoms in order to give flexibility to the s-orbital. The ground 
state model was also optimised with the extended basis set to ensure appropriate 
comparison with the ISOEFF98 program. The increase in basis set had a similar effect on 
both functionals with isotope effects predicted closer to the expected value of near unity 
(Figure 4.14). The α-secondary followed a similar trend in both functionals with similar 
isotope effects predicted across the bond lengths investigated.  
 
 
Figure  4.14. Results of the grid search with B3LYP and CAM-B3LYP functionals and the extended 6-




Overall the CAM-B3LYP did not give significant improvement over the B3LYP functional, in 
particular around the area were the transition states for ATP-PRTase enzymes were 
expected (1′-14C intrinsic KIEs of 1.031–1.028). In addition B3LYP has the most precedent in 
literature for this type of reaction mechanism and was thus the preferred functional for 
further refinement of the transition state models.61,85,126  
Phosphonacetic acid was fully protonated during the transition state model generation to 
prevent unrealistic interactions upon extension of the N-ribosidic bond. Phosphonacetic acid 
has a pK1 = 2.0,  pK2 = 5.1, and pK3 = 8.7. At pH = 8.5 the carboxylic acid was therefore 
expected to be deprotonated.137 From Figure 4.14 a transition state with a C1′-OPA of >2.1 
was expected. Starting at this bond length the transition state structure was further refined 
with an anionic PA nucleophile. Deprotonation of the carboxylic acid did not have any 
adverse effect on the transition state model, but did significantly affect the calculated 
primary isotope effect. The anionic PA was expected to be the most realistic representation 
of the transition state for the ATP-PRTase enzymes and thus used to find a good match to 
the experimental KIE values. 
After refinement the best match for M. tuberculosis was at a C1′-OPA bond length of 2.75 Å. 
The bond length for C. jejuni ATP-PRTase was predicted to be close, at 2.65 Å. Also the short 
form of the ATP-PRTase enzyme from L.lactis gave a very similar late stage transition state 
with a C1′-OPA bond length of 2.50 Å (Table 4.4) (Appendix . The substrates in all three 
enzymes show carbocation characteristics with a positive charge build up at the anomeric 
centre which is stabilised by the ribose ring oxygen, highlighted by the Mulliken charges 
(Table 4.5). Mulliken charges provide a means of estimating partial atomic charges from QM 
calculations.138,139  
Table  4.4. Results from the refined search for the transition state structures of M. tuberculosis, C. jejuni 
and L. lactis ATP-PRTase. 
ATP-PRTase 
from  










L. lactis  2.50 Å 1.407 1.031 1.147 ± 0.008 1.031 ± 0.001 
C. jejuni  2.65 Å 1.441 1.029 1.212 ± 0.002 1.029 ± 0.001 
M. tuberculosis  2.75 Å 1.457 1.028 1.250 ± 0.008 1.028 ± 0.002 
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Table  4.5. The predicted Mulliken charges of the primary and α-secondary position to support the 
changes going from the ground state to the transition state. The ring oxygen was included to show the change 
in charge at this centre. 
ATP-PRTase  1′-C 1′-H Ribose ring O  
L. lactis  0.253 0.226 -0.013  
C. jejuni  0.275 0.235   0.004  
M. tuberculosis  0.290 0.236   0.019  
GS  -0.560 0.112 -0.302  
 
4.5.4 Discussion of the transition state model 
4.5.4.1 Transition state model for Mycobacterium tuberculosis ATP-PRTase 
The transition state was matched closely to the primary 1’-14C intrinsic kinetic isotope effect, 
because not only does this position report most accurately on the reaction mechanism, it is 
also insensitive to geometry changes upon binding and is expected not to be affected by 
interactions at the active site.140 It was found that a C1′-OPA bond distance of 2.75 Å was in 
good agreement with the primary isotope effects. The calculated α-secondary KIE was 
substantially larger than the experimental value. This sometimes arises from over 
estimation by in vacuo computation of the KIE at this position due to uncertainty around the 
H1′ position.61,102,104,124 A bond length of 2.75 Å corresponds to a late associative DN*AN‡ 
transition state  (Section 4.2 and Figure 4.15). Going from the ground state to the transition 
state there is a positive charge build-up at the C1′ position as indicated by the change in 
Mulliken charge of -0.560 compared to 0.290 at the transition state. The ribose ring oxygen 
stabilises the positive charge, resulting in the generation of a double bond characteristic, as 
this centre undergoes a hybridisation change from sp3 towards sp2, characteristic for a 
carbocation species. The Mulliken charge again highlights this change with reduced 
negativity at the oxygen atom. The double bond characteristic is also reflected in the C1′-
Oribose bond length which is shortened by 0.18 Å from 1.43 Å in the ground state to 1.25 Å at 
the transition state. The divalent magnesium cation plays an important role in placing the 
incoming nucleophile in the right position by coordinating the nucleophilic phosphonate 
oxygen and carboxylic acid functionality. When the MEPS map of the transition state is 
compared to the ground state model, the difference in charge around the reaction centre is 
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emphasised with an electron deficient anomeric carbon and also a less electron negative 









Figure  4.15. The transition state structure of M. tuberculosis ATP-PRTase and the corresponding MEPS 
map, in two orientations. Scale gives the colour coding with electron rich parts indicated in red and electron 





4.5.4.2 Transition state model for Campylobacter jejuni ATP-PRTase 
The best match of the calculated KIEs to the intrinsic primary 14C KIE was found for a 
transition state structure with a C1′-OPA bond length of 2.65 Å. For this transition state 
model the calculated α-secondary KIE was substantially larger than the experimental value 
attributed to condensed phase uncertainty around the C1′-H1′ region.61,102,104,124 The 
anomeric carbon at this bond length has become more positive compared to the ground 
state, with an increase in Mulliken charge of 0.85 (Table 4.5). This change also reflects on 
the α-secondary proton with an increase in positive charge. The ribose ring oxygen stabilises 
the positive charge at the anomeric carbon by sharing its lone pair of electrons, shortening 
the Cα-Oribose bond from 1.43 Å to 1.26 Å. The double bond characteristics between the 
anomeric carbon and ribose ring oxygen has a ring flattening effect. The carbocation is also 
evident from the electrostatic potential map with a more electron deficient anomeric 
carbon. The sharing of the lone pair of electrons has reduced the electron richness of the 
ring oxygen compared to the ground state structure (Section 4.4 and Figure 4.16). The 
octahedral coordinated magnesium plays a vital role in placing the phosphonate under the 
anomeric carbon. Overall the transition state model supports a late associative DN*AN‡ 








Figure  4.16. The transition state structure of C. jejuni ATP-PRTase and the corresponding MEPS map, in 





    
Figure 4.16. (continued) 
 
4.5.4.3 Transition state model for Lactococcus lactis ATP-PRTase 
The short form ATP-PRTase enzyme from the organism L. lactis was found to go through a 
very similar transition state to the long form ATP-PRTase enzymes discussed above. Here, 
the best match to the intrinsic isotope effects was for a transition state with a C1′-OPA bond 
length of 2.50 Å. This corresponds to a late associative DN*AN‡ transition state (Section 4.2). 
The calculated α-secondary KIE was slightly larger than the experimental value due to 
overestimation of the KIE at this position by in vacuo computation, due to condensed-phase 
uncertainty around the C1′-H1′ region.61,102,104,124 Furthermore, constraints from van der 
Waals interactions at the active sites are proposed to suppress the experimental 1′-3H 
KIEs.61 The Mulliken charge change at the anomeric carbon from -0.560 to + 0.253 illustrates 
the carbocation characteristics. Participation by lone pair electrons of the ribose ring oxygen 
helps stabilise the positive charge of the carbocation species (Table 4.5). This leads to a 
double bond characteristic, with shortening of the bond from 1.43 Å in the ground state to 
1.26 Å at the transition state, and flattening of the ribose ring. The observed changes at this 
centre also reflect on the α-secondary proton with an increase in Mulliken charge from 




anomeric proton (Figure 4.17). The electrostatic potential around the ring oxygen has 
changed from an electron rich position in the ground state to a more neutral position at the 









Figure  4.17. The transition state structure  of L. lactis ATP-PRTase and the corresponding MEPS map. Scale 





4.6 ATP-PRTase compared to other PRTase enzymes 
Goitein et al. studied the primary 14C and α-secondary 3H KIEs for three 
phosphoribosyltransferase enzymes including ATP-PRTase from Salmonella typhimurium.58 
In their study commitment to catalysis suppressed the observed isotope effect in both 
forward and reverse directions (Section 3.2).58 Human hypoxanthine guanine PRTase 
(HGPRTase) gave a primary isotope effect of 1.05 and an α-secondary isotope effect of 1.30. 
Yeast orotate PRTase (OPRTase) gave a primary KIE of 1.03 and an α-secondary isotope 
effect of 1.17. A more detailed transition state analysis based on experimental KIEs has also 
been carried out for OPRTase from Salmonella typhimurium by Tao et al. and Plasmodium 
falciparum, and human orotate phosphoribosyltransferase by Zhang et al. through the use 
of the alternative substrate phosphonoacetic acid.60,61 OPRTase from S. typhimurium gave a 
primary KIE of 1.040 ± 0.004 and a α-secondary KIE 1.200 ± 0.007 supporting a DN*AN 
transition state.60 A relatively low nitrogen isotope effect was observed for double 
isotopically labelled orotate with a KIE of 1.006 ± 0.005. The transition state was modelled 
with a C1′-N1 bond distance of 1.85 Å and no involvement of the incoming nucleophile. This 
corresponds to a DN‡*AN or a late dissociative reaction mechanism. P. falciparum and 
human OPRTase gave smaller primary isotope effects of 1.034 ± 0.002 for P. falciparum and 
1.035 ± 0.003 for human OPRTase. The smaller primary isotope effect was supported by 
large α-secondary isotope effects of 1.261 ± 0.014 and 1.199 ± 0.015. In addition large N1 
isotope effects of 1.028 ± 0.003 and 1.025 ± 0.005 were reported.61 The transition state that 
agreed best with the experimental intrinsic KIEs had a fully dissociated dianionic orotate and 
a C1′-OPA bond distance of 2.15 for P. falciparum and 2.14 for H. sapiens OPRTase which 
corresponds to a DN*AN‡ or late associative transition state. P. falciparum and H. sapiens 
orotate OPRTase has also been studied by Tao et al. with the natural substrate 
pyrophosphate. For this, commitment to catalysis was overcome through the use of 
orotidine instead of the natural substrate orotidine monophosphate (OMP) as a slow 
substrate. Also here a DN*AN‡ type mechanism was found, although a slight increase in the 
nucleophile bond distance to the anomeric position was modelled.  
The transition state models for P. falciparum and H. sapiens OPRTase matches closest to the 
results found for ATP-PRTase. Both exhibit fully dissociated nitrogenous bases and a DN*AN‡ 
type mechanism based on the transition state analysis. The transition state model of P. 
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falciparum and H. sapiens OPRTase studied with PA however did not include magnesium at 
the transition state and was found to have a significantly shorter C1′-OPA bond distance. In 
addition the PA nucleophile was modelled fully protonated. Based on the pKa profile of PA it 
is likely that the carboxylic acid would be deprotonated similar to the transition state 
models proposed in this study. Deprotonation of the PA had a significant effect on the 
model used here and it may be these changes that led to significant differences between 
the models. 
4.7 Long versus short; comparison of the two forms of ATP-PRTase 
enzyme  
Previously significant differences between the transition state of human and bovine purine 
nucleoside phosphorylase (PNP) have been reported.104,123,141 Bovine PNP goes through an 
early transition state with a distance of 1.8 Å between the C1′ and N9. Human PNP on the 
other hand was determined to resemble a fully dissociated carbocation with a distances of 
≥3.0 Å for the leaving group and nucleophile to the C1’. These are remarkable differences 
for enzymes with 87% sequence identity. Further study showed that a single point mutation 
of the Human PNP enzyme could change the transition state to resemble that of the bovine 
PNP.142 Comparatively, P. falciparum and H. sapiens OPRTase share only 26% identity in 
amino acid sequence but display very similar transition states. S. typhimurium OPRTase on 
the other hand was shown to go through a DN‡*AN or a late dissociative reaction 
mechanism.  
These examples show that variation among the transition states for enzymes catalysing the 
same reaction is not uncommon. Although these enzymes are similar structurally, and in 
some cases in amino acid sequence, this does not necessarily lead to similar transition 
states. The ATP-PRTase long and short form are different from the given examples in that 
they share a common catalytic core but have vastly different means of regulation. Overall 
the ATP-PRTase enzymes studied share ~30% sequence identity, regardless of the difference 
in structure. The transition states for M. tuberculosis, C. jejuni, and L. lactis ATP-PRTase were 
found to be very similar with C1′-OPA bond distances within 0.25 Å across the three enzymes 
and all three enzymes going through a DN*AN‡ or a late associative transition state. The close 
resemblance of the transition states for ATP-PRTase long form and ATP-PRTase short form 
support the findings that the regulatory domains are recruited for control of the complex 
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metabolic systems of cellular organisms and do not affect the reaction mechanism. These 
findings support the idea that both forms of ATP-PRTase share a common ancestor and that 
through divergent evolution the challenge of regulation was overcome for this metabolically 
important enzyme.  
4.8 The reaction coordinate for ATP-PRTase 
As mentioned in Section 4.3, experimental KIEs report on the difference between the 
substrate free in solution to the highest energy barrier along the reaction coordinate, the 
transition state. Intrinsic KIEs do not directly report on the steps leading to the formation of 
the TS. The TS models do however allow classification of a reaction (Section 4.2) and provide 
insight into the potential steps leading towards the transition state. In addition, Smith 
predicted a reaction mechanism through “nucleophilic displacement by electrophile 
migration”.112 This prediction was made from crystal structures with substrate, substrate 
analogues and transition state analogues bound at the active site of human HGPRT. It was 
also found that the nitrogenous base and pyrophosphate were held in place with most of 
the movement coming from the central atom, the anomeric carbon C1′.143  
These findings support that the pyrophosphate and adenine are held in place at the active 
site of ATP-PRTases, with most of the movement during catalysis arising from migration of 
the central atom along the reaction coordinate. Depending on the interatomic distance 
between the nucleophilic oxygen on the PA phosphonate and the N1 of adenine, small 
variation in the transition state and the reaction coordinate may be found. This could help 
to further explain the subtle differences between the studied enzymes. 
The three ATP-PRTase enzymes were modelled with similar transition states based on the 
primary 14C and α-secondary 3H. A bigger difference was found around the isotope effects 
associated with the adenine base 1-15N and 6-15N. The variation in active site may give rise 
to these observed differences and as a result the steps leading to the transition state could 
vary between the studied ATP-PRTase enzymes.  
Large 1-15N isotope effects for M. tuberculosis and L. lactis support the suggested DN*AN‡ 
reaction mechanism with ATP fully dissociated at the transition state or a bond distance 
≥3.0 Å and weak interaction of the incoming nucleophile. A DN*AN‡ reaction mechanism 
suggests the presence of an unstable carbocation intermediate or TS. However, the KIE 
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results do not provide direct proof of this. Another explanation could be that the transition 
state is reached without going through this discrete intermediate and transition between 
dissociation of the nucleophile (1st TS) at a late stage is complemented by weak interaction 
of the incoming nucleophile (2nd TS), without formation of a discrete intermediate (Figure A 
4.18).  
C. jejuni ATP-PRTase on the other hand gave a primary nitrogen isotope effect near unity. An 
isotope effect at unity may be a result of the adenine dissociation step (1st TS) being further 
separated from the transition state on the reaction (2nd TS) (Figure B 4.18). The separation 
would allow for equilibration and restoration of the aromatic ring nullifying the KIE. This 
would further suggest that formation of a carbocation intermediate proceeds before the 
transition state of the reaction is reached (Figure B 4.18). 
 
    
Figure  4.18. Proposed difference in the reaction coordinate diagram between A the M. tuberculosis and L. 
lactis  ATP-PRTase with dissociation of the nitrogenous base and incoming of the nucleophile without going 
through a discrete intermediate and B the reaction coordinate for C. jejuni ATP-PRTase with adenine 
dissociation (1st TS) separated by formation of an intermediate (carbocation) followed by incoming of the 





4.9 Summary  
This chapter covered the generation of transition state models with the experimental 
intrinsic KIEs as boundary conditions. The ground state structure was successfully generated 
starting from PRATP bound to the C. jejuni ATP-PRTase core mutant. The full length 
structure was truncated at the ribose triphosphate which was shown to not adversely affect 
the calculated KIEs more than three bonds away. The nitrogen isotope effects for 1-15N and 
6-15N were calculated for different charge and tautomeric states of the adenine ring system. 
The large 1-15N isotope effect for ATP-PRTase from M. tuberculosis in combination with the 
residues at the active site make a neutral N3 and N7 tautomer possible, with the N3 
tautomer considered the most likely because of a coordinated water in close proximity to 
this position. L. lactis ATP-PRTase was also found to have a fully dissociated adenine base, 
here in addition to the neutral N3 and N7 tautomers of adenine an anionic leaving group 
could not be ruled out with additional interactions to adenine proposed at the active site. 
The N7 tautomer was considered a more likely candidate, as an anionic adenine ring would 
form a poor leaving group. In addition, in the physiological reaction order this would require 
deprotonation of the adenine amine. Given the pKa of ~16 at this position, this was 
considered less likely to occur even if multiple interactions would facilitate this step. C. 
jejuni ATP-PRTase was considered to have a fully dissociated adenine based on the findings 
of the other two enzymes, and that the transition state resembles the PRPA product. The 
high level of conservation for the PRPP binding loop across phosphoribosyl transferase 
enzymes allowed PRPP to be used as a starting structure and the generation of the PRPA 
transition state model. The ribose magnesium complex was refined separately and the C1′-
OPA bond incrementally elongated. The 5′-phosphate was then built back into the model and 
refined further to give the transition states models. To study the effect of different 
functionals a grid search was carried out with the B3LYP functional performing best out of 
the functionals tested. A C1′-OPA bond length of 2.75 Å gave the best match to the 
experimental data of M. tuberculosis ATP-PRTase. C. jejuni ATP-PRTase gave a very similar 
result with a bond length of 2.65 Å. Also the ATP-PRTase short form had a transition state 
with a C1′-OPA bond length of 2.50 Å. This indicates that all three enzymes go through a late 
associative DN*AN‡ transition state. Magnesium plays an important role in anchoring the 
reactants in place during transition state formation by coordinating the reactants in an 
octahedral configuration. The carbocation is stabilised by the ribose ring oxygen which 
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shares the electrons of a filled lone-pair orbital with an empty p-orbital of the carbocation. 
This results in a double bond characteristic which has a ring flattening effect on the ribose 
ring. The work presented revealed a similar transition state for the three enzymes and 
supports the proposed reaction mechanism that the carbocation drives the reaction with 
“nucleophilic displacement by electrophile migration”. Small differences are likely to be 
found in the steps leading to the transition state particularly around the adenine base and 
leaving group departure and that the nature of the transition states is determined by the 





Chapter 5  
Synthesis of transition state analogues   
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5.1  Tight binding of transition state analogues 
The original proposal by Pauling that enzymes bind tightly to the transition state was based 
on transition state theory (TST) which states that reactions are in equilibrium with the 
transition state.144 Pauling proposed that the catalytic potential of an enzyme was achieved 
through tight binding, and therefore stabilisation, of the transition state complex to the 
enzyme. Based on this and the notion that reaction rate is proportional to the fraction of the 
reactant in the transition state complex, Wolfenden and co-workers further hypothesized 
that enzymes are able to alter this equilibrium through specific tight binding to the 
transition state therefore providing stabilisation of the transition state complex.145,146 The 
binding affinity of the enzyme for the transition state was proposed to be proportionate to 
the rate increase, of 1010 to 1020 times the uncatalysed rate, imposed by the enzyme.147 An 
inhibitor that can capture some of the nature of the transition state geometry, van der 
Waals interactions and charge are predicted to bind tightly to the enzyme, with the binding 
energy of the transition state analogue proportional to the catalytic rate enhancement.145  
Examples of tight binding, when enough of the transition state properties are captured, are 
well reported.141,148–150 Some of the transition state mimics bind with staggering picomolar 
to femtomolar affinity to their target. Furthermore, in the case of purine nucleoside 
phosphorylase (PNP) it was shown that bovine and human PNP have different transition 
states. The difference in transition state could be exploited in transition state analogue 
design by insertion of a methylene bridge between the ribose- and purine- mimicking 
moyity. The enzyme exhibiting a more dissociated transition state was able to bind the 
extended transition state analogue more tightly then the enzyme displaying an earlier 
transition state.2,123,141 
This chapter discusses work towards finding alternative means to target the ATP-PRTase 
enzymes of pathogenic bacteria, in particular the ATP-PRTase enzymes from M. tuberculosis 
and C. jejuni. Work involving the design and synthesis of transition state analogues as a 
means to inhibit these enzymes is described. 
5.2 Transition state analogue design 
Enzymes with an altered geometry and/or charge at the transition state are good candidates 
for transition state analogue design.108 At the start of this work a detailed description of the 
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transition state structure was unavailable. Based on crystal structures and work done on 
other phosphoribosyl transferases the ATP-PRTase enzyme was predicted to follow an SN1 
like transition state (Section 1.11). This suggests a carbocationic species with charge build up 
around the anomeric centre and an altered geometry at the site of the reaction, from sp3 or 
tetrahedral geometry, to more sp2 trigonal planar geometry.  
Knowledge of the nature of the transition state allows for more informed design of 
inhibitors, leading to the very potent inhibitors mentioned earlier. Synthesis of these 
inhibitors, however still remains challenging and time consuming. To this end inhibitors 
based around the ribocation portion were chosen first, before embarking on a full length 
PRATP based analogue.  
Iminosugars are sugar derivatives with the ring oxygen replaced by nitrogen. These are 
protonated at physiological pH and represent the positive charge of the transition state. It is 
these particular species that have been shown to bind with such high potency, and based on 
this, targets 5.1 and 5.2 were chosen (Figure 5.1). The phosphate group plays an important 
role in binding PRPP, so it was therefore included. In addition, the phosphonate isostere was 
chosen for the iminosugar derivative as a stable analogue of the phosphate group which is 
easily accessible through similar intermediates as compound 5.1. 
The positive charge, built up at the anomeric carbon during ribocation formation, is 
stabilised by the ring oxygen through its lone pair electrons. This results in double bond 
characteristics and the trigonal planar species. To capture the geometry of the flattened 
ribose ring cyclopentene 5.3 was chosen to be synthesised (Figure 5.1).  
 
 
Figure  5.1. The proposed intermediates: iminosugars 5.1 and 5.2 as a mimic of the ribocation 
intermediate and the cyclopentene 5.3 as a mimic of the ring flattening effect. 
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5.3 Iminoribitol transition state analogue 
5.3.1 Retrosynthetic analysis of the shared iminosugar portion.  
Both phosphate 5.1 and phosphonate 5.2 were envisioned to be accessible from the shared 
intermediate hydroxymethyl 5.4 which, in turn, was envisioned to be accessed in five 
synthetic steps (Scheme 5.1). It was proposed that orthogonally protected hydroxymethyl 
containing iminosugar 5.4 could be obtained in one step from fully protected iminoribitol 
5.5 by desilylation. Silane 5.5 in turn was expected to be accessible in two steps from diol 
5.6 by installation of the mesylate leaving group followed by a double displacement with 
benzylamine and inversion of the stereochemistry at the C4-position. Diol 5.6 itself was 
thought to be accessible from lactone 5.7 via silane protection of the 5-position followed by 
reduction of the lactone portion. 
 
Scheme 5.1. Retrosynthetic analysis of iminosugar 5. 
 
5.3.2 Synthesis of the iminosugar portion 
The starting lactone was kindly provided by Prof. P. Tyler from the Ferrier Research Institute, 
Wellington NZ. The synthesis commenced with protection of the 5-position of the starting 
material by subjecting lactone 5.7 to tert-butyldimethylsilyl chloride (TBDMSCl) and 
imidazole in dimethylformamide (DMF) (Scheme 5.2). This resulted in the unexpected 
appearance of two products by thin layer chromatography (TLC), with one of these later 
confirmed to come from an impurity in the starting material carried over from the previous 
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step. The product could readily be separated from the unwanted side product by flash 
chromatography and identity of the desired product was confirmed by X-ray crystallography 
with a flack value of 0.01 ± 0.03 (Figure 5.2, appendix IV). Subsequent reduction proceeded 
smoothly by subjecting protected lactone 5.8 to sodium borohydride in tetrahydrofuran 
(THF). NMR analysis suggested full conversion and no apparent side product; therefore, diol 
5.6 was used without further purification. 
 
Scheme 5.2. Synthesis of diol 5.6 from lactone 5.7 in two steps via protection of the primary hydroxyl 
followed by reduction with NaBH4. 
 
Figure  5.2. The crystal structure of lactone 5.8 confirming the right stereochemistry and product.  
 
Following a modified procedure of Fleet et al., diol 5.6 was subjected to methanesulphonyl 
chloride (MsCl) and DMAP in pyridine (Scheme 5.3).151 In this reaction it was found that a 
better yield was obtained when MsCl was activated with DMAP prior to the addition of diol 
5.6. Following the adopted method, good formation of dimesyl 5.9 was observed (>95%). To 
perform the double displacement, dimesyl 5.9 was dissolved in benzyl amine and heated to 
115 
 
160 oC for four hours. This gave clean conversion of the starting material to the protected 
amine product 5.5, in excellent yield (>95%). 
 
Scheme 5.3. Installation of the mesyl leaving group followed by a double displacement with benzyl amine 
to give iminosugar 5.5. 
 
The next step in the synthesis was the deprotection at the 5-position of orthogonally 
protected amine 5.5 for subsequent modifications around this centre. Therefore amine 5.5 
was subjected to tetrabutylammonium fluoride trihydrate in THF, to give primary alcohol 
5.4 in near quantitative yield (Scheme 5.4). 
 
Scheme 5.4. Deprotection of 5.5 to give orthogonally protected primary alcohol 5.4. 
 
5.3.3 Synthesis of the iminoribitol phosphate 
5.3.3.1 Retrosynthetic analysis of iminoribitol phosphate 
The desired iminoribitol phosphate 5.1 was expected to be accessible in three steps from 
primary alcohol 5.4 (Scheme 5.5). Global deprotection of fully protected iminoribitol 5.10 
was expected to be possible in two steps through acid catalysed hydrolysis of the acetonide 
followed by hydrogenation. Installation of the phosphate functional group itself was 
envisioned to be accessible in one step from alcohol 5.4 in a two-step one-pot procedure by 
phosphorus coupling with phophoramidite and a weak acid followed by oxidation of the 
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Scheme 5.5. Retrosynthetic analysis of iminoribitol phosphate 5.1. 
 
5.3.3.2 Synthesis of the iminoribitol phosphate 
The hydroxymethyl 5.4 was subjected to dibenzyl N,N-di-isopropyl-phosphoramidite and 
tetrazole (Scheme 5.6).152 When TLC analysis showed complete consumption of starting 
material meta-chloroperoxybenzoic acid (m-CPBA) was added to give protected phosphate 
5.10 in a moderate 42% yield.  
 
Scheme 5.6. Phosphorylation of hydroxymethyl 5.4. 
Although formed in modest yield, the amount of protected iminoribitol phosphate 5.10 was 
considered sufficient for the two step deprotection (Scheme 5.7). Following a method by 
Zhang et al. hydrolysis of the acetonite protecting group was readily achieved in methanol 
and a catalytic amount of HCl to give the 2,3-dihydroxy product 5.11 in a good yield 
(>95%).150 In this step longer reaction times resulted in the loss of one of the O-benzyl 
protecting groups as well. Subsequent hydrogenation then gave the desired product 




Scheme 5.7. Deprotection of iminoribitol 5.10 via hydrolysis of the acetonite protecting group followed by 
hydrogenation. 
 
5.3.4 Synthesis of the iminoribitol phosphonate transition state analogue 
5.3.4.1 Retrosynthetic analysis of iminoribitol phosphonate 
Phosphonate 5.2 was envisioned to be accessible in four synthetic steps from the shared 
hydroxymethyl 5.4 (Scheme 5.8). Introduction of the phosphonate was anticipated to be 
possible by introducing a good leaving group (5.13) at the 5-position and subsequently 
displaced by a phosphonate based nucleophile. Deprotection was expected to be possible in 
a two-step process of acid hydrolysis followed by hydrogenation.   
 
Scheme 5.8. retrosynthetic analysis of iminoribitol phosphonate 5.2. 
 
5.3.4.2 Synthesis of iminoribitol phosphonate 
The trifluoromethansulphonyl (Tf) leaving group was chosen as the leaving group because of 
the highly activated nature and high reactivity towards nucleophilic displacement. Primary 
alcohol 5.4 was therefore subjected to trifluoromethanesulphonic anhydride and 2,6-di-tert-
butyl-4-methylpyridine (DBMP) as a base (Scheme 5.9). However, analysis by NMR and mass 
spectrometry revealed that only eliminated product was formed. Formation of the 
eliminated product from triflate 5.12 was attributed to the activated nature of the triflate 
leaving group. A less activated leaving group, such as an iodide or methyl sulphonyl, could 
potentially reduce the formation of the eliminated product and their synthesis was 
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attempted. Installing the mesylate resulted in the formation of multiple side products 
during the reaction and was not followed up further. Mass spectrometry analysis on the 
iodide gave a product with the correct mass, as well as a small amount of an eliminated 
product. Structural analysis by NMR spectroscopy, however did not match the expected 
product for the iodide with a peak at 29 ppm corresponding to a secondary iodide by the 
HSQC spectrum (Figure 5.3). 
 
 
Scheme 5.9. The installation of a triflate leaving group did not yield the desired product 
 
Figure  5.3. [1H,13C]-HSQC spectrum of the secondary iodide with all CH and CH3 centres in yellow and the 





Formation of a secondary iodide can be explained through the participation of the ring 
nitrogen which sits in close proximity to the leaving group (Scheme 5.10). Mechanistically 
this can be explained by the ability of the filled orbital of the lone pair on nitrogen to 
displace the installed leaving group, resulting in a positively charged aziridine intermediate 
(5.14). Nucleophilic attack on this strained ring system by the released leaving group then 
results in ring expansion to give the six membered ring 5.15. The participation of the ring 
nitrogen is further improved by the electron donating effect of the benzyl protecting group. 
Ring expansion was also observed by Malladi et al. when attempting to introduce the mesyl 
leaving group.153 β-elimination of 5.15 then leads to alkene 5.16. 
 
Scheme 5.10. Formation of the ring expanded product 5.15 and subsequent β-elimination leading to alkene 
5.16. 
 
To circumvent the problem around the ring nitrogen participating in the reaction, two 
approaches were considered. If the centre of interest would be oxidised instead, 
participation by the ring nitrogen was not expected to lead to the discussed side products. 
Another option would be to change the nitrogen protecting group to tert-butyloxycarbonyl 
(Boc). The formed carbanate has an electron withdrawing effect on the nitrogen, thus 
reducing the nucleophilicity of the nitrogen. The oxidation method was the preferred option 
as this would not introduce additional steps. Alcohol 5.4 was therefore subjected to a Swern 
oxidation to give aldehyde 5.17 and dimethylsulphide (Me2S) as the only observed products 
by NMR in the crude reaction (Scheme 5.11). The aldehyde was used without further 
purification to prevent side product formation observed during purification by silica flash 
chromatography. Treatment of aldehyde 5.17 under HWE conditions led to product 




Scheme 5.11. Installation of the phosphonate functionality via the aldehyde 5.17 to give phosphonate 5.18. 
 
With the fully protected phosphonate 5.18 in hand, deprotection was attempted (Scheme 
5.12). Hydrolysis of the ethyl esters was the first step in the deprotection regimen, to this 
end phosphonate 5.18 was subjected to TMSBr in CH2Cl2. This resulted in clean formation of 
the free acid. Subsequent removal of the isopropylidine was then achieved by acid catalysed 
hydrolysis with acetic acid/water 1/1 v/v at 70 oC. When clean conversion was confirmed by 
mass spectrometry the crude reaction mixture was subjected to 10% palladium on carbon 
with hydrogen gas in methanol to give iminoribitol phosphonate 5.2 in 83% yield over three 
steps after purification. Overall this gave the phosphonate 5.2 in 8 steps with an overall 
yield of 26%. 
 
Scheme 5.12.  Deprotection of iminoribitol phosphonate 5.18. 
5.3.5 Inhibition studies on iminoribitol based analogues. 
The iminoribitol phosphate 5.1 and iminoribitol phosphonate 5.2 were tested under 
competitive conditions (Section 8.5.3). The inhibitors were expected to be competitive 
towards PRPP binding; therefore, the concentration of PRPP was varied (1–3 times Km: 50-
150 µM for the M. tuberculosis ATP-PRTase enzyme70 and 11–33 µM for the C. jejuni ATP-
PRTase enzyme66) while keeping ATP concentrations constant (750 µM M. tuberculosis ATP-
PRTase and 500 µM C. jejuni ATP-PRTase enzyme ), at an inhibitor concentration of up to 
500 µM.  
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No inhibition for the ATP-PRTase enzyme from M. tuberculosis and C. jejuni under these 
conditions was observed for either analogue. The iminoribitol based inhibitors mimic the 
ribose-5-phosphate moiety  which is only a small part of the full length PRATP structure able 
to bind at the active site. Potentially, the adenine base or a similar moiety may be needed to 
allow binding of the TS analogues in the right geometry to effectively inhibit these 
enzymes.141  
5.4 Ribose cyclopentene analogue  
5.4.1 Retrosynthetic analysis 
A scheme for the synthesis of cyclopentene 5.3 was devised and comprises ten steps 
starting from D-mannose 5.23 (Scheme 5.13). It was envisioned that phosphorylated 
cyclopentene 5.3 could be obtained from protected cyclopentene 5.19 in two steps via a 
protected phosphoryl chloride and an organic base followed by global deprotection. 
Following a literature procedure by Overkleeft et al. cyclopentene 5.19 itself has been 
synthesised in eight steps.154 Cyclopentene 5.19 was synthesised through the condensation 
of tributyl(iodomethyl)stannane with cyclopentene 5.20 followed by a Still-Wittig 
rearrangement. Cyclopentene 5.20 was synthesised from dialkene 5.21 using ring closing 
metathesis (RCM) with Grubbs 1st generation catalyst. Dialkene 5.21 in turn was obtained 
from orthogonally protected alkene 5.22 via de-benzoylation and consecutive Wittig 
olefination. Alkene 5.22 was obtained via protecting group manipulations and acid catalysed 




Scheme 5.13. Retrosynthetic analysis for the synthesis of the cyclopentene 5.3. 
 
5.4.2 Synthesis of the cyclopentene transition state analogue 
Protected mannose 5.25 was obtained in 2-steps from D-mannose 5.23 (Scheme 5.14). The 
acetonide protecting group was chosen to favour the mannose ring in its furanose form and 
the ability to modify the 5,6 isopropylidine protecting group selectively at a later stage in 
the synthesis. D-Mannose 5.23 was subjected to the condensation reaction with 2,2-
dimethoxypropane in dry acetone and catalytic H2SO4 to give di-isopropylidine 5.24 in 79% 
yield. Benzoylation of the anomeric hydroxyl was then achieved with benzoyl chloride in dry 
pyridine and a catalytic amount of 4-dimethylaminopyridine (DMAP) to give fully protected 
mannose 5.25 in a good yield (88%).155 
Scheme 5.14. Synthesis of benzoyl 2,3:5,6-di-O-isopropylidine-α-D-mannose 12. 
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With the protected mannose 5.25 in hand, attempts were made at the selective 
deprotection, reprotection and thermal rearrangement at the 5,6 position to give protected 
alkene 5.22 (Scheme 5.15). Regio-selective removal of the 5,6-isopropylidine was achieved 
by treating protected mannose 5.25 with 70% acetic acid in H2O at 45oC for five hours. It 
was important to monitor the progress of the reaction, as prolonged reaction time can lead 
to loss of the 2,3-isopropylidine as well. The crude product was then subjected to 
triethylorthoformate, followed by acid catalysed thermal rearrangement. In the literature 
Ph3CCO2H has been used for reaction at elevated temperatures as it is a less volatile acid 
catalyst.156 Ph3CCO2H was unavailable at this point and therefore Ph2CHCO2H was used 
instead as this has similar properties and was present in the laboratory at the time. This 
gave protected alkene 5.22 in 80% yield over 3-steps. Subsequent deprotection of the 
benzoyl protecting group was readily achieved with t-BuOK in methanol to give lactol 5.26 in 
excellent yield (95%). 
Scheme 5.15. Acid catalysed thermal rearrangement leading to alkene 5.22 followed by deprotection of the 
benzoyl protecting group to liberate the anomeric proton. 
 
 
With lactol 5.26 successfully synthesised, Wittig olefination was then explored. In an initial 
attempt, the lactol 5.26 was subjected to methyltriphenylphosphonium bromide and n-butyl 
lithium (n-BuLi) in THF .157 Although product formation was observed over the course of the 
reaction (Rf 0.69, PE/EtOAc, 1/1, v/v), after purification no significant amount of product 
was isolated (<20%). A change of condition to t-BuOK in THF/ hexamethylphosphoramide 
was attempted in order to install the additional alkene (Scheme 5.16). However, this did not 
significantly improve the yield, although complete consumption of starting material to a 
higher running product was observed by TLC analysis. It was later realised that the dialkene 
product was volatile under reduced pressure and care had to be taken when drying the 
product under reduced pressure. When the reaction was repeated, bearing this in mind 
(vacuum >150 mbar and the water bath at 35°C), dialkene 5.21 was isolated in a yield of 
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75%. RCM with Grubbs 1st generation catalyst then gave cycloalkene 5.20 in a 52% yield.158 
Although this yield was modest, enough of the cyclic product 5.20 was obtained to continue 
with the synthesis and was therefore not further optimised. 
Scheme 5.16. Wittig olefination followed by RCM with Grubs 1st generation catalyst leading to 
cyclopentene 5.20. 
 
The next key step in the synthesis was the Still-Wittig [2,3] sigmatropic rearrangement. The 
Still-Wittig rearrangement is a variation of the traditional [2,3] Wittig sigmatropic 
rearrangement where the allylic ether is replaced by α-alkoxystannane, which after 
transmetalation with lithium can undergo the rearrangement step. 
The tributyl(iodomethyl)stannane needed for this reaction was not readily commercially 
available and it was therefore synthesised. Following a procedure by Lohse-Fraefel et al. the 
tributyl(iodomethyl)stannane was synthesised in two steps (Scheme 5.17).159 First tributyltin 
hydride was subjected to LDA and para-formaldehyde in THF leading to the formation of 
tributyl(hydroxylmethyl) stannane in 60% yield. The hydroxyl intermediate could be readily 
purified by flash chromatography. Subsequent iodonation with N-iodosuccinimide (NIS) and 
triphenylphosphine in THF then gave tributyl(iodomethyl)stannane in an 80% yield.  
 
Scheme 5.17. Synthesis of tributyl(iodomethyl)stannane. 
 
Starting from the iodomethyl stannane reagent, precursor 5.27 was then synthesised. 
Cyclopentene 5.20 was subjected to potassium hydride in THF, followed by the addition of 
tributyl(iodomethyl)stannane, to give ether 5.27 in an 87% yield (Scheme 5.18). Still-Wittig 
rearrangement was then achieved by subjecting precursor 5.27 to n-BuLi in THF to give the 





Scheme 5.18. [2,3] Still-Wittig sigmatropic rearrangement. 
 
The Still-Wittig rearrangement leaves the hydroxymethyl conveniently available for 
subsequent instalment of a phosphate group. The phenyl protected phosphate was chosen 
because it can be readily deprotected using a Birch reduction and avoids the use of TMSBr, 
which can be hard to remove in the final stages. Subjecting hydroxymethyl 5.19 to 
diphenylphosphoryl chloride and triethyl amine in dichloromethane gave the desired 
phosphate 5.28 in an 80% yield (Scheme 5.19). Removal of the acetonitrile protecting group 
was then achieved by subjecting 5.28 to concentrated HCl in methanol for two minutes 
followed by evaporation to dryness on a rotary evaporator. This gave diol 5.29 as the only 
observed product by NMR and was used without further purification. Subsequent 
deprotection by Birch reduction gave the desired phophocyclopentene 5.3 as the only 
observed product at >95% yield. 
Scheme 5.19. Phosphorylation and deprotection of phosphocyclopentene 5.3. 
 
5.4.3 Inhibition study on cyclopentene phosphate 
The IC50, or the concentration of cyclopentene phosphate 5.3 that provokes a response of 
half of the maximum inhibition, was measured for the M. tuberculosis ATP-PRTase enzyme. 
During these measurements the ability to inhibit catalysis was assessed at various 
concentration of the cyclophopentene phosphate inhibitor while the PRPP and ATP 
concentration were kept constant. It was found that the analogue was able to inhibit the M. 
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tuberculosis ATP-PRTase enzyme with an IC50 of 48 ± 4 µM (Figure 5.4). The IC50 was 
calculated according to Equation 14 employed in the graphpad prism 6.0 program. 























Figure  5.4. Dose response curve for the inhibitor 5.3 against M. tuberculosis ATP-PRTase. Error bars 
represent the error as the standard deviation with each datapoint from at least two independend 
measurements. 
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + (𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚)/(1 + 10((𝑙𝑜𝑔𝐼𝐶50−𝑋)∗𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒)) Equation 14 
 
Cyclopentene phosphate 5.3 was also tested for inhibition again the C. jejuni ATP-PRTase 
enzyme (Section 8.5.3). The inhibitors was expected to be competitive towards PRPP 
binding, therefore the concentration of PRPP was varied (1 to 3 times Km: 11–33 µM)67 while 
keeping ATP concentrations constant (500 µM)(Equation 15 and 16 and Figure 5.5). 
Cyclopentene phosphate 5.3 was found to be a moderate inhibitor for the C. jejuni ATP-




Figure  5.5. Inhibition of C. jejuni ATP-PRTase by cyclopentene 5.3. Inhibition was measured at varying 
PRPP concentration while keeping ATP constant. Error bars represent the error as the standard deviation with 
each datapoint from at least two independend measurements. 
 
𝐾𝑚𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 = 𝐾𝑚 ∗ (1 + [𝐼]/𝐾𝑖) Equation 15 
  




The cyclopentene phosphate was successfully synthesised in eleven steps starting from D-
mannose. This molecule was found to be a inhibitory for both enzymes with an IC50 of 48 ± 
4 µM for the M. tuberculosis ATP-PRTase enzyme and an apparent Ki observed of 282 ± 66 
µM for C. jejuni ATP-PRTase. These results illustrate that inhibition can be observed even if 
small components of the transition state are captured in an analogue. Several attempts at 
co-crystallising (inhibitor concentrations of up to 10mM) or soaking (up to 50 mM) did not 
result in the observation of clear electron density, but based on the structural similarity of 
the inhibitor to PRPP, the cyclopentene phosphate is expected to bind in the PRPP binding 
site. The phosphate group is expected to be accommodated by the phosphate binding loop 
and the cyclopentene ring hydroxyl groups to interacting with Glu141 and Asp154. The 
observation that the cyclopentene phosphate is a competitive inhibitor for PRPP suggests 
that it would form a good starting point for further inhibitor design. The incorporation of 
structural features of the second substrate ATP could be a good starting point for further 
development of this inhibitor (discussed in more detail in Section 7.3.1).  
The iminoribitol phosphate and phosphonate were synthesised from a common 
intermediate in eight and ten steps respectively. It was found that both analogues were 
unable to inhibit the ATP-PRTase enzyme from M. tuberculosis and C. jejuni under the 
conditions tested. This suggests that this initial analogue was unable to mimic enough of 
either the substrates or transition state for effective binding. Given the ability of the 
cyclopentene phosphate 5.3 to outcompete PRPP suggests that the altered geometry 
around the reaction centre is an important aspect of the inhibitor which may not be 
captured enough by the iminoribitol based analogue. An explanation could be the presence 
of a hydrogen at what would normally be the anomeric centre. This could introduce steric 
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constraints with the ATP substrate known to bind first at the active site. As a result this may 
place the ribose ring in a less optimal position for binding and overall result in no observable 
binding under competitive conditions. Extending the iminoribitol towards the ATP binding 












6.1 Fragment based lead discovery  
Fragment based lead discovery (FBLD) is a method proven to be successful in drug design 
and development, with the first fragment derived drug approved by the United States food 
and drug association (U.S. FDA) in 2011, and with another 25 drugs in clinical trials.160,161 
What is of particular interest is that FBLD has been able to provide lead compounds where 
traditional methods such as high throughput screening (HTS) have been unsuccessful. 
Probably the most successful example of this is the development of beta-secretase 1 
(BACE1) inhibitors, with four drugs in clinical trials, all of which were derived from 
fragments.160,162,163 The central idea of fragment based lead discovery is to screen a target 
against low-molecular-weight compounds (≤300 mw) to identify relatively poor inhibitors. 
Although the fragments only bind with low affinity (Kd in micromolar to millimollar range), 
their small size allows exploration of different parts of the target enzyme active site with 
different fragments making the hits highly ligand efficient (LE).164,165 Due to the smaller 
starting point there is more space to further optimise the structure by traditional medicinal 
chemistry with more direct control over the properties of the derived drugs. When multiple 
hits are found merging and linking these specific binders can rapidly enhance potency into 
lead-like compounds.  
The definition of a fragment varies in the literature, but generally compounds with a 
maximum of 14 to 20 (150 to 350 mw) non hydrogen atoms are included.166–168 As with 
Lipinski’s rule of five to evaluate the “druglikeness” of a compound, a similar set of criteria 
has been established for FBLD called the rule of three.169 The rule of three provides a 
guideline for fragments with a molecular weight cut off ≤300 Da, the number of hydrogen 
donors ≤3, the number of hydrogen acceptors ≤3 and a clogP of ≤3. In addition unwanted 
functional groups associated with toxicity, or functionalities that lead to false positives 
(aldehydes, disulphide bonds, etc.) are excluded from the compound libraries.166 The next 
step then is very much dependent on the target (or targets) and chosen method of 
screening. Physical methods for screening these low affinity binders such as nuclear 
magnetic resonance (NMR) and thermal shift measurements only provide a medium 
throughput set up, therefore screening large libraries of several thousand compounds is not 
ideal.170 To ensure that the full chemical space is included in a library a diversity screen is 
sometimes used. A diversity screen looks at the chemical similarity of compounds within a 
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set based on functionalities, such as hydrogen donor, hydrogen acceptor, or hydrophobic 
group, and the distance between the functionalities within a molecule. Compounds with the 
same functionality profile are excluded leading to a diverse small library.171 Virtual screening 
provides another platform which allows for a more target focussed subset of compounds to 
be selected from larger libraries and can substantially reduce the amount of compounds 
that are physically screened. Virtual screening uses computational algorithms to predict the 
binding mode of compounds to a predefined active site.172,173 Scoring function, 
mathematical methods to predict the strength of the non-covalent interactions of a ligand 
and receptor, can then be used to rank the individual compounds according to the quality of 
the interactions. The combination of predicted binding orientation and binding affinity is 
commonly referred to as docking. With the growing interest and success of FBLD substantial 
efforts have been made towards fragment docking and a number of successful examples are 
available.174–176 One of the big challenges generally in docking experiments is the correct 
scoring of the binding energies of the different binding poses. In fragment docking these 
challenges are amplified in the correct scoring of small differences in binding energy for 
different binding poses of small molecules as well as distinguishing quality of binding 
between different fragments.177  
After a fragment library or subset has been obtained the next challenge is screening the 
fragments for binding. The Ligands bind with relatively low affinity, it is therefore essential 
to confirm binding through a variety of techniques. The most common techniques used are 
NMR, surface plasma resonance (SPR), thermal shift assays and X-ray 
crystallography.161,178,179 Of these techniques X-ray crystallography has of particular 
advantage that structural information can be obtained to help make decisions for further 
development of fragments into more lead like compounds easier. When a fragment shows a 
positive result in a combination of techniques this can be considered as a positive hit and a 
starting point for subsequent structure activity relationship (SAR) studies. 
The ATP-PRTase active site was considered an ideal target for this approach as it has a large 
and solvent exposed active site providing a platform for multiple fragments to bind. This 
chapter reports on the virtual screening of a fragment library and ligand screening effort in 
an attempt to find novel scaffolds to inhibit ATP-PRTase from M. tuberculosis. Glide XP part 
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of the Schrödinger software suite was used for docking and the process of receptor 
preparation, docking procedure and selection of potential hits will be discussed. 
6.2 Fragment library docking 
6.2.1 Docking procedure 
The general docking process can be divided in three parts.180 
1. Receptor grid generation: The computational costs of evaluating a target are 
minimised in Glide by employing a grid based approach. A grid is a three dimensional 
description of the binding site which is generated by pre-calculating the interaction-
potentials for each point on the grid. The grid only has to be calculated once which 
significantly speeds up the subsequent evaluation of docking poses.181 
2. The docking methodology employed by Glide uses a series of filters also referred to 
as a “docking funnel” approach. The first step is the evaluation of the initial ligand 
conformations, pre-generated minima in the ligand torsion-angle space in the 
absence of the receptor, across the entire phase space. The poses selected by the 
initial screen are then further optimised in presence of the receptor active site and 
subjected to more exhaustive conformational searches.  
3. The final step is the scoring function. Glide scoring is the empirically based 
ChemScore function of Eldrige et al. which describes contributions and quality of 
hydrophobic interactions, ligand receptor H-bonding interactions, and Coulomb 
interactions.181,182 Steric clashes are panelised. Glide employs two forms of 
GlideScore: (i) GlideScore (SP), used by standard precision Glide docking; (ii) 
GlideScore XP, used by extra-precision Glide docking. The SP scoring function is a 
“softer” more forgiving function and is aimed to minimize false negatives. In contrast 
the XP gives larger penalties for poses that violate physical chemistry principles and 
aims to minimize false positives and can be considered in studies where limited 
numbers of compounds will be screened physically. 
6.2.2 Receptor preparation 
The receptor preparation and the virtual screen were carried out by Dr. W. Jiao. The crystal 
structure of M. tuberculosis ATP-PRTase in complex with the inhibitor AMP and allosteric 
inhibitor histidine was used as the receptor for docking (PDB: 1NH8).47 The receptor 
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preparation was done following the standard procedure used in protein preparation wizard. 
In short, all the water molecules and sulphate ions present in the original structure were 
removed except for the active site ligand AMP, this was kept in the structure to help define 
the centre of the grid file later. The missing hydrogens from the experimental structure 
were placed back in and the H-bonds optimised. After this the structure was minimized. The 
grid file for virtual screening was generated before the virtual screening workflow. Using the 
prepared structure the centre of the grid is defined by centroid of residues within 8 Å of 
Tyr116 and, the grid size was set to “dock ligands with length ≤ 16 Å”. 
6.2.3 Preparation of the library 
The fragment library from the Zinc database of commercially available compounds was used 
for docking.183 The fragment library is a collection of over 500,000 compounds with 
calculated logP values of <= 3.5, molecular weight <= 250 Da, the number of rotational 
bonds <= 5 and unwanted functionalities are removed.183 This set was prepared for docking 
applying Ligprep, part of the Schrödinger program package. The fragment library was 
searched for undefined chiral centres, which were removed, and the ligand protonation 
state was set to be consistent with to pH 8.0 ± 0.5.  
6.2.4 Docking results and compound selection 
The compounds were ranked by GlideXP docking score and the top 500 poses were visually 
inspected. Compounds selections were based on the following criteria: 
 Interactions with key residues in the active site: Ligands that were predicted to form 
positive interactions with residues involved in substrate binding were chosen 
preferentially. 
 Complementary fit to the binding site: Ligands whose van der Waals radii structure 
gave a tight fit with the active sites geometry, e.g. filling up of buried pockets and 
complementary electrostatic potential. 
 Good geometry of ligand-receptor H-bonds: Interactions between a H-bond donor 
atom X-H and an acceptor atom :Y with a free pair of electrons were regarded as H-
bonds if the distance between X and Y was between 1.8 and 3.0 Å, and the X-H-Y 




 Absence of steric clashes: Small clashes between ligand and receptor as well as 
interamolecular clashes were tolerated, however clashes between ligand and key 
residues, multiple small clashed, or any bad clashes were penalised and led to 
rejection of the ligand. 
 Potential for further development: Predicted binding poses that show potential for 
elaboration to other part of the active site where prioritised. 
The active site of M. tuberculosis can be divided in to two sub-sites namely the ATP binding 
site and the PRPP binding site (Section 1.10).38 The key residues are the charged phosphate 
binding loop (Gly 157- Arg 160) and Glu 141 and Asp 154 which are involved in binding the 
2,3-OH groups of the ribose ring. At the time of this research there was no structure 
available with ATP bound to the active site of an ATP-PRTase enzyme. Sacchettini et al. used 
information from the E. coli ATP-PRTase structure with PRATP partially bound (PDB 1Q1K) to 
dock the PRATP product into the active site of M. tuberculosis ATP-PRTase (1NH8). 
Information on the ATP binding site was taken from this study. This work suggested that Asp 
70 interacts with the ribose 2,3-hydroxyl groups and Tyr 116 and Lys 51 formed interaction 
with the triphosphate part of ATP. These residues were considered essential to ligand 
binding and fragments interacting with these portions were chosen preferentially. 
Selections were further based on the position of the fragments across the active site to 
ensure an even distribution and to increase the chance of finding complementary small 
ligands. Based on these criteria a shortlist of approximately 40 compounds was selected 
which were checked for availability, this gave a final short list of 16 compounds that were 
commercially available in sufficient quantity (Figure 6.1). 
The predicted poses of the purchased fragments by docking are shown below, yellow 
dashed line shows the predicted H-bonding interactions. Non polar hydrogen atoms are 




















Figure  6.1. Structures and docking poses of compounds selected and purchased based on the virtual screen of the Zinc fragment library. To the active site of ATP-








































































Figure 6.2.1. (continued)   
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The selected fragments can be divided into three groups based on the predicted position of 
binding. VS1-VS4 generally interact with the phosphate binding loop through a charged 
head group and further reach towards a hydrophobic envelope part of the predicted ATP 
binding site. VS5-VS9 also interact with the charged phosphate binding loop but the side 
groups bridge towards Glu141 and Asp154 and mostly occupy the PRPP binding site. VS10-
VS16 are found at the ATP binding site in the pocket buried deep into the active site of ATP-
PRTase, the side chains mostly sit in a hydrophobic groove. 
A more detailed evaluation of the purchased fragments (Figure 6.1) is given below. 
- VS1 is docked with a rich H-bonding network to the phosphate binding loop. 
Interactions are made with both the carboxylate head group, as well as the ether 
linker. The hydrophobic benzimidazole ring has a complementary fit to the active site 
were the purine base is expected to bind. 
- The predicted docking pose for VS2 forms multiple H-bonding interactions with a 
good geometry to the carboxylate head group. The six membered ring has a 
complementary fit to the active site and the benzoxazole interacting with the 
adenine binding envelope between Ala11 and Val155. 
- VS3 and VS4 share the same charged head group and were chosen for their fit to the 
PRPP binding site. The substituted aromatic rings were chosen to investigate the 
effect of a slightly different substitution pattern. 
- VS5 was the only available fragment that reached all the way across the PRPP 
binding site forming both H-bonding interactions at the phosphate binding loop and 
the backbone oxygen of Ala139. The pyrrole nitrogen could provide an easy way to 
further functionalise this molecule.  
- VS6 The sulphate group resembles the natural substrate’s 5-phosphate group and 
gave a complementary fit to this site. The substitution pattern around the ring could 
allow for rapid expansion of this ligand into other parts of the active site. 
- VS7 the size and multitude of H-bonding around the two carboxyl groups made this 
an interesting ligand. 
- VS8 and VS9 show the same complementary fit of the sulphate to the phosphate 
binding loop as discussed for VS6 and the close resemblance to the adenine ring led 
to the selection of these ligands.  
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- VS10 the amine and hydroxyl provide H-bonding with good geometry and the 
aromatic ring occupies the buried pocket without many bad interactions. This also 
has potential for development towards other part of the active site. 
- VS11 shows an H-bond with Asp70 and a good complementary fit to the hydrophobic 
binding pocket towards Lys51. 
- VS12 the triazole gave a good fit to the buried pocket as well as additional H-bonding 
to the backbone amide of Gly88. In addition the carboxylate gave H-bonds with good 
geometry to the backbone amide of Ala11 and Leu12.  
- VS13 is a similar to VS12, again the pyrazole ring complements the buried pocket and 
the aromatic ring is accommodates a hydrophobic part of the active site. 
- VS14 again shows a complementary fit to the active site and H-bonding with good 
geometry around the carboxylic acid. In addition a hydrogen bonding interaction 
between the secondary amine and Asp70 was predicted. 
- VS15 the primary ammonium ion forms H-bond with good geometry with Asp 70 and 
the five membered ring has a complementary fit to the active site. 
- VS16 this ligand was selected for the complementary fit to the ATP binding pocket. 
6.3 Hit validation 
Validation of fragment binding to a target of interest is one of the challenging aspects of 
fragment based lead discovery, not only do these fragments bind with relative low binding 
constants (Kd), there is the potential for nonspecific binding to either the surface of the 
protein and/or other site such as allosteric sites. To rule out false positives or false negatives 
ideally a fragment is shown to interact with a target through a number of techniques. In this 
study three techniques were attempted, namely; detection by nuclear magnetic resonance 
(NMR), differential scanning fluorimetry (DSF), and crystallography. It is important to note 
that for a part of this research the M. tuberculosis ATP-PRTase enzyme was not available in 
the laboratory. The C. jejuni wt ATP-PRTase and a core mutant of this enzyme, which lacks 
the regulatory domain (domain III), were available and some of the techniques were set up 
using these enzymes. The C. jejuni ATP-PRTase enzyme has variations around the active site 
such as two charged residues around the ATP binding site where the triphosphate part is 
expected to bind and an arginine instead of Ala11. The arginine sits over the adenine 
binding envelope. Despite these differences the C. jejuni ATP-PRTase enzymes were 
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considered a reasonable model system based on similar conserved residues around the rest 
of the active site. In addition small fragments have been shown to interact across targets 
previously with specificity towards a target built in to the inhibitor controlled in the SAR 
stage.184 
6.3.1 Saturation transfer diffusion NMR 
Saturation transfer diffusion (STD) nuclear magnetic resonance (NMR) relies on the ability of 
an enzyme to transfer excitation to interacting ligands. The longitudinal relaxation rate (R1) 
of protons in proteins is dominated by cross relaxation. This allows for selective saturation 
of a single resonance of a protein and through rapid spread of the magnetisation over the 
protein (spin diffusion) the entire protein is saturated.170 When a ligand is interacting 
reversibly with the protein, the ligand will also get saturated. Because the relaxation of 
small molecules is slower than that of the protein the amount of saturated ligand builds up, 
which can subsequently be detected. Because only ligands that interact with the protein are 
excited, these can be visualised specifically.170,185 
This work was carried out in collaboration with Dr H. Wong and Prof. P. Tyler part of the 
Ferrier Research Institute. At the start of the project this technique was not established at 
the University of Canterbury or the Ferrier research institute and work towards establishing 
this technique was carried out first. This work was carried out on the C. jejuni wt ATP-
PRTase enzyme. NMR techniques require longer experiment times so first the stability of the 
enzyme was tested over a six day time period with the specific activity as a measure of 
degradation (appendix I). The enzyme was found sufficiently stable for up to two days under 
conditions similar to that of the NMR experiment. The technique was set up using the 
known inhibitor AMP in presence of two non-binders cyclohexylamine and tryptophan at 2 
mM. After optimisation no signal was observed in absence of the enzyme (Appendix III) 
when the enzyme was added to the sample AMP showed stronger excitation then two non-
binders. A small signal was still observed also for these compounds. The difference was 
considered sufficiently different to identify non binders (Appendix III). When the experiment 
was repeated with a ligand mixture of VS2, VS4 and VS15 two of the three ligands showed 
to interact (Figure 6.2). The ligands that gave a positive signal were VS2 and VS4 predicted 
to bind at the phosphate binding loop towards the adenine binding envelope. To test 
specificity of binding the competitive inhibitor AMP was added, which has been shown 
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crystallographically to bind across this part of the active site as well (Section 1.8.1.2). Known 
binders should compete for binding at the active site and reduce or completely remove 
signals from other ligands. AMP however was unable to reduce the signals arising from the 
tested ligands suggesting non-specific interactions. With the technique being particularly 
time intensive and the limited success this technique was abandoned and other screening 
techniques were considered to test the selected fragments for binding.  
 
Figure  6.2. In blue is shown the STD-difference NMR spectrum with signals from VS2 and VS4. In red is a 
normal 1D-proton spectrum with water suppression of the same sample. 
 
6.3.2 Differential scanning fluorimetry  
Differential scanning fluorimetry (DSF) is a thermal shift assay that quantifies the melting 
temperature (Tm) of a protein. Interaction between a ligand and protein usually induces 
changes in protein thermal stability which modifies the midpoint denaturation 
temperature.186 In a DSF experiments this shows as an increase or decrease in melting 
temperature and the extent of the stabilisation or destabilisation is an indication of the 
strength of binding. In drug discovery efforts generally a stabilising effect, which indicates 
enthalpically driven binding, is desirable for the initial starting point.161,187–189 An enthalpic 
binding event is commonly associated with the formation of H-bonds and sometimes used 
as an indicator for specific molecular interactions with an active site.188,190,191 Although DSF 
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is only a crude indicator for binding the low material cost and relative high throughput 
screening makes it a good initial screening technique. One of the challenges in DSF is that 
small changes in Tm, 0.5-2 °C, may be hidden by the melting profile of a protein through a 
slow transition or multiple small denaturing events.192 Unfavourable melting profiles were 
observed for both M. tuberculosis and C. jejuni ATP-PRTase wt enzyme (Figure 6.3, A and B). 
AMP, a known inhibitor of the ATP-PRTase enzymes, gave no observable change in melting 
temperature for the M. tuberculosis ATP-PRTase enzyme (Figure 6.3, A). With no change in 
melting temperature observed for the natural substrate this technique was considered 
unsuitable for screening the ligands against M. tuberculosis ATP-PRTase. C. jejuni ATP-
PRTase gave a suboptimal baseline however a difference for AMP binding was observed 
(Figure 6.3, B). The functional C. jejuni ATP-PRTase core mutant displayed a much better Tm 
profile for both the unliganded and in presence of AMP (Figure 6.3, C). Based on the melting 
profile the core mutant was considered a better candidate for the DSF work. The fragments 
were screened again the C. jejuni ATP-PRTase core mutant at a concentration of 2 mM and 
using replicates of three (Table 6.1). The blank protein, only containing a small amount of 
DMSO, gave a melting temperature of 48.7 ± 0.2 °C ligand able to invoke a change ≥ ± 1.5 °C 
were considered.  
The fragment screen showed no stabilisation of the target protein for any of the screened 
ligands. Three ligands showed destabilising effects to the protein by more than 1.5 °C with 
the strongest response from VS4, yielding a destabilising effect of -4.3 ± 0.2°C, and VS3 and 
VS13 -1.5 ± 0.2 °C and -2.1 ± 0.2 °C respectively. VS4 also showed a positive response in STD-
NMR however specificity of binding could not be confirmed. The based on the NMR results 






Figure  6.3. The melting profile for M. tuberculosis ATP-PRTase(A), C. jejuni wt ATp-PRTase(B), and C. 
jejuni core mutant ATP-PRTase(C). Red line shows the melting curve for the enzyme in absence of ligands, blue 
line shows the change in melting temperature in presence of known competitive inhibitor AMP at 1 mM. 
Specific melting temperatures where found from the inflection point of the first derivative curve. 
Table  6.1. Results from the fragment screen by DSF for the C. jejuni ATP-PRTase core mutant. The 



































































Conditions to grow apo crystals for C. jejuni wt ATP-PRTase enzyme were not available. The 
C. jejuni ATP-PRTase core mutant on the other hand was successfully crystallised in the apo 
form and the natural ligands ATP, PRPP, and PRATP successfully soaked into these crystals at 
good resolution 1.8-2.2 Å.67 The C. jejuni ATP-PRTase core mutant was crystallised according 
to established procedures, 0.1 M sodium acetate, 0.01 M ZnCl2, 7-10 % w/v PEG 6000, pH 
5.0 protein concentration ≥10 mg/mL.67 Crystals for M. tuberculosis were grown according 
to published conditions, 1.6 M MgSO4, MES pH 6.5 at protein concentration ranging from 15 
to 20 mg/mL.47 Ligands were either co-crystallised at concentrations ranging from 5 to 50 
mM depending on the solubility of the ligand or the apo crystal soaked in presence of the 
ligand at concentrations within the same range. Generally crystals that did not break up or 
dissolve during this treatment were looped, cryoprotected and flash frozen 30-120 min 
afterwards. Several datasets were collected for both enzymes however no ligand density 
was observed for any of the ligands. 
6.4 Discussion 
There were several factors that could contribute to the unsuccessful outcome of this 
project. Firstly, although docking of fragments has been successful and examples have been 
published, correctly docking and scoring of small molecule to a target still remains 
challenging. The incorrect docking tends to arise from incorrect scoring of the generated 
binding poses which in turn arises from the small difference in binding energy for different 
binding poses of the small molecules.177 The incorrect scoring also affects discrimination 
between different fragments and makes distinguishing actual binders harder. In addition to 
test the ability of a docking program to correctly dock a ligand the native substrate and/or 
inhibitors could be used to ensure the ability of the program to correctly model the binding 
poses. Furthermore only a small subset of the high ranking ligands has been purchased for 
testing, the information from the initial screen could be used to feed back into finding 
alternative fragments. 
Effective screening by DSF of the fragment library was challenging for M. tuberculosis ATP-
PRTase with the melting profile hiding stabilisation for the natural ligands making the 
technique unsuitable for this enzyme. The C. jejuni ATP-PRTase core mutant allowed for 
screening of the fragment library, however no stabilisation was observed for any of the 
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selected compounds. With the library tailored for the M. tuberculosis ATP-PRTase enzyme 
and the differences at the active site, such as an Arg16 in place of an alanine in M. 
tuberculosis ATP-PRTase and the later revealed difference in binding mode of ATP, this 
result is maybe not surprising. Three ligands were found to destabilise the C. jejuni ATP-
PRTase core mutant, however their specificity of binding could not be established through 
crystallographic efforts. Crystallisation efforts were made for both enzymes through co-
crystallisation and soaking experiment of all ligands however this did not yield any 













The work discussed in this thesis contributes to the knowledge of the structure and function 
and inhibition of the ATP-PRTase enzyme. All the initial research aims were achieved, with 
two crystal structures of C. jejuni ATP-PRTase providing further insight into substrate binding 
and how this enzyme may function as a hexameric species. Based on the structures a 
structural basis for allosteric inhibition has been proposed. The reaction mechanism was 
successfully investigated through KIE studies and transition state analysis. Furthermore, 
inhibition of the ATP-PRTase enzyme through non-natural ligands was achieved. These 
findings are expanded below. 
7.1 Structural basis for the inhibition of C. jejuni ATP-PRTase 
A crystal structure for the C. jejuni ATP-PRTase enzyme was obtained with the natural 
substrate ATP bound at the active site. This is the first time clear density for this ligand has 
been reported at the active site of the ATP-PRTase enzyme. Previously a dynamic 
equilibrium of oligomeric states with an active dimer and the inhibited hexamer had been 
suggested.193 However, solution studies performed prior to this work did not show a dimeric 
species even at low enzyme concentration, making a dynamic equilibrium unlikely and 
supporting a functional hexamer.66 Analysis of the interface of the active ATP-bound crystal 
structure further supports this finding with a more significant contribution of the trimer 
interface contributing to the hexamer. The hexameric arrangement places the active site 
cavity on the inside of the hexamer, raising the question of how substrates and products 
enter and leave the overall structure. The active ATP bound form of the enzyme has a large 
entry at the trimer interface, and a small entrance can be observed at the dimer interface 
which may provide direct access to the active site. A second structure with histidine and 
AMP bound to C. jejuni ATP-PRTase was also obtained. Comparison of the AMP binding 
mode to the ATP-bound structure supports the competitive nature of AMP towards both 
substrates ATP and PRPP with the competitive inhibitor binding across both sites. These 
findings were consistent with the previously proposed mechanism. The inhibitor-bound 
structure provided further insight into the origin of the reduced activity of the protein in the 
inhibited form and an alternative mechanism of inhibition has been proposed which does 
not require a dimer hexamer equilibrium. The allosterically inhibited structure displays a 
more rigid and narrow structure then the ATP bound form with a more extensive trimer 
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interface. This results from a regulatory twisting motion which brings the monomeric units 
closer together, reducing the size of the entrance at the trimer interface and limiting the 
access into the hexamer interior. Histidine binding further stabilises the hexamer, 
demonstrated by a thermal shift assay which resulted in an increase in thermal stability 
upon binding of the allosteric ligand.66 The reduced dynamics are likely to be partly 
responsible for loss of activity of the inhibited structure. 
7.1.1 ATP binding to ATP-PRTase 
In addition to the ATP bound structure for the C. jejuni ATP-PRTase enzyme, a crystal 
structure with ATP bound at the active site of M. tuberculosis ATP-PRTase was also 
obtained. With the ATP binding site only partially conserved in these two ATP-PRTases, the 
two structures provide insight into how these differences impact the binding mode. The 
binding of the adenosine part was found to be very similar regardless of the variation in 
amino acids around the adenine base. In the C. jejuni ATP-PRTase the adenine base binds in 
a hydrophobic region of the active site with an arginine residue (Arg16) sitting over the top 
forming a π-π stacking interaction. Although directly involved in binding, this residue is not 
conserved in M. tuberculosis ATP-PRTase, where an alanine (Ala11) is found in this position. 
The triphosphate group of ATP for C. jejuni ATP-PRTase is held in place through strong 
interactions with a double aspartate motif through a divalent magnesium cation. This motif 
is not conserved among ATP-PRTase enzymes, and for the M. tuberculosis ATP-PRTase a 
proline is found at this position. Binding of the triphosphate is still associated with Mg2+, 
however fewer interactions occur with the active site directly. Coordination of Mg2+ to the 
triphosphate places the cation in the centre of the active site. An additional Mg2+ cation is 
found at the dimer interface where it is coordinated to the γ-phosphate of two ATP ligands. 





Figure  7.1. ATP binding at the active site of C. jejuni ATP-PRTase with the interactions around Mg2+ 
indicated with yellow dashed lines. Main chain in purple, oxygen in red, nitrogen in blue, sulphur in yellow and 
phosphate in orange. 
 
Figure  7.2. ATP binding at the active site of M. tuberculosis ATP-PRTase with the interactions around 
Mg2+ indicated with yellow dashed lines. Main chain in purple, oxygen in red, nitrogen in blue, sulphur in yellow 
and phosphate in orange. 
7.2 The transition state of ATP-PRTase enzymes 
A kinetic isotope effect guided transition state analysis was conducted for both the long and 
short form of ATP-PRTase. For this study, methods for the chemo-enzymatic synthesis and 
purification of isotopically labelled PRATP, and the conditions for the measurement of 
intrinsic KIEs through internal competition were established. The reaction was studied in the 
reverse direction which allowed commitment to catalysis to be overcome through the use of 
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the pyrophosphate alternative phosphonoacetic acid (PA), lowering commitment values to 
within experimental uncertainty and the measured KIEs were thus intrinsic. The primary 14C 
and α-secondary 3H KIEs were obtained for M. tuberculosis, C. jejuni and L. lactis ATP-
PRTase, showing small primary KIEs of 1.028-1.031. This supports a dissociative reaction 
mechanism for the studied enzymes, further reinforced by the large α-secondary 3H KIEs of 
1.147-1.250. The involvement of ATP was established through 15N isotope effects at the N1 
and N6 position. Transition state models were generated with the experimental KIE values 
forming the boundary conditions for the structures. The transition state was located with 
density functional theory at the B3LYP/6-31+G(d,p) level, and through several iterations a 
close match between the model and experimental values was found. The transition state 
models supported a dissociated reaction mechanism implied by both the primary and α-
secondary KIEs. The ATP-PRTase enzymes for M. tuberculosis, C. jejuni (long forms) and L. 
lactis (short form) were all found to go through dissociative DN*AN‡ reaction mechanism 
with partial bonding to the PA nucleophile at the transition state and a well-developed 
carbocation (Figure 7.3). 
The modelled nitrogen isotope effects support a fully dissociated adenine basis for all 
enzymes, however variations in the involvement of the adenine and tautomeric states were 
predicted. A large primary 15N isotope effect of 1.024 ± 0.001 for M. tuberculosis ATP-
PRTase supports a fully dissociated base as either the neutral N7 or N3 tautomer base, with 
the N3 tautomer considered more likely based on a conserved water molecule. For L. lactis 
ATP-PRTase a primary 15N of similar magnitude to the M. tuberculosis enzyme was observed 
with a KIE of 1.028 ± 0.001. For this enzyme, the N7 protonated state might also be possible 
with the presence of Glu158 in close proximity of the adenine binding site. C. jejuni ATP-
PRTase gave a 15N KIE near unity at 0.995 ± 0.003. A primary nitrogen KIE at unity has not 
been observed previously for a nitrogenous base. A KIE near unity suggests that either no 
change in vibrational freedom takes place or that the bond changes are compensated for at 
the transition state. The difference may arise from a small difference in the overall reaction 
coordinates, with the adenine dissociation step for C. jejuni ATP-PRTase further separated 




The involvement of the incoming nucleophile, phosphonoacetic acid, was still observed at 
the transition state with C1′-OPA atom separation ranging from 2.50 Å for the L. lactis ATP-
PRTase enzyme to 2.65 Å and 2.75 Å for C. jejuni and M. tuberculosis ATP-PRTase enzymes 
respectively. The model further revealed the importance of the catalytically essential Mg2+ 
cation in both anchoring the ribose-5-phosphate and nucleophile in place for effective 
catalysis. Furthermore, the Mg2+ helps stabilise the charged nucleophile at the transition 
state. The positively charged anomeric centre at the transition state was predicted to be 
stabilised by the ribose ring oxygen resulting in a flattened ring and a less negatively charged 
ribose ring oxygen, typical for ribocations (Figure 7.3).  
 
Figure  7.3. At the transition state a well-developed carbocation is formed with partial bonding to the 
incoming nucleophile, which agrees with a DN*AN‡ reaction mechanism.  
 
Overall this study is the first detailed analysis of the transition state of adenosine 
triphosphate phosphoribosyltransferase with the transition state successfully modelled 
based on experimental intrinsic KIE values.  
7.2.1 Future directions 
The transition state models generated in these studies were all calculated in vacuo and 
although this has been used throughout literature to accurately model transition state 
structures, it still raises questions about how interactions from the active site might 
influence the transition state. A quantum mechanics/molecular mechanics (QM/MM) 
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approach may provide further insight into the role of the active site at the transition state. 
In particular the interactions of the active site to the adenine base may provide insight into 
the variations observed around the 15N isotope effects, which are difficult to infer from in 
vacuo calculations alone.  
The active sites of M. tuberculosis, C. jejuni and L. lactis ATP-PRTase all vary to some degree 
particularly around the binding site of the adenine base. Two of the enzymes bind the 
adenine part between the guanidinium group of arginine and hydrophobic residues. 
Although clearly involved in binding, this arginine residue is not conserved. In M. 
tuberculosis ATP-PRTase for example an alanine is found at this position.  Presence of an 
alanine does not alter the binding mode around this part, how the difference in interactions 
influences the transition state is hard to predict. In addition for C. jejuni ATP-PRTase, a 
serine is found in close proximity to the adenine amino group and this residue is not 
observed for the other two enzymes. Mutation of some of the residues involved in adenine 
binding such as Arg16 to an alanine in C. jejuni ATP-PRTase, or Ala11 to an arginine in M. 
tuberculosis ATP-PRTase, and remeasuring the 15N isotope effects could provide further 
insight into the importance of these interactions at the transition state. 
7.3  Fragment based lead discovery 
A fragment based lead discovery technique was explored for the M. tuberculosis ATP-
PRTase enzyme through fragment docking, followed by screening the selected fragments for 
binding. Docking as the first screening technique allowed for a smaller set of compounds to 
be selected for physical screening. A challenge around docking fragments is that scoring the 
weaker interactions can be difficult. A library of over 500,000 fragments was docked into 
the active site of the target enzyme and a selection of compounds acquired. STD-NMR was 
chosen as the first screening technique; however the challenges around setting up the 
technique meant that the method was abandoned. An alternative screening technique was 
therefore explored. DSF provided a platform to screen fragments in a medium throughput 
set up. Here, unfavourable melting profiles made detection of ligand binding for the target 
protein M. tuberculosis ATP-PRTase challenging and the alternative C. jejuni ATP-PRTase 
core mutant was used for screening. This was unable to show any favourable binding from 
the selected fragments. The differences in active site residues particularly around the ATP 
binding may have influenced these results. Overall the uncertainties around the ligand 
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docking in combination with the challenge of screening these small molecules for binding to 
a target enzyme led to an unsatisfactory outcome of this particular part of the project.  
Although the FBLD technique presented was unsuccessful, the large solvent exposed active 
site the ATP-PRTase enzyme should provide a good target for FBLD. Screening of 
commercially available libraries has successfully been used to identify binding fragments 
and may form a better starting point for the screening regimen.194–196 In addition, 
optimisation of the DSF conditions, such as alternative assay buffers, could improve the 
melting profile and allow measurement of the fragments to the M. tuberculosis ATP-PRTase 
enzyme to be made directly. 
7.4  Synthesis and inhibition of ATP-PRTase through non-natural 
inhibition 
Three transition state analogues were designed, synthesised and tested for inhibition for 
inhibition for M. tuberculosis and C. jejuni ATP-PRTase. Although the transition state of ATP-
PRTase was unknown at the time, based on related enzymes a dissociative reaction 
mechanism was expected prior to the design of the transition state analogues. Three 
intermediates were proposed, based on the carbocation intermediate. One analogue, the 
cyclopentene analogue, was designed to represent the altered geometry around the 
anomeric centre of the ribocation species. Two analogues, the iminoribitol phosphate and 
the iminoribostol phosphonate, were based around the charge change at the transition 
state (Figure 7.4). The cyclopentene analogue was shown to be a competitive inhibitor for 
the M. tuberculosis and C. jejuni ATP-PRTase enzymes. This result illustrates that even if 
small parts of the transition state are captured, inhibition may be observed. The iminoribitol 
based analogues were less successful, with no inhibition observed for either of these 
analogues under the conditions tested. The iminoribitol analogue does not capture the 
altered geometry around the anomeric centre. The presence of a hydrogen at this position 




Figure  7.4. The three synthesised transition state analogues. 
7.3.1 Future directions 
The transition state analogues only represent a small part of the full length ligands that are 
able to bind at the active site of ATP-PRTase. Although relatively weak, the observed 
competitive inhibition of the cyclopentene analogue towards PRPP is encouraging. To 
enhance potency, it would be interesting to capture more of the ATP binding interactions. A 
good starting point could be the adenine ring system. The transition state analysis supports 
a fully dissociated adenine base at least 3.0 Å away from the anomeric centre of the ribose 
ring for both C. jejuni and M. tuberculosis ATP-PRTase. A methylene or ethylene bridge 
might therefore need to be included to allow for appropriate positioning of both the 
adenine ring and the ribocation portions of the inhibitor. 
For the cyclopentene based analogues, substitution directly to the double bond will likely 
place the substituent more planar to the ribose ring, making direct linking of the adenine at 
the N1 less than ideal. A crystal structure with PRATP bound to C. jejuni ATP-PRTase core 
mutant shows that the C2 could be a good alternative linking site (Figures 7.5 and 7.6).67 
Another advantage of linking to the C2 position is that it overcomes the problem around the 
Dimroth rearrangement shown to affect N1 substituted adenine rings.99 
Additional structural information through crystallography of the cyclopentene inhibitor 
bound at the active site would provide valuable insight on potential alternative ways to link 




Figure  7.5. PRATP (white) bound at the active site of C. jejuni ATP-PRTase core mutant. Main chain in 
brown, oxygen in red, nitrogen in blue, sulphur in yellow and phosphate in orange. Polar interactions are 
highlighted by yellow dashed lines. 
 
 
Figure  7.6. Example of an expanded cyclopentene-based transition state analogue. 
 
Although the iminoribitol did not demonstrate any inhibition, based on previously reported 
success for these types of inhibitors, it would be worth extending this analogue. The 
addition of an aromatic functional group might place the iminoribitol ring in a better 
position for binding. Given the predicted bond distance of at least 3.0 Å between the N1 and 
the anomeric position it could be worth including a methylene bridge to better mimic this 
feature (Figure 7.7). Furthermore to overcome problems around the Dimroth 
rearrangement it might be advantages to replace the N1 with a carbon atom to provide a 
more stable analogue. 
 
Figure  7.7. Proposed expansion of the iminoribitol based inhibitor. To ensure a stable intermediate the 





Chapter 8  




8.1 General Experimental procedures 
8.1.1 Reagents and solvents 
Reagents were obtained from commercial suppliers and used without further purification 
unless stated otherwise. Before use, solvents were dried by passage through alumina 
columns in a solvent purification system custom-built by the Chemistry Department 
workshop according to published plans.197 
8.1.2 Chromatography 
Merck Kieselgel 60F254 pre-coated aluminium-backed plates were used for all thin layer 
chromatography (TLC). Visualisation of product was achieved by UV lamp at 254nm 
followed by staining with either basic permanganate solution or 10% H2SO4 in ethanol and 
heating in a stream of hot air. Amines were also visualised in acidified ethanolic ninhydrin. 
Flash chromatography was carried out on silica gel, 230-400mesh. Chromatographic 
petroleum ether and ethyl acetate were distilled on a rotary evaporator prior to use; 
analytical grade diethyl ether, toluene, methanol and ethanol were used without further 
purification.  
8.1.3 pH measurements  
A Denver Instruments UB-10 Ultra-Basic pH meter, with a standard probe was used for the 
determination of the pH of all buffers and other aqueous solutions. pH adjustments were 
made using hydrochloric acid, 1 M or 12 M, or sodium hydroxide, 1 M or 10 M. Volatile 
buffers were adjusted in pH by the addition of acetic acid as a 5% solution in Milli-Q or as 
the concentrated acid.  
8.1.4 Mass spectrometry 
The molecular mass of molecules and proteins were determined on by Mass spectroscopy 
on a Bruker maXis 3G UHF-TOF tandem mass spectrometer. Proteins were buffer exchanged 
into 10 mM AcONH4 buffer and analysised at 1 mg/mL. Small molecules were dissolved in 




8.1.5 Preparation of buffers and kinetic assay solutions  
Buffers and kinetic assay solutions were prepared in water purified with a Milli-Q® intergral 
Water Purification system from Merck Millipore, this will be referred to Milli-Q throughout 
this thesis. After preparation and pH adjustments were made all buffers were filtered either 
through a 0.2 micron Durapore®membrane filter or 0.2 micron syringe filter. Assay solutions 
were pH adjusted and filtered through a 0.45 micron syringe filter.  
8.1.6 Enzyme storage 
Concentrated protein solutions (5-15 mg/mL depending on the enzyme) were dispensed 
into aliquots of 50 µL to 200 µL in volume and either flash frozen, by submerging in liquid 
nitrogen or packing in dry ice, or stored at 4 °C, immediately after purification depending on 
the intended use. Enzymes were kept on ice when in use. 
8.1.7 determination of protein concentration 
Protein concentrations were measured by absorbance at 280 nm on a Nanodrop® ND-1000 
spectrometer blanked with the appropriate buffer. The protein concentration was 
calculated from the molar extinction coefficient or by 1% absorbance. Molar extinction 
coefficient values and percentile absorbance’s were calculated from the protein sequence 
using the ProtParam tool on the ExPASy Proteomics server. 
Enzyme  Molar extinction coefficient  
(M-1 cm-1) 
Absorbance (1%)  
(=1 mg/mL) 
C. jejuni ATP-PRTase wt  14440 4.29 
C. jejuni ATP-PRTase core mutant  7450 3.31 
L. lactis ATP-PRTase  26945 5.06 
M. tuberculosis ATP-PRTase  19940 6.54 
   
     
8.1.8 Protein concentration and buffer exchange 
Proteins were concentrated by centrifugation in either a 5 ml or 20 mL concentrator with a 
10,000 Da molecular weight cut off membrane. Buffer exchange was carried out by 
concentrating protein to a small volume followed by dilution with the desired buffer. This 
process was repeated at least 3 times. 
8.1.9 Standard kinetics assay 
The activity of ATP-PRTase enzymes was monitored at 290 nm following a modified 
methods by Morton and Parsons.56 The kinetic assays were carried out on a Varian Cary 100 
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UV-visible spectrophotometer or a Varian Cary 300 UV-visible spectrophotometer. All 
reactions were carried out in quartz cuvettes with a path length of 1 cm. Reaction mixtures 
were prepared by pipetting the appropriate volume from stock solutions. Assays were 
carried out at 25 °C. All kinetic assays where carried out in a tris buffer (100 mM NaCl, 50 
mM KCl, 10 mM MgCl2 and 50 mM Tris pH 8.0). The assay was initiated after the solutions 
were equilibrated in temperature and a steady baseline was observed. Initial rates were 
determined by a linear least square fit of the UV trace from 20 sec to 50 sec after initiation. 
Rate measurements were either as single point measurements or measured as duplicates. 
Fitting of the rate data to models was carried out using the GraphPad Prism 6 program.  
Assay conditions in the physiological/forward direction: A typical assay contained: PRPP (0-
250 µM), ATP (250-750 µM), E. coli PPase (5 x the concentratrion of ATP-PRTase enzyme), 
ATP-PRTase enzyme (50-70 nM L. lactis ATP-PRTase, 160-180 nM C. jejuni ATP-PRTase, 280-
300 nM M. tuberculosis ATP-PRTase), and assay buffer to make up 1 mL reaction volume. 
Reactions were initiated by the addition of PRPP, or sometimes ATP-PRTase enzyme after 
equilibration.  
Assay conditions in the reverse direction typical assays contained: PPi (0-2 mM), PRATP (0-
200 µM PRATP), ATP-PRTase enzyme (50-70 nM L. lactis ATP-PRTase, 160-180 nM C. jejuni 
ATP-PRTase, 280-300 nM M. tuberculosis ATP-PRTase), and assay buffer to make up 1 mL 
reaction volume. Reactions were initiated by the addition of PPi, or in some cases PRATP. 
8.1.10 Determination of PRPP and PRATP concentration 
Reactions were carried out as outlined in section 8.1.9. The concentration of PRPP was 
determined by the addition of a limiting amount of PRPP and an excess of ATP at least 20 
times the concentration of that expected for PRPP. The reaction was initiated by the 
addition of PRPP and the reactions were allowed to go to completion (stable baseline). The 
change in absorbance (Δreaction) was corrected for the increase in absorbance by addition of 
PRPP (ΔPRPP) in absence of enzyme(Δabsorbance = Δreaction – ΔPRPP). Normal Lamber Beer law was 
then used to calculate the concentration in the reaction assay. The concentratrion of the 
stock solution was then back calculated from this. The molar extinction coefficient of 3600 
M-1 cm-1 was used to calculate the concentration.56 
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The concentration of PRATP was either determined by standard kinetic assays or on a 
Nanodrop® ND-1000 spectrometer blanked with the appropriate buffer measuring at a 
wavelength of 290 nm and ensuring a pH of 8.0. Lambert Beer law was used to calculated 
the concentration (molar extinction coefficient of 3600 M-1 cm-1).  Determination of PRATP 
by standard kinetic assay conditions was carried out similar to the method described for 
PRPP. To ensure completion of the reaction pyrophosphate was added in access (1 mM to 
1.5 mM) over the PRATP substrate. The reaction was initiated by the addition of enzyme and 
the reactions were allowed to go to completion (stable baseline). again the change in 
absorbance was corrected for the addition of the enzyme. 
All concentration determinations were carried out in duplicates or triplicates. 
8.1.11 Purification of E. coli PPase 
E. coli PPase/pDEST17/E.coli Bl21* (DE3) cell cultures were grown in autoclaved LB (Lennox 
LB) at 20 g/L containing the appropriate antibiotics (Ampicillin, chloroamphenicol). Pre-
cultures in LB (Lennox LB) media containing the appropriate antibiotics were inoculated 
using a single culture grown from a glycerol stock and grown overnight with shaking (180 
rpm) at 37 °C. Approximately 20 mL of pre-culture per litre of cell culture were used to 
inoculate growths (OD600 of 0.1 AU). Cells were grown at 37 °C until mid-logarithmic phase 
(OD600 of 0.4–0.6 AU) and protein expression was induced by addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG, 0.5 mM final concentration). Growth was continued for an 
additional 4 hours and the cells then harvested by centrifugation (14,000 g for 15 min at 4 
°C). The cell pellet was flash-frozen in liquid nitrogen and stored at −80 oC. Prior to use the 
cell pellet was thawed and then resuspended in low imidazole buffer (50 mM Na2HPO4, 
500mM NaCl, 5mM MgCl2 and 20mM imidazole at pH 8.5), lysed for 3x 5min 70 % power at 
30% pulsation, and then spun down for 30 min at 40,000 g. The E. coli PPase enzyme was in 
the insoluble fraction at this stage. The supernatant was discarded and the pellet dissolved 
in 8 M urea, left to stand on ice for 20 min after which it was diluted 10 times. This was spun 
down again for 30 min at 40,000 g. The supernatant was then filtered and loaded onto a 5 
mL GE Healthcare His trap HP column. Protein which bound to the column was eluted with 
high imidazole buffer (50 mM Na2HPO4, 500mM NaCl, 5mM MgCl2 and 500mM imidazole at 
pH 8.5). E. coli PPase would elute as two peaks with the first peak containing soluble active 
E. coli PPase, the second peak precipitated out after a few minutes. Fractions containing 
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active enzyme were pooled together and buffer exchanged into a Tris buffer (50mM Tris, 
100mM NaCl, 5mM MgCl2 at pH 8.0). The enzyme was then concentrated to 4 mg/mL 
aliquoted out into 50 µL portions and flash-frozen in liquid N2 and stored at -80 °C.  
8.1.12 Protein structure and molecular model figures 
The Protein structure and molecular model figures were all generated using PyMOL 
Molecular Graphics System version 1.7.4.0 from Schrodinger©, LLC. Density maps represent 
the unbiased ligand density (FO – FC) contoured at 3.0. 
8.1.13  Polymerase chain reaction (PCR) 
PCR reactions were carried out using a Veriti 96 well thermal cycle AB applied biosystems. 
The PCR reactions were carried out using the In-Fusion® Cloning kit with Phusion® High-
Fidelity DNA Polymerase (Clonetech ®). Reactions were set up on a 50 µL scale according to 
Table 8.1. The amplification protocol outlined in Table 8.2 was used for the PCR reaction. 
Products were purified by agarose gel electrophoresis. 
Table  8.1. The reaction components for PCRs. 
Component  Per 50 µL reaction 
Buffer 5x  10 µL 
dNTP mix (10 mM of each dNTP)  1 µL 
FWD Primer  2.5 µL 
REV Primer  2.5 µL 
Template DNA  1 µL 
Phusion DNA Polymerase  0.5 µL 
Nuclease free water  32.5 µL 
Table  8.2. Touch down PCR protocol. 
Stage Temperature (°C) Time (min) Cycles 















4 72.0 10.0 1 x 
 8.1.14 Colony PCR 
Colony PCR reactions were carried out using a Veriti 96 well thermal cycle AB applied 
biosystems. The PCR reactions were carried out using taq DNA Polymerase (Invitrogen®). 
Reactions were set up on a 25 µL scale according to table 8.3. Template DNA was added as a 
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small amount of a single colony. The amplification protocol was according to manufacturer’s 
instructions.  
Table  8.3.  The reaction components for PCRs. 
Component  Per 50 µL reaction 
Standard taq buffer  2.5 µL 
dNTP mix (10 mM of each dNTP)  0.5 µL 
T7 FWD Primer (10 µM)  0.5 µL 
T7 REV Primer (10 µM)  0.5 µL 
Template DNA  1 colony 
Taq DNA Polymerase  0.125 µL 
Nuclease free water  20.88 µL 
 
8.1.15  Agarose gel electrophoresis 
Agarose gel electrophoresis was carried out on a Mini-Sub® Cell GT (Bio-Rad). Visualisation 
and photographs of DNA were done using a Molecular Imager® Gel DocTM XR (Bio-Rad). 
Agerose gel was prepared by mixing 0.3 gram of agarose with 29.4 mL of Milli-Q water and 
600 µL 50 X TAE buffer (2.5 M Tris, 50 mM EDTA, 1 M acetic acid). Agarose was dissolved by 
heating using a microwave until fully dissolved. The gel was allowed to cool to 
approximately 60 °C in the oven (approximately 20 min) followed by the addition of 3 µL 
SYBSafe dye. After mixing the gel was poured into a sealed gel tray including a comb and left 
to set. 1 portion loading dye (60 mM Tris-HCl, 60 mM EDTA, 0.2% (w/v) orange G, 0.05% 
(w/v) xylene cyanol, 60% (v/v) glycerol) was mixed with 5 portions sample and loaded on 
the gel. A DNA ladder was also included for size identification purposes. The electrophoresis 
was performed for 45 min at 80 V. 
8.1.16  Transformation 
Appropriate chemically competent cells (50 µL) were carefully thawed on ice followed by 
the addition of purified plasmid (75 – 120 ng/µL). The cells were left to stand on ice for 30 
min then placed on a heat block at 42 °C for 30-45 seconds and then back on ice for 2 
minutes. To this 250 µL of SOC medium (2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgSO4, 20 mM glucose. Filter sterilised) was added and left to 
grow at 37 °C for 1 hour. The transformed cells (20 µL to 100 µL) were plated out on LB-agar 
containing the appropriate antibiotic(s) and left to grow overnight at 37 °C. 
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8.1.17  Plasmid extraction and purification 
Cells used for plasmid extraction and purification were grown overnight as 5 mL cultures in 
presence of the appropriate antibiotic(s). Typically 1 mL of culture was processed according 
to procedures provided with the extraction kit. (ZR Plasmid miniprepTM –classic, Zymo 
Research) concentration of the purified plasmid was established by measuring the 
absorbance at 260 nm an on appropriately blanked Nanodrop ND-1000 spectrophotometer. 
8.1.18  Sequencing 
The verification of the DNA sequence was performed after subcloning into the destination 
vector. Candidates for sequencing were identified by colony PCR as described in Section 
8.1.14. Sequencing was carried out by Massy university, Palmerston north NZ. Samples were 
prepared with 60-125 ng and 4 pM T7 FWD or REV primers made up to 20 µL with nuclease 
free water. 
8.1.19  Glycerol stocks 
Glycerol stocks were made from cell cultures grown overnight at 37 °C in presence of the 
appropriate antibiotics. 800 µL of cell culture was mixed with 400 µL of autoclaved glycerol 
(50% v/v) stock solution and flash frozen by submerging in liquid nitrogen. Stocks were 
made either in a 1.6 mL sterile Eppendorf or screw-top tube. 
8.1.20  General procedure protein expression in autoinduction media 
The method developed by Studier was used for autoinduction of protein expression.198 
general description for a 1 liter culture: To 960 mL of water was added 10 g tryptone and 5 g 
yeast extract and autoclaved  in a 3 liter baffled flask. To this 20 mL 50 X M stock solution 
(1.25 M Na2HPO4, 1.25 M KH2PO4, 2.5 M NH4Cl, 0.25 M Na2SO4. Autoclaved), 20 mL 50 X 
5052 stock solution (25% (w/v) glycerol, 2.5% (w/v) glucose, and 10% (w/v) lactose, filter 
sterilised),0.2 mL trace metal solution (50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2/ZnSO4, 2 
mM CoCl2, 2 mM CuCl2, 2 mM NiCl2, 2 mM NaMoO4, 2mM Na2SeO3, and  2mM H3Bo3 in 60 
mM HCl) and 1 mL of 1M MgSO4 was added. This culture medium was inoculated with pre-
culture to yield a starting OD600 of 0.1 AU. Cultures were grown at 37 °C for 20 hours with 
shaking (180 rpm).  
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8.1.21  antibiotics  
Antibiotics used were added from a 1000 times concentrated stock. Stocks were prepared in 
batch and stored at -80 °C. Sufficient stock was added to achieve final concentrations of 100 
µg/mL ampicillin, 50 µg/mL kanamycin, 50 µg/mL spectinomycin and chloramphenicol 25 
µg/mL. 
8.1.22  Cell lysis 
Cell lysis was carried by sonication on a Omni-Ruptor 4000 Ultrasonic Homogenizer from 
Omni International. Typically the cell pellet was resuspended in ice cooled lysis buffer (20 
mL to 100 mL) and 2 µL Benzonase nuclease® (Novagen) was added to break down DNA. 
Sonication was performed in a glass beaker surrounded by packet ice generally for 3 cycles 
of  5 min at 30 % to 40 % pulsation and 70 % power. 
The soluble fraction was separated by centrifugation at 40,000 g for 30 min at 4°C, 
transferred to a clean tube and spun for an additional 15 min. 
8.2 Experimental procedures for chapter 2 
8.2.1 Cloning of M. tuberculosis ATP-PRTase 
The cloning of M. tuberculosis ATP-PRT made use of the In-Fusion® HD Cloning Kit 
(Clontech® Laboratories Inc.). Primer design was carried out by Dr G. Mittlestädt according 
to published procedures. In the FWD primer the thrombin cleavage site was replaced by a 
TEV recognition site. PCR was carried out according to Section 8.1.13, PCR fragments were 
assessed for appropriate size by agarose gel electrophoresis and ligated into vector pET28a. 
MtuHisGin28aFWD:  CGCGCGGCAGCCATATGGAAAACCTGTATTTTCAGGGCAGCGGCGCGATG 
   CTGCGGGTCGCGGTTCC 
MtuHisGin28aREV: GGTGGTGGTGCTCGAGTCATCAGAATCGGCAGAACCTGAT 
8.2.2 Purification of Campylobacter jejuni ATP-PRTase  
Expression and purification of C. jejuni ATP-PRTase was carried out according to established 
procedures by Dr G. H. mittlestäd. C. jejuni ATP-PRTase/pDEST17/E.coli Bl21* (DE3) 
pBB540/pBB542 (Chaperone 3) cell cultures were grown in autoclaved LB (Lennox LB) at 20 
g/L containing the appropriate antibiotics (Ampicillin, chloroamphenicol and 
spectinomycin). Pre-cultures in LB (Lennox LB) media containing the appropriate antibiotics 
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were inoculated using a single culture grown from a glycerol stock or on an agar plate and 
grown overnight with shaking (180 rpm) at 37 °C. Approximately 20 mL of pre-culture per 
litre of cell culture were used to inoculate growths (OD600 of 0.1 AU). Cells were grown at 37 
°C until mid-logarithmic phase (OD600 of 0.4–0.6 AU). The temperature was lowered to 23 °C 
before induction of protein expression by addition of isopropyl β-D-1-thiogalactopyranoside 
(IPTG, 0.5 mM final concentration), and growth was continued overnight. Cells were 
harvested by centrifugation (14,000 g for 15 min at 4 °C) and the cell pellet was flash-frozen 
in liquid nitrogen and stored at −80 °C for purification at a later stage or used the same day. 
The cell pellet was resuspended in low imidazole buffer (50 mM Na2HPO4, 500 mM NaCl, 5 
mM MgCl2 and 20 mM imidazole at pH 8.5), lysed for 3x 5min 80 %, spun down for 30 min at 
40,000 g. The supernatant was filtered and loaded onto a 5 mL GE Healthcare His trap HP 
column. Protein which bound to the column was eluted with high imidazole buffer (50 mM 
Na2HPO4, 500 mM NaCl, 5 mM MgCl2 and 500 mM imidazole at pH 8.5) and fractions 
containing enzyme were pooled together. Pooled fractions were buffer exchanged into a 
Tris buffer (50 mM Tris, 100 mM NaCl, 5 mM MgCl2 at pH 8.5) and treated with TEV 
protease at a 1% mol/mol concentration at 4°C for three days. TEV treated enzyme was run 
through a 26/60 size exclusion column into buffer containing 50 mM Tris and 100mM NaCl 
at pH 8.5. Fractions containing C. jejuni ATP-PRTase were concentrated and 50 µL aliquots at 
a concentration of 10-12 mg/mL, flash-frozen in liquid N2 and stored at -80 °C. 2 litres of 
culture would yield approximately 20-30 mg of protein per purification 
8.2.3 Purification of ATP-PRTase from Mycobacterium tuberculosis 
Expression and purification of M. tuberculosis ATP-PRTase was carried out according to 
published procedures.47,70 M. tuberculosis ATP-PRTase/pET28a/ E. coli BL21 (DE3) Star pLysS 
cell cultures were grown in autoinduction media (Methods 8.1.20)containing Kanamycin. 
Pre-cultures (50-100 mL) in LB (Lennox LB) media containing Kanamycin were inoculated 
using a single culture as a glycerol stock or from an agar plate and grown overnight with 
shaking (180 rpm) at 37 °C. Approximately 40 mL of pre-culture per litre of cell culture were 
used to inoculate growths (OD600 of 0.1 AU). Cells were grown with shaking (180 rpm) at 37 
°C for 1 day. Cells were harvested by centrifugation (14,000 g for 15 min at 4 °C). The cell 
pellet was resuspended in low imidazole buffer (50 mM Na2HPO4, 500mM NaCl and 10mM 
imidazole at pH 7.8), lysed for 3x 5min 80% power and 30% pulse, spun down for 30 min at 
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40,000 g, supernatant transferred to a second tube and spun for a further 15 min at 40,000 
g. The supernatant was filtered and loaded onto a 5 mL GE Healthcare Hitrap TALON® crude 
column. Protein which bound to the column was eluted with high imidazole buffer (50 mM 
Na2HPO4, 500 mM NaCl, and 250 mM imidazole at pH 7.8) and fractions containing enzyme 
were pooled together. Pooled fractions were buffer exchanged into a Tris buffer (50 mM 
Tris, 100 mM NaCl, 5 mM MgCl2 at pH 7.8) and treated with TEV protease at a 1% mol/mol 
concentration at 37 °C for 2-3 hours. TEV treated enzyme was run through a 26/60 size 
exclusion column into Tris buffer. Fractions containing M. tuberculosis ATP-PRTase were 
concentrated to 15-20 mg/mL and divided into 50-100 µL aliquots and either used within 
the next week or flash-frozen in liquid N2 and stored at -80 °C. A 1 litre culture typically 
yielded approximately 100 mg of pure active protein. 
8.2.4 Crystallography 
8.2.4.1 Data collection and processing 
Single crystal X-ray diffraction data was collected at the Australian Synchrotron on the MX1 
and MX2 beamlines running the Blu-Ice software. XDS, iMosflm, and aimless were used for 
data processing. 199–201 Resolution cut-off was based on CC1/2 > 0.5 values.202  
8.2.4.2 Crystal conditions for M. tuberculosis ATP-PRTase 
Crystals were grown according to published conditions for the growth of APO crystals (1.8 M 
MgSO4, 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) pH 6.5) with the addition of 10 
mM ATP. Crystals were obtained by mixing equal volume of 15-20 mg/mL protein with 90-
100% condition (1-2µL each) using the hanging drop vapour diffusion method. Crystals 
formed  between 12 to 48 hours. Crystals grew as uniform triangular prisms of various size. 
Protein crystals were cryoprotected by dipping the crystal in a second droplet of condition 
including 20% glycerol.  
8.2.4.3 Structure solution M. tuberculosis ATP-PRTase 
Initial phases were solved by a molecular replacement strategy using the CCP4 program 
suite.201 The initial search model was generated from the APO M. tuberculosis ATP-PRT (PDB 
code: 1NH7). The ligands and water molecules were removed from the search model. 
Refinement of the structure was done using multiple rounds of refinement using coot.203 
The structure was validated using the MolProbity server and wwPDB validation server.204,205 
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8.2.4.4 Crystal conditions for C. jejuni ATP-PRTase 
Initial crystallisation screens were performed with mosquito® Crystal robot (TTP Labtech), 
and the JCSG-plusTM HT-96, Clear StrategyTM I HT-96 and Clear StrategyTM II HT-96 
crystallisation screens (Molecular Dimensions), and 96-well sitting drop iQ plates (TTP 
Labtech). Each compartment contained 40 µL condition which was mixed 1/1 v/v with 
protein to give a final drop volume of 800 nL. Screens were set up with freshly purified 
protein premixed with either ATP or His/AMP. A final protein concentration of 3.5 mg/mL in 
the drop was used. This yielded a number of promising conditions which were further 
optimised. Optimisations were carried out on a 24-well VDX plates (Hampton Research) 
using hanging-drop vapour diffusion at 20 °C. Wells would contain 500 µL condition and 
protein was mixed 1/1 with condition. The His/AMP crystals were put down at 2 µL and the 
ATP crystals were put down at 4 µL. Slow addition of an equil volume of 40 % glycerol in 
conditions  to the crystal drop prior to crystal looping provided cryoprotection 
 
Screening condition Ligand concentration Refined condition  




0.1 M Tris pH 7.5 
0.2 M MgCl2 
13-15 % w/vPEG 4000 
Clear strategyTM I HT-96 
A9 
10 M ATP 
0.1 M AcONa pH 5.5 
0.1 M MgCl2 
13-15 % w/vPEG 4000 
 
8.2.4.5 Structure solution C. jejuni ATP-PRTase 
Initial phases were solved by a molecular replacement strategy using the CCP4 program 
suite.201 The initial search model was generated from C. jejuni ATP-PRTase with histidine 
bound (PDB code: 4YB5). For the His/AMP bound structure the search model contained the 
full hexamer which gave a single solution, further refinement of the structure was done 
using coot.203 The search model for the ATP bound structure containing only domain I and II. 
A suitable dimeric unit was identified and used in subsequent runs until two hexameric 
arrangement were found. The missing regulatory domains were added through multiple 
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rounds of refinement using Coot. Both structures were validated using the MolProbity 
server and wwPDB validation server before deposition.204,205 
8.3 Experimental procedures for chapter 3 
8.3.1. Expression and purification of M. tuberculosis PRPPase. 
Plasmids encoding the M. tuberculosis PRPPase gene were kindly provided by Prof V. L. 
Schramm. M. tuberculosis PRPPase/E.coli Bl21 (DE3) pBB540/pBB542 (Chaperone 3) cell 
cultures were grown in autoclaved LB (Lennox LB) at 20 g L-1 containing the appropriate 
antibiotics (Kanamycin , chloramphenicol and spectinomycin). Pre-cultures in LB (Lennox LB) 
media containing the appropriate antibiotics were inoculated using a single culture grown 
from a glycerol stock or on an agar plate and grown overnight with shaking (180 rpm) at 37 
oC. approximately 45 mL of pre-culture per litre of cell culture were used to inoculate 
growths (OD600 of 0.1 AU). Cells were grown at 37 oC until mid-logarithmic phase (OD600 of 
0.4–0.6 AU). The temperature was lowered to 23 oC before induction of protein expression 
by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.1 mM final concentration), 
and growth was continued overnight. Cells were harvested by centrifugation (14,000 g for 
15 min at 4 ºC) and the cell pellet was either used the same day or flash-frozen in liquid 
nitrogen and stored at −80 oC for purification at a later date. The cell pellet of 2 liters of cell 
culture was resuspended in 40mL of low imidazole buffer (50 mM Na2HPO4, 300 mM NaCl 
and 20mM imidazole at pH 8.5), lysed for 3x 5min 80%, spun down for 30 min at 40,000 g. 
The supernatant was filtered and loaded onto a 5 mL GE Healthcare His trap HP colomn. 
Protein which bound to the column was eluted over a 4 CV gradient with high imidazole 
buffer (50 mM Na2HPO4, 500mM NaCl, 5mM MgCl2 and 450mM imidazole at pH 8.5) 
resulting in two elution peaks. The second peak corresponded to the protein of interest and 
fractions containing enzyme were pooled together (Figure 8.1). Pooled fractions were buffer 
exchanged into a tris buffer (50 mM Tris, 100mM NaCl, 5 mM MgCl2 at pH 8.5). The protein 
was then concentrated to approximately 5 mg/mL and devided into 50 µL aliquots, flash-
frozen in liquid N2 and stored at -80 °C. 2 litres of culture would yield approximately 50 mg 





Figure  8.1. PRPPase SDS page gel. Lane 1 cell pellet, lane 2 Peak 1, Lane 3 the target protein as peak 2. 
 
8.3.2 Purification of ribose kinase 
Plasmids encoding the His tagged gene were kindly provided by Prof V. L. Schramm. Ribose 
kinase/E.coli TOP10 cell cultures were grown in autoclaved LB (Lennox LB) at 20 g L-1 
containing 50 µg/mL ampicillin. Pre-cultures in LB (Lennox LB) media containing the 
appropriate antibiotics were inoculated using a single culture grown from a glycerol stock 
and grown overnight with shaking (180 rpm) at 37 oC. approximately 20 mL of pre-culture 
per litre of cell culture were used to inoculate 1L growths (OD600 of 0.1 AU). Cells were 
grown at 37 oC until mid-logarithmic phase (OD600 of 0.4–0.6 AU). Protein expression was 
induced with 0.2 % L(+)-arabinose (2 g/L) final concentration, and growth was continued for 
at least 4 hours. Cells were harvested by centrifugation (14,000 g for 15 min at 4 °C) and the 
cell pellet washed with cold buffer (50 mM Tris HCl, 300 mM NaCl, at pH 7.8), centrifuged 
another time (14,000 g for 15 min at 4 ºC). The cell pellet of 1 liter of cell culture was 
resuspended in 20mL of Tris buffer (50 mM Tris HCl, 300 mM NaCl at pH 7.8), lysed for 3x 





a 5 mL GE Healthcare His trap HP colomn. Protein which bound to the column was eluted 
over an 7CV gradient with RK eluting as a single peak with high imidazole buffer (50 mM Tris 
HCl, 300 mM NaCl, and 450 mM imidazole at pH 8.5). Fractions containing enzyme were 
pooled together (Figure 8.2). Pooled fractions were buffer exchanged into a low imidazole 
buffer (50mM Tris, 100mM NaCl, 5mM MgCl2 at pH 8.5). The protein was then concentrated 
to approximately 10 mg/mL and devided into 50 µL aliquots, flash-frozen in liquid N2 and 
stored at -80 °C. 1 litres of culture would yield approximately 70 mg of protein per 
purification.  
 
Figure  8.2. Gel image of fraction containing ribokinase. 
 
8.3.3 Methods 
8.3.3.1 synthesis of [1-15N]adenine: 
[1-15N]adenine 3.6: A mass spectrometry vial containing a stir bar and 4-





flow of nitrogen gas for 30 min. 0.5 mL of 15N formamide (Cambridge Isotope Laboratories) 
was added and the 4-amino-imidazole-5-carbonitrile was fully dissolved before heating on a 
preheated oil bath at 180 °C for 2.5 hours with active stirring. The reaction was allowed to 
cool down upon which solids formed. The crude reaction mixture was further cooled on ice 
for 30 min and solids filtered over a cotton wool plug. The excess 15N formamide was 
recovered. The solids were washed 2 X with ice cold water to give the final [1-15N]adenine 
product as a yellow powder which was used without further purification. (35 mg, 52% yield). 
The spectroscopic analysis was in agreement with reported literature for this structure.100 IR 
(ν): 537.6, 633.1, 720.3, 793.6, 843.1, 903.5, 936.3, 1123.3, 1246.2, 1305.0, 1365.7, 1416.3, 
1448.9, 1591.1, 1668.5, 2788.4, 3107.4 cm-1): 1H NMR (400 MHz, DMSO-D6); δ 7.06 (bs, 2H, 
NH2), 8.07 (s, 1H, H8), 8.09 (d, J = 15.3 1H, H2); HRMS(ESI) m/z calcld. for [C5H6N415N]+: 
137.0588 obsd.: 137.0583.  
8.3.3.2 [6-15N]Adenine synthesis 
6-Chloro-N9-(2-tetrahydropyranyl)-purine (3.9): 6-chloro-purine (1.94 mmol, 
300mg) was heated to 60°C in 7 mL of ethyl acetate. Pare-toluenesulphonic 
acid (0.1 mmol, 20 mg) was added and the suspension left to stir for an 
additional 20 min. 2,3-dihydro-2H-pyran (2.52 mmol, 230 µL) was dropwise 
added over 5-10 min. after approximately 10 min all solids were dissolved and the resulting 
mixture left to stir for an additional 1.5 hours.  t.l.c. analysis (CH2Cl2/MeOH, 95/5, v/v) 
showed formation of a higher running product (Rf 0.4). Concentrated ammonia was added, 
0.2 mL, left to stir for an additional 5 min and the organic phase washed 2 X with water and 
1x with brine, dried over anhydrous MgSO4 and filtered. Purification by flash 
chromatography (silica gel, CH2Cl2/MeOH, 96/4, v/v) gave the title compound 3.5 as a white 
solid at 93% yield (430 mg, 1.8 mmol). The product was in good agreement with the 
reported spectra.103 IR (ν): cm-1): 1H NMR (400 MHz, DMSO-D6); δ 1.56-1.62 (m, 2H, 2xH4′), 
1.68-1.78 (m, 1H, H3′b), 1.79-2.02 (m, 2H, H2′b, H3′a), 2.27-2.37 (m, 1H, H2′a), 3.67-3.74 (m, 
1H, H5′b), 3.99-4.02 (m, 1H, H5′a), 5.77 (dd, J = 2 Hz, J = 10.8 Hz, 1H, H1′), 8.78, 8.89 (2x s, 2x 
1H, H2, H8); 13C NMR (101 MHz, DMSO-D6); δ 22.64 (C2′), 24.87 (C4′), 30.12 (C3′), 68.20 




N9-(2-Tetrahydropyranyl)-[6-15N]-adenine (3.10): To a Kevlar® coated metal 
pressure reactor 6-Chloro-N9-(2-tetrahydropyranyl)-purine 3.5 (0.1.27 mmol, 
300 mg), NaHCO3 (3.77 mmol, 318 mg), and 15NH4Cl (2.5 mmol, 139 mg) was 
added. DMSO (1.9 mL) was added and the reactor sealed immediately after 
this to enclose the released ammonia. The reactor was heated at 80 °C for 4.5 days. The 
resulting suspension was filtered through celite and concentrated on a rotary evaporator (1 
day). Purification by flash chromatography (silica gel, CH2Cl2/MeOH, 99/1  96/4, v/v) gave 
the title compound 3.3 as a white solid at 84% yield (430 mg, 1.8 mmol). The product was in 
good agreement with the reported spectra.103 IR (ν): 449.8, 485.0, 544.4, 567.6, 634.7, 
648.7, 675.3, 781.8, 794.9, 821.6, 856.2, 877.2, 904.5, 948.1, 1040.5, 1082.6, 1108.9, 
1143.5, 1179.1, 1207.0, 1221.9, 1266.1, 1335.7, 1396.3, 1442.5, 1483.8, 1563.3, 1592.7 cm-
1: 1H NMR (400 MHz, DMSO-D6); δ 1.60-1.80 (m, 3H, H3′b, 2x H4′), 1.96-2.11 (m, 3H, 2xH2′, 
H3′a), 3.75 (t, J = 11.7 Hz, 1H, H5′b), 4.14 (d, J = 12.0 Hz, 1H, H5′a), 5.69 (d, J = 10.8 Hz, 1H, 
H1′), 6.31 (d, J = 90.0 Hz, 2H, 15NH2), 8.01, 8.34 (2x s, 1x1H, H2, H8); 13C NMR (101 MHz, 
DMSO-D6); δ 22.79 (C3′), 24.87 (C4′), 31.87 (C2′), 68.77 (C5′), 81.85 (C1′), 138.23, 149.24, 
152.85, 155.52, 155.72 (C2, C4, C5, C6, C8). 
[6-15N]-Adenine (3.8). N9-(2-Tetrahydropyranyl)-[6-15N]-adenine (3.6) (1.07 
mmol, 234 mg) was dissolved in dioxane (3.8 mL) and 7.6 mL 0.01 M HCl in 
water added. The pH was further adjusted to 2.0 by the addition of 20 drops of 
concentrated HCl. After addition of acid a cloudy solution is formed which went 
clear after 15 min of additional stirring. The reaction was left overnight and then the volume 
reduced to 20 mL. an additional 20 mL of water was added and the volume reduced to 20 
mL. This step was repeated 3 times and the solution further neutralised by the addition of 
NaHCO3 (~pH 7.0 by pH paper) and concentrated. This gave [6-15N]adenine as the only 
observed product. The adenine product was in good agreement with the reported 
spectra.103 IR (ν): 537.6, 632.9, 720.2, 793.5, 843.3, 903.4, 936.1, 1123.4, 1246.1, 1304.8, 
1365.7, 1416.3, 1589.8, 1668.2, 2785.7, 3076.6 cm-1: 1H NMR (400 MHz, DMSO-D6); δ 7.06 
(d, J = 89.6 Hz, 15NH2), 8.07, 8.09 (2x s, 2x 1H, H2, H8); 13C NMR (101 MHz, DMSO-D6); δ 
117.56, 140.44, 152.62, 155.36, 155.57 (C2, C4, C5, C6, C8). HRMS(ESI) m/z calcld. for 
[C5H6N415N]+: 137.0588, obsd.: 137.0594. 
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8.3.4 Coupled enzymatic synthesis of PRATP from ribose 
Reactions were set up according to the condition outline in table 8.4, generally on a 12.5 mL 
scale. All reaction components were combined except for C. jejuni ATP-PRTase and E. coli 
PPase. The reaction was left at 37 °C for 30 min after which the remaining two enzymes 
were also added. The reaction was  allowed to stand for an additional 90 min  before 
acidification by the addition of 1M HCl until pH 6.0 by litmus paper. The solution was frozen 
in liquid nitrogen and lyophilised. The resulting white powder was taken up in a minimal 
amount of buffer (50 mM AcONH4 pH 6.0), spun down for 10 min at 14,000 g to remove 
solids, and filtered through a 0.45 micron syringe filter. The reaction mixture was loaded 
onto a P2 (Bio-Rad®)size exclusion gel made up in a XK 16/40 column. The PRATP product 
eluted together with the rearranged 6-N-PRATP product. Fraction containing PRATP were 
combined, frozen in liquid nitrogen and lyophilised overnight. The resulting product was 
used without further purification. 
Table  8.4. Components of the couled enzymatic synthesis of PRATP from ribose. 
Component Final concentratrion  
Na2HPO4 50 mM 
NaCl 100 mM 
MgCl2 10 mM 
PEP (Na salt) 20 mM 
D -ribose 2.0 mM 
ATP 2.2 mM 
Myokinase 5 U/mL 
Pyruvate Kinase 20 U/mL 
Ribokinase 40 µg/mL 
PRPPase 32 µg/mL 
C. jejuni ATP-PRTase  1.1 µM 
PPase 1.1 µM 
 
8.3.5 Coupled enzymatic synthesis of isotopically labelled PRATP from ribose 
Reactions were set up according to the condition outline in table 8.5, generally reactions 
were carried out on a 500 µL scale. All reaction components were combined except for C. 
jejuni ATP-PRTase and E. coli PPase. The reaction was left at 37 °C for 30 min after which the 
remaining two enzymes were added. If the reaction involved the 3H isotopic label additional 
unlabelled D-ribose (0.5 mM) was added prior to the addition of the C. jejuni ATP-PRTase 
and E. coli PPase and incubated for an additional 15 min before the remaining two enzymes 
were also added. The reaction was then monitored by HPLC according to the general 
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method described in Section 8.3.3. The reaction was quenched by the addition of 100 µL 
0.1M H2SO4, filtered through a spin concentrater at 4 °C and purified according to the 
general procedure described in section 8.3.7.  
Table  8.5. Components of the coupled enzymatic synthesis of isotopically labelled PRATP from ribose.  
Component Final concentratrion  
Isotopically labelled D-ribose 20 µCi  to 50 µCi 
Na2HPO4 50 mM 
NaCl 100 mM 
MgCl2 10 mM 
PEP (Na salt) 20 mM 
ATP 0.7 mM 
Myokinase 5 U/mL 
Pyruvate Kinase 20 U/mL 
Ribokinase 40 µg/mL 
PRPPase 32 µg/mL 
C. jejuni ATP-PRTase  1.1 µM 
PPase 1.1 µM 
 
8.3.6 Preparation of HPLC eluents 
Aqueous HPLC buffers were prepared with Milli-Q water and adjusted in pH were made as 
per Section 8.1.5. The aqueous buffer component was filter sterilised before the organic 
solvent component was added. Buffers were used within a week and stored at 4 °C when 
not in use. Phosphate buffers were made by mixing the appropriate mono- and di-basic 
phosphate salts as a 100 mM stock solution until the desired pH was achieved. 
- Ion-paring buffer: Buffer A: 50 mM KH2PO4, 8 mM (n-Bu)4NHSO4 at pH 5.0, Buffer B; 
50% v/v buffer A/Acetonitrile 
- Desalting buffer PRATP: Buffer A: 50 mM AcONH4 at pH 5.8, Buffer B: 50% v/v buffer 
A/Acetonitrile 
- Desalting buffer ATP: Buffer A: 0.1% formic acid, Buffer B: 50% v/v buffer 
A/Acetonitrile 
All organic solvents used in were of HPLC grade and used without further filtering. 
8.3.7 HPLC methods 
Purification of compounds were performed on a Phenomenex Kinetex C18 5u 100 Å 250-
4.70 mm reverse phase column, linked to a Water Alliance 2695 HPLC with a waters 2487 
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Dual Absorbance Detector. Columns were equilibrated for at least 1 hour before use at a 
flowrate of 1 mL/min. All purifications were carried out at the same flowrate of 1 mL/min. 
The purification of PRATP and ATP were carried out in a two-step process by separation 
from the reaction mixture by the ion paring method (Section 8.3.6), PRATP eluted at 21 min 
and ATP at 22 min, followed by desalting (Section 8.3.6) with the appropriate eluent system, 
PRATP eluted at 15 min ATP eluted at 16 min.  
Ion paring method: 
Time (min) Buffer A  Buffer B 
0-2 100 % 0 % 
2-25 0 % 100 % 
25-27 0 % 100% 
27-28 100 % 0 % 
28 -35 100 % 0 % 
Desalting method 
Time (min) Buffer A  Buffer B 
0-3 100 % 0 % 
3-10 0 % 100 % 
10-23 0 % 100% 
23-24 100 % 0 % 
24 -30 100 % 0 % 
 
8.3.8 Measuring KIEs  
8.3.8.1 Condition for the measurement of KIES for M. tuberculosis ATP-
PRTase 
Kinetic isotope effects were measured under competitive conditions. An experiment would 
include 4 reactions of partial conversion (20%-40%), 2 100% conversion reactions and 1 
negative control (Table 8.7). A master mix (Table 8.6) was made containing, equal amounts 
of 3H and 14C isotopically labelled PRATP. Per reaction enough label was added to give 
45,000 CPM/reaction/per isotope so a total of 315,000 CPM/per isotope in total in the 
master mix (Table 8.6). Additional unlabelled PRATP was added to give a final concentration 
of 9-10 µM (achieving this concentration after enzyme and buffer is added to the individual 
reactions) after enzyme was also added. this was made up in a tris buffer (100 mM NaCl, 50 
mM KCl, 10 mM MgCl2 and 50 mM Tris HCl pH 8.5) and phosphonoacetic acid was added to 




Table  8.6. Components of the master mix for M. tuberculosis ATP-PRTase. 
Descriptor  Amount/concentration 
Master mix total volume  ~ 1350 µL 
3H labelled PRATP  315,000 CPM 
14C labelled PRATP  315,000 CPM 
PRATP  Final concentration of 9 µM 
Phosphonoacetic acid  10 mM 
 
Table  8.7. Set up of the individual reactions. 
Descriptor  20-40% conversion 100% conversion Blank 
Master mix  190 µL 190 µL 190 µL 
Enzyme  244 nM 16 µM 0 
Buffer  8.25-8.5 µL 0 µL 10 µL 
Number of RXN  4X 2X 1X 
 
After enzyme was added the reaction was incubated at 25 °C for 17 min, 20 µL 0.1M H2SO4 
was then added to each tube to quench the reaction. Processing of the sample was done 
according to the general procedure described in Section 8.3.8.4 immediately after. 
8.3.8.2 Condition for the measurement of KIEs for C. jejuni ATP-PRTase 
Kinetic isotope effects were measured under competitive conditions. An experiment would 
include 4 reactions of partial conversion (20%-40%), 2 100% conversion reactions and 1 
negative control (Table 8.9). A master mix (Table 8.8) was made containing, equal amounts 
of 3H and 14C isotopically labelled PRATP. Per reaction 315,000 CPM/per isotope was added, 
additional unlabelled PRATP would be added to give a concentration of 18-19 µM in the 
reaction (so enough PRATP that after the addition of the enzyme and buffer the PRATP 
concentration of isotopically labelled and unlabelled PRATP would be 18-19 µM). This was 
made up in a Tris buffer (100 mM NaCl, 50 mM KCl, 10 mM MgCl2 and 50 mM Tris HCl pH 






Table  8.8. Components of the master mix for C. jejuni ATP-PRTase 
Descriptor  Amount/concentration 
Total volume  ~ 1350 µL 
3H labelled PRATP  315,000 CPM 
14C labelled PRATP  315,000 CPM 
PRATP  Final concentration of 18.5 µM 
Phosphonoacetic acid  10 mM 
 
 
Table  8.9. Set up of the individual reactions. 
Descriptor  20-40% conversion 100% conversion Blank 
Master mix  190 µL 190 µL 190 µL 
Enzyme  1.7 µM 18 µM 0 
Buffer  6-7 µL 0 µL 10 µL 
Number of RXN  4X 2X 1X 
 
After enzyme was added the reaction was incubated at 25 °C for 20 min, 20 µL 0.1M H2SO4 
was then added to quench the reaction. Processing of the sample was done according to the 
general procedure described in Section 8.3.8.4 immediately after. 
8.3.8.3 Condition for the measurement of KIEs for L. lactis ATP-PRTase 
Kinetic isotope effects were measured under competitive conditions. An experiment would 
include 4 reactions of partial conversion (20%-40%), 2 100% conversion reactions and 1 
negative control (Table 8.11). A master mix (Table 8.10) was made containing, equal 
amounts of 3H and 14C isotopically labelled PRATP. Per reaction 315,000 CPM/per isotope 
was added, additional unlabelled PRATP would be added to give a concentration of 18-19 
µM in the reaction (so enough PRATP that after the addition of the enzyme and buffer the 
PRATP concentration of isotopically labelled and unlabelled PRATP would be 18-19 µM). This 
was made up in a Tris buffer (100 mM NaCl, 50 mM KCl, 10 mM MgCl2 and 50 mM Tris HCl 
pH 8.5) and phosphonoacetic acid was added to a final concentration of 10mM in the 
reaction. 
Table  8.10. Components of the master mix for C. jejuni ATP-PRTase 
Descriptor  Amount/concentration 
Total volume  ~ 1350 µL 
3H labelled PRATP  315,000 CPM 
14C labelled PRATP  315,000 CPM 
PRATP  Final concentration of 35 µM 
Phosphonoacetic acid  10 mM 
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Table  8.11. Set up of the individual reactions. 
Descriptor  20-40% conversion 100% conversion Blank 
Master mix  190 µL 190 µL 190 µL 
Enzyme  150 nM 940 nM 0 
Buffer  6-7 µL 0 µL 10 µL 
Number of RXN  4X 2X 1X 
 
After enzyme was added the reaction was incubated at 25 °C for 20 min, 20 µL 0.1M H2SO4 
was then added to quench the reaction. Processing of the sample was done according to the 
general procedure described in Section 8.3.8.4 immediately after. 
8.3.8.4 General procedure for separation of substrate and products by solid 
phase extraction: 
Reactions were loaded onto a pre-equilibrated (2x 4mL H2O and 2x 4mL elution buffer, 
50mM (NH4)2CO3 at pH 6.0 with AcOH) Grace Extract-Clean SPE carbo 150mg/4mL column. 
Columns were eluted with 4x 1 mL of elution buffer and the flowthrough collected directly 
into a scintallation vial. Samples were dried under speed vacuum evaporation for at least 12 
hours and the resulting solids were taken up in MilliQ water (500 µL). 10 mL Ultima Gold™ 
Cocktail was added, here it was found important to make sure all solids had completely 
disolved in water before scintillation counting liquid was added. Samples were mixed for 2x 
20 sec on vortex mixer and left to stand for 1 hour to allow the formed air bubbles to clear. 
Each vial was then counted for 10 cycles of 10 min. Channel A was set for 3H (0-25 keV) and 
channel B for the remaining 14C signal (25-400 keV). In each sample set, a 14C standard was 
included to correct for channel overlap between the two isotopes.  
8.3.8.5 Processing of the scintillation data: 
The isotope effects were calculated from the average cpm/isotope by equation 3.9 (Section 
3.1.6). Processing was done in Microsoft Excel 2010. The specific  counts for 3H and 14C were 
found by correcting for channel overlap of 14C. The correction factor Coverlap was found 
through Equation 8.1 from the average CPM of channel A (0-25 keV)(CPMAaverage) and the 
average CPM of channel B (25-400 keV )(CPMBaverage)  of 10 cycles. with an example given in 
Table 8.12. 











From this factor the proportion of 3H could be found by Equation 8.2 and 14C by equation 
8.3 and an example of each is given in table 8.13. 
 
𝐶𝑃𝑀𝐴𝑎𝑣𝑒𝑟𝑎𝑔𝑒 − (𝐶𝑃𝑀𝐵𝑎𝑣𝑎𝑟𝑎𝑔𝑒 ∗ 𝐶𝑜𝑣𝑒𝑟𝑙𝑎𝑝) = 𝐶𝑃𝑀 𝐻 
3  Equation 8.2 
  
𝐶𝑃𝑀𝐴𝑎𝑣𝑒𝑟𝑎𝑔𝑒 + (𝐶𝑃𝑀𝐵𝑎𝑣𝑎𝑟𝑎𝑔𝑒 ∗ 𝐶𝑜𝑣𝑒𝑟𝑙𝑎𝑝) = 𝐶𝑃𝑀 𝐶 
14  Equation 8.3 
 
Table  8.13.  An example of the amount of 3H and 14C found from the average CPMs.  
CPMAaverage CPMBaverage  3H 14C 
20834 7995  17390 11439 
 
The 14C and 3H ratios for the partial and full conversion experiments could then be found according 
by equation 8.4 if the internal standard contained 3H and equations 8.5 if the internal standard 
contained 14C. 
𝐶𝑃𝑀 𝐶/ 
14 𝐶𝑃𝑀 𝐻 
3 = 𝑅𝑝 Equation 8.4 
  
𝐶𝑃𝑀 𝐻/ 
3 𝐶𝑃𝑀 𝐶 
14 = 𝑅𝑝 Equation 8.5 
 
This information could then be used to calculate the ratio of 14C and 3H of the samples and the 
associated KIEs could be found through Equation 3.9 (Section 3.1.6). fractional conversions were also 








Table  8.14.  example of a data set and the calculated kinetic isotope effects 
 
3H 14C Rp F KIE 
KIE1 12277 12570 0.977 0.281 1.0029 
KIE2 11452 11777 0.972 0.263 1.0080 
KIE3 14039 14442 0.972 0.323 1.0088 
KIE4 14441 14827 0.974 0.332 1.0064 
 3H 14C Ro Average Ro 
Average 
KIE 
100 % 43891 44744 0.981 0.979 1.0065 
100 % 43628 44648 0.977   
 
8.3.9 Measuring commitment to catalysis 
The forward commitment to catalysis or the partitioning of the Michaelis complex to 
product relative to substrate release (kcat/koff) was measured by the isotope trapping 
method.85 The experiment determines the fraction of enzyme bound isotopically labelled 
PRATP that converts to product after a large excess of unlabelled PRATP and the second 
substrate PA is added. Fractions are taken after one and several turnovers and extrapolated 
back to find the initial amount of substrate turned over. The commitment factor can be 
found through equation Equation 12-14 including an example calculation for C. jejuni ATP-
PRTase Section 3.3.2. 
[𝐸𝑡][ C 
14 PRATP]

















C. jejuni ATP-PRTase L. lactis ATP-PRTase 
[20 µM][50 µM]
10 µM + [50 µM]
= [16.6µM] 
[20 µM][50 µM]

















More specifically, enzyme 20 µm (final concentration) was mixed with 50 µM final 
concentration of [5′-14C]PRATP to give a total volume of 20µL and incubated for 10 seconds 
before a chase solution containing 500 µM unlabelled PRATP and 10 mM PA was added (480 
µL). 120 µL samples were then taken after 1, 2, 4, and 8 catalytic turnovers and quenched 
onto 10 µL H2SO4 0.1 M. samples where processed according to the standard method 
Section 8.3.8.4. A no enzyme control was added to correct for non-enzymatic degradation. 
The concentration of formed PRPA was back extrapolated and the y intercept gave the 
[PRPA] at time 0. The concentratrion of PRPA was calculated based on the fraction of 
radiation recovered and the total amount of radiation in cpm available. Graphs obtained 
after 1 and several turnovers can be found in appendix II. 
8.4 Experimental procedures for chapter 4 
8.4.1 Generation of electrostatic potential maps 
The molecular electrostatic potential surfaces (ESP) were calculated from the optimised 
structures using the Cubegen utility provided with Gaussian 09 program.113 The electrostatic 
potential was calculated first, followed by the generation of the ESP map. Maps were 
generated at an isovalue of 0.05 and the arbitrary colour scale adjusted to represent 
appropriate colour coding.  
8.4.2 ISOEFF98 input file: 
The ISOEFF98 program is available free of charge by contacting Prof Piotr Paneth on 
piotr.paneth@p.lodz.pl 
An example of the used input file system is given below. All files were generated with the 
jEdit text editing program. Highlighted in red requires the input of the mass of the used 
isotope. Highlighter in yellow are the areas that need referencing to, or input from, the 
structure. The input file, ISOEFF98.exe, loopfile, and .log file were placed in the same folder. 




The input file, {filename.inp} 
----1_3H----- 
-$ISOEFF HMA(methyl) = Atomic mass of used isotopic substitution (example 3H = 3) KIE= .T. EIE= .F. 
$END 
 $ISOEFF HMASS(Position label in GS) = 3 HMATS(position label in TS) = 3 KIE= .T. EIE= .F. RMTRIV = 
.F.  
  cutlts = 1 cutlss = 1 cututs = 10000 cutuss = 10000  





for n in [insert TS file name] *.log; do 
 m=`echo $n | cut -d'.' -f1`; 
 for x in [insert TS file name]*.log ; do 
  y=`echo $x | cut -d'.' -f1`; 
  echo \ \$GLOBAL MEMORY=10000000 \$END > $y$m; 
  echo \ \$IODEF SSINP = $x TSINP = $n \$END >> $y$m; 
  cat The input file.inp >> $y$m; 
  ./isoeff.exe $y$m; 




8.4.3 Coordinates for the ground state structure 
Visualisation of the structures was done using the Gausview program. 
Input structure Output structure 
-2 1 
 O                 -9.90400000  -25.26500000  -32.83600000 
 O                 -9.45000000  -26.38500000  -34.75500000 
 O                 -8.84000000  -27.45000000  -32.60200000 
 P                 -8.91400000  -26.16000000  -33.33200000 
 C                 -6.33100000  -26.47600000  -32.93300000 
 O                 -7.43200000  -25.67900000  -33.33900000 
 C                 -5.14900000  -25.74100000  -32.25400000 
 O                 -4.49800000  -24.74900000  -33.06800000 
 C                 -5.54500000  -25.02600000  -30.98100000 
 O                 -4.56600000  -25.28300000  -30.08400000 
 C                 -5.44300000  -23.55400000  -31.36500000 
 O                 -5.05300000  -22.85700000  -30.24000000 
 C                 -4.29200000  -23.58200000  -32.30700000 
 N                 -4.24600000  -22.54100000  -33.35600000 
 C                 -5.41140028  -22.02535755  -33.83944292 
 N                 -5.36734329  -21.03058923  -34.78685623 
 C                 -4.21956770  -20.57246939  -35.23156220 
 C                 -3.09918645  -21.08912803  -34.75352799 
 C                 -3.11509181  -22.05158279  -33.83185025 
 N                 -1.95676789  -22.51382777  -33.41546428 
-2 1 
 O                  1.74502200   -1.85686900    1.18272500 
 O                  3.03877600   -3.15982500   -0.68110200 
 O                  3.97982900   -0.89795000    0.25482700 
 P                  2.77551700   -1.82832600    0.01124000 
 C                  2.30421000    0.23014800   -1.80901700 
 O                  1.78321400   -0.88495500   -1.15478300 
 C                  1.87397900    1.56433400   -1.17199800 
 O                  0.41440300    1.70160100   -1.16503600 
 C                  2.27917000    1.71760700    0.28858100 
 O                  2.34264400    3.12176500    0.63927300 
 C                  1.10773600    1.03891400    1.00427000 
 O                  0.93751500    1.50816800    2.35872700 
 C                 -0.08819100    1.44253500    0.13513300 
 N                 -1.23045400    0.49861300    0.07352400 
 C                 -1.07678900   -0.83177100    0.40666400 
 N                 -2.06884700   -1.69040500    0.50625800 
 C                 -3.27675100   -1.14073200    0.23978900 
 C                 -3.57299300    0.15220000   -0.16264700 
 C                 -2.47675700    1.07626500   -0.37147500 
 N                 -2.61676700    2.24779200   -0.88987900 
184 
 
 N                 -2.12880867  -20.45224245  -35.35453440 
 C                 -2.63079301  -19.56887076  -36.19962149 
 N                 -3.93736517  -19.65726639  -36.14555301 
 H                 -6.72123487  -27.13180550  -32.18297607 
 H                 -5.92757125  -26.87875611  -33.83850139 
 H                 -4.47525692  -26.54991012  -32.06259811 
 H                 -6.50213937  -25.30134529  -30.58988722 
 H                 -4.71405911  -24.76277211  -29.29087867 
 H                 -6.33877825  -23.12029433  -31.75791311 
 H                 -3.41697804  -23.47789620  -31.70004122 
 H                 -6.35204993  -22.39166313  -33.48462121 
 H                 -1.92245745  -23.17484957  -32.66588242 
 H                 -2.06991733  -18.89996007  -36.81839201 
 H                 -4.59392776  -19.13460816  -36.68938565 
 H                 -5.09755333  -21.89808667  -30.22998882 
 
 N                 -4.93600300    0.30456400   -0.36240700 
 C                 -5.44931000   -0.87131200   -0.07734200 
 N                 -4.49030500   -1.79279000    0.29488200 
 H                  3.40653400    0.21789000   -1.81876300 
 H                  1.94088900    0.24127400   -2.85367700 
 H                  2.25777000    2.40175300   -1.77088600 
 H                  3.22149000    1.20174400    0.50313900 
 H                  2.10391800    3.14866400    1.57936200 
 H                  1.30092500   -0.04317200    1.02694600 
 H                 -0.52124400    2.36479700    0.54611000 
 H                 -0.06043600   -1.20049500    0.60878600 
 H                 -1.71522400    2.69450200   -1.04967500 
 H                 -6.50111900   -1.12294800   -0.11393000 
 H                 -4.61202100   -2.76483800    0.53505100 
 H                  1.26534900    0.78670800    2.91349100 
 
 
8.4.4 Coordinates for the truncated transition state input structure  
Truncated input structure 
2 1 
Mg                -0.33811700    1.35735400    0.41011000 
 P                  1.48097400   -1.39931200    0.55831100 
 C                 -0.91109400   -1.36040600   -1.02761500 
 O                  0.09358200   -0.59152900   -0.04809800 
 O                  1.27907600   -1.33673200    2.05616200 
 O                  1.43278000    1.82082700   -0.53589900 
 C                 -1.86561000   -0.23125700   -1.46355200 
 O                 -1.26342600    1.05836900   -1.57553800 
 O                  1.73414700   -2.58599400   -0.29371500 
 C                 -2.87155100   -0.20553900   -0.29347300 
 O                 -2.34792800    0.72054300    0.69452100 
 C                 -2.86226600   -1.66615500    0.17290200 
 O                 -1.67012100   -2.27290700   -0.37509300 
 O                 -0.70014700    3.38825700    0.55146600 
 O                  0.06109900    0.91605000    2.35670600 
 H                 -0.26422600   -1.84821300   -1.75239800 
 H                 -2.37444100   -0.50825100   -2.39312800 
 H                 -3.86249300    0.14433100   -0.58984900 
 H                 -2.84613500   -1.76650100    1.26370600 
 H                 -0.06729500    3.99215000    0.12790500 
 H                  0.53848500    0.00140600    2.41238100 
 H                 -0.63533100    1.07335100   -2.31848100 
 H                 -1.57192500    3.81385500    0.52238300 
 H                  0.41478300    1.48536900    3.05624400 
 C                  2.77583800   -0.03566200    0.17210500 
 H                  3.68258700   -0.55010000   -0.15574200 
 H                  2.97630900    0.48471300    1.11004000 
 C                  2.25701200    0.93351300   -0.82135700 
 O                  2.59478300    0.81925600   -2.10061900 
 H                 -3.72129800   -2.22035500   -0.21461200 
 H                  3.24977600    0.10942400   -2.23160800 
 H                 -2.52074600    0.39415400    1.59397700 




8.4.5 Coordinates for the M. tuberculosis transitions state structure 
Input structure Output structure 
1 1 
 Mg                -2.23604661   -0.94868445    0.64844343 
 P                 -2.04052161    1.90943555   -0.00376557 
 C                  0.34428461   -0.77811555   -2.03924043 
 O                 -1.29630761    0.55931255   -0.28360857 
 O                 -2.11501261    2.20487055    1.48851143 
 O                 -4.01749561   -0.40527745    0.08938643 
 C                 -0.05735039   -2.05946055   -1.35631743 
 O                 -1.44613139   -2.14812255   -1.19593043 
 O                 -1.20322261    3.05151855   -0.80159257 
 C                  0.75205461   -1.99921455   -0.01096343 
 O                 -0.19135739   -1.78484155    1.02620657 
 C                  1.76201061   -0.85474455   -0.23324443 
 O                  1.36227661   -0.23159355   -1.55125243 
 O                 -3.41054261   -2.71478745    0.87648743 
 O                 -1.91213261   -0.11790645    2.53307843 
 H                 -0.08847739   -0.35407855   -2.94430743 
 H                  0.32555061   -2.87073855   -1.99609543 
 H                  1.27498861   -2.94486655    0.16920457 
 H                  1.64298061   -0.02030655    0.46213257 
 H                 -4.20451061   -2.18568845    0.60972643 
 H                 -1.95888700    0.86998800    2.26932200 
 H                 -1.76910939   -3.06220955   -1.23775843 
 H                 -3.65708561   -3.30915045    1.59630543 
 H                 -2.48038461   -0.25200545    3.30299943 
 C                 -3.67282061    1.84249855   -0.80906657 
 H                 -3.51311761    1.81812555   -1.89376457 
 H                 -4.21303561    2.76903455   -0.59470457 
 C                 -4.59606361    0.64643055   -0.44293157 
 O                 -5.78306461    0.73395755   -0.69749457 
 H                  0.16366161   -1.30533855    1.79248657 
 H                 -1.10690261    3.86745755   -0.28761357 
 C                  3.22273461   -1.27582155   -0.33726143 
 H                  3.54890661   -1.60506955    0.65609457 
 H                  3.35056761   -2.10467555   -1.04276943 
 O                  3.98923761   -0.17969455   -0.81314843 
 P                  5.02002561    0.64232445    0.13784357 
 O                  4.01055861    0.95539745    1.36202157 
 H                  4.37665061    1.54702045    2.03809557 
 O                  5.97134261   -0.49328955    0.78001157 
 H                  6.87567661   -0.45879355    0.42954357 
 O                  5.69092461    1.75271645   -0.55103143 
 
B 3 4 F 
D 13 12 32 33 F 
D 12 32 35 36 F  
1 1 
 Mg                -2.21702500   -0.93467800    0.64720600 
 P                 -1.95099000    1.90296500   -0.03929100 
 C                  0.32669600   -0.90375800   -2.05065300 
 O                 -1.23881500    0.53432000   -0.30605900 
 O                 -2.02274400    2.21624600    1.45011100 
 O                 -3.98444200   -0.36060700    0.07374400 
 C                 -0.10106400   -2.13965300   -1.30291600 
 O                 -1.49136700   -2.17977000   -1.13556200 
 O                 -1.08512800    3.01866800   -0.84417800 
 C                  0.71492600   -2.03265000    0.03675800 
 O                 -0.22600500   -1.79309500    1.06985100 
 C                  1.71735600   -0.88822600   -0.22119300 
 O                  1.34001000   -0.33755000   -1.57934400 
 O                 -3.43714700   -2.67443700    0.88657200 
 O                 -1.88774700   -0.09447100    2.52407600 
 H                 -0.09421600   -0.52362900   -2.98094100 
 H                  0.25633200   -2.99202000   -1.90248800 
 H                  1.24485400   -2.96945800    0.24144400 
 H                  1.56805700   -0.02054900    0.42599000 
 H                 -4.21211900   -2.12363700    0.60575200 
 H                 -1.92075100    0.90438600    2.26169600 
 H                 -1.84150800   -3.08500000   -1.12678400 
 H                 -3.70819900   -3.24639400    1.61576000 
 H                 -2.46905100   -0.20303100    3.28823300 
 C                 -3.58347600    1.86843800   -0.84737800 
 H                 -3.42245800    1.83207500   -1.93151200 
 H                 -4.10210400    2.80908300   -0.64123900 
 C                 -4.53576200    0.69783400   -0.47457600 
 O                 -5.71887800    0.80859400   -0.73793600 
 H                  0.14411900   -1.33752200    1.84343600 
 H                 -0.98100700    3.84026000   -0.34088000 
 C                  3.18487900   -1.29342100   -0.27276600 
 H                  3.49298400   -1.56760400    0.74295000 
 H                  3.33908100   -2.15475500   -0.93260600 
 O                  3.94773100   -0.21179000   -0.78608900 
 P                  4.94686300    0.67076100    0.14442900 
 O                  3.90851800    1.02583900    1.33216000 
 H                  4.25117600    1.65604000    1.98524500 
 O                  5.90161800   -0.41805500    0.85864300 
 H                  6.81200100   -0.38675800    0.52389900 
 O                  5.61535200    1.75703000   -0.58413800 
 
 
8.4.6 Coordinates for the C. jejuni transitions state structure 




 Mg                -2.23405500   -1.01722900    0.59965900 
 P                 -2.10870800    1.88054300    0.02718500 
 C                  0.33118486   -0.51197748   -1.97387525 
 O                 -1.36624294    0.56967453   -0.25013867 
 O                 -2.18148800    2.13541500    1.52486500 
 O                 -4.02659700   -0.48392600    0.06818900 
 C                 -0.04770700   -1.86053200   -1.41357000 
 O                 -1.42978100   -2.04199100   -1.27041600 
 O                 -1.29610000    3.05267400   -0.75165600 
 C                  0.75711900   -1.91617300   -0.06916200 
 O                 -0.18597400   -1.77037600    0.98276900 
 C                  1.77899400   -0.77051300   -0.20892100 
 O                  1.33587500    0.00142600   -1.42578600 
 O                 -3.36153900   -2.80547400    0.78748200 
 O                 -1.92052000   -0.22179300    2.50559300 
 H                 -0.15409300    0.02212900   -2.78656500 
 H                  0.37606900   -2.57288500   -2.13956500 
 H                  1.26778800   -2.87881600    0.04199800 
 H                  1.71766000   -0.02115700    0.58400600 
 H                 -4.17852800   -2.30249800    0.54689900 
 H                 -2.00745700    0.78019400    2.29268300 
 H                 -1.70160000   -2.96025700   -1.42352200 
 H                 -3.57607200   -3.44765300    1.47554400 
 H                 -2.47801500   -0.39505600    3.27566800 
 C                 -3.73916500    1.79248100   -0.77702400 
 H                 -3.58191700    1.79663900   -1.86234900 
 H                 -4.29988100    2.70117800   -0.54000600 
 C                 -4.63224800    0.56595500   -0.43446500 
 O                 -5.82229300    0.63402400   -0.68060500 
 H                  0.14965200   -1.28156200    1.75180200 
 H                 -1.19020900    3.85237300   -0.21436900 
 C                  3.22390100   -1.20639300   -0.42535600 
 H                  3.58671800   -1.65067700    0.50842200 
 H                  3.30046500   -1.95322100   -1.22377800 
 O                  3.99523800   -0.07917800   -0.81353500 
 P                  5.08572800    0.61333000    0.17219400 
 O                  4.13796900    0.81539600    1.46749800 
 H                  4.55226900    1.31606600    2.18777100 
 O                  6.03395100   -0.60413000    0.64816900 
 H                  6.92353400   -0.55102400    0.26392200 
 O                  5.75630800    1.77683600   -0.42316100 
B 3 4 F 
D 13 12 32 33 F 
D 12 32 35 36 F   
1 1 
 Mg                -2.22516700   -0.98172300    0.62075600 
 P                 -2.06786400    1.89143200   -0.00273200 
 C                  0.32295500   -0.65955000   -1.99634200 
 O                 -1.30665300    0.55161700   -0.29341700 
 O                 -2.14308800    2.17184000    1.49174700 
 O                 -4.01326700   -0.45020900    0.07187000 
 C                 -0.05813700   -1.97539300   -1.36901800 
 O                 -1.44484200   -2.10031700   -1.21444100 
 O                 -1.24528100    3.04886400   -0.79347600 
 C                  0.74845800   -1.95657200   -0.02200200 
 O                 -0.19542700   -1.76553200    1.02015900 
 C                  1.76373500   -0.81186700   -0.21447500 
 O                  1.34698500   -0.13184000   -1.49692500 
 O                 -3.37488600   -2.76087600    0.83565400 
 O                 -1.90579600   -0.16203000    2.51256500 
 H                 -0.11873800   -0.20072000   -2.87939300 
 H                  0.34188000   -2.75130300   -2.04146600 
 H                  1.26619800   -2.90918000    0.13460000 
 H                  1.66749400   -0.00704000    0.51832900 
 H                 -4.17964700   -2.24431700    0.57892800 
 H                 -1.98224400    0.83874600    2.27717500 
 H                 -1.74778600   -3.01813500   -1.29835200 
 H                 -3.60690600   -3.37285100    1.54538800 
 H                 -2.46750600   -0.31297900    3.28420000 
 C                 -3.69928100    1.80960100   -0.80738800 
 H                 -3.54024500    1.79537200   -1.89237400 
 H                 -4.25085700    2.72763900   -0.58552000 
 C                 -4.60650800    0.59874100   -0.44881300 
 O                 -5.79527400    0.67446600   -0.69890700 
 H                  0.15033400   -1.27639100    1.78458900 
 H                 -1.14839800    3.85868800   -0.26994900 
 C                  3.21870600   -1.24152700   -0.36059700 
 H                  3.55881700   -1.61440000    0.61235300 
 H                  3.32670700   -2.04152600   -1.10181800 
 O                  3.98743600   -0.13358100   -0.80468700 
 P                  5.04168400    0.63975700    0.16100300 
 O                  4.05517800    0.91449300    1.41298800 
 H                  4.43953500    1.47324800    2.10665700 
 O                  5.99099200   -0.52961000    0.74288600 
 H                  6.89009900   -0.49018800    0.37971800 
 O                  5.71347300    1.76991200   -0.49406500 
 
 
8.4.7 Coordinates for the L. lactis transitions state structure 
Input structure Output structure 
1 1 
 Mg                -2.22036400   -1.04975100    0.58013300 
 P                 -2.13281900    1.86779200    0.05837800 
 C                  0.27635122   -0.30495453   -1.88561258 
 O                 -1.34762043    0.56567764   -0.19602219 
1 1 
 Mg                -2.23755700   -1.03361100    0.58973700 
 P                 -2.11840600    1.87546000    0.03927400 
 C                  0.28473100   -0.41947200   -1.91359300 
 O                 -1.34217400    0.54526500   -0.27882700 
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 O                 -2.23933600    2.10971200    1.54945700 
 O                 -4.02026800   -0.52180500    0.08877700 
 C                 -0.06408900   -1.71196500   -1.46380300 
 O                 -1.44085100   -1.94458700   -1.33801300 
 O                 -1.32931600    3.05160100   -0.70945700 
 C                  0.75200100   -1.87444100   -0.13705800 
 O                 -0.17638200   -1.80712900    0.93871900 
 C                  1.77744700   -0.72735900   -0.20618300 
 O                  1.30786200    0.15188600   -1.32852000 
 O                 -3.29693700   -2.86631700    0.67212400 
 O                 -1.90534700   -0.30043700    2.50019700 
 H                 -0.20810200    0.28732000   -2.65471700 
 H                  0.37351000   -2.33912700   -2.25723100 
 H                  1.25648600   -2.84572200   -0.10082600 
 H                  1.75781900   -0.05787400    0.65690700 
 H                 -4.10553200   -2.33671500    0.43830300 
 H                 -2.00631700    0.69902900    2.30723900 
 H                 -1.65935500   -2.88485400   -1.46455400 
 H                 -3.52798500   -3.44133700    1.41791800 
 H                 -2.50881000   -0.48836400    3.23686900 
 C                 -3.73107100    1.73457600   -0.79525100 
 H                 -3.53542900    1.67150500   -1.87349900 
 H                 -4.29943400    2.65536800   -0.63559100 
 C                 -4.63831900    0.53070100   -0.40228100 
 O                 -5.83104300    0.61135300   -0.60215900 
 H                  0.13725900   -1.27212900    1.69005500 
 H                 -1.18552100    3.81483000   -0.12416400 
 C                  3.21032900   -1.15454800   -0.51033300 
 H                  3.60134000   -1.68551200    0.36472300 
 H                  3.24476400   -1.82965000   -1.37329800 
 O                  3.97531800   -0.00434900   -0.82716500 
 P                  5.10180100    0.58080800    0.18795800 
 O                  4.19167400    0.66833300    1.52283100 
 H                  4.66546200    1.06912100    2.27273800 
 O                  6.04901200   -0.68167800    0.52786900 
 H                  6.91355600   -0.60016400    0.08759700 
 O                  5.76761800    1.78462200   -0.32043700 
B 3 4 F 
D 13 12 32 33 F 
D 12 32 35 36 F   
 O                 -2.18798000    2.11995300    1.53803900 
 O                 -4.03060300   -0.49388800    0.06711800 
 C                 -0.04696000   -1.81029300   -1.43391200 
 O                 -1.42657700   -2.01589600   -1.29655800 
 O                 -1.30673400    3.05034400   -0.73613700 
 C                  0.75826000   -1.90187400   -0.09294400 
 O                 -0.18391500   -1.77857600    0.96368300 
 C                  1.78215400   -0.75561900   -0.20713800 
 O                  1.32813800    0.05654600   -1.39178300 
 O                 -3.36012400   -2.82220600    0.76661500 
 O                 -1.92510700   -0.24903100    2.50162300 
 H                 -0.17162000    0.11754100   -2.74194300 
 H                  0.38565200   -2.49200900   -2.18357900 
 H                  1.26613000   -2.86829100   -0.00460000 
 H                  1.73491800   -0.03394900    0.61202300 
 H                 -4.18151400   -2.32384100    0.53366900 
 H                 -2.01262600    0.75347800    2.29858200 
 H                 -1.68492300   -2.93223800   -1.48045200 
 H                 -3.56768800   -3.47782400    1.44398400 
 H                 -2.48247200   -0.42970600    3.27013200 
 C                 -3.74917200    1.78858300   -0.76357700 
 H                 -3.59339200    1.79859300   -1.84907900 
 H                 -4.31088300    2.69516900   -0.52089300 
 C                 -4.63946400    0.55844400   -0.42558400 
 O                 -5.83049500    0.62744600   -0.66658800 
 H                  0.14982900   -1.29647800    1.73767100 
 H                 -1.19424300    3.84613200   -0.19433400 
 C                  3.22258200   -1.19054300   -0.45464600 
 H                  3.59510700   -1.66646600    0.45943500 
 H                  3.28616400   -1.91113400   -1.27791900 
 O                  3.99460300   -0.05463400   -0.81572100 
 P                  5.09969500    0.60140100    0.17816400 
 O                  4.16812100    0.76856800    1.49020300 
 H                  4.59455600    1.24319700    2.22094500 
 O                  6.04683700   -0.63480600    0.60589300 
 H                  6.93237600   -0.57405600    0.21354100 
 O                  5.77016000    1.77928400   -0.38846600 
 
8.5 Experimental procedures for chapter 5 
8.5.1 Lanzetta assay for detection and quantification of phosphates 
The Lanzetta reagent was made according to published procedures.206 The reagent was 
made fresh prior to use by combining 3 parts 0.045% w/v malachite green in water, 1 part 
4.2% w/v ammonium molybdate in 4M HCl and 0.1 part 1.5% v/v Triton X-100 in water. The 
parts were combined in a beaker wrapped in tin foil and stirred in the dark for at least 1 
hour. The solution was then filtered through a 0.45-micron syringe filter again avoiding 
exposure to direct light as much as possible.  
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Calabration curve: KH2PO4 was dried at 100 °C for at least one day and followed by further 
drying under vacuum overnight in a desiccator. A calibration curve for the determination of 
phosphate concentration  was made ranging from 9 µM to 150 µM. 10 µL of stock solution 
was mixed with 700 µL of Lanzetta reagent and samples incubate for 20 min in the dark 
prior to measure the absorbance at 600 nm .  
The concentration of inhibitor was measured by cleaving the phosphate group with calf 
alkaline phosphatase (5 units/mL in 4mM MgCl2). Sample preparation: 40 µL of inhibitor 
solution (within 25-100 µM based on weight), 10 µL alkaline phosphatase stock, and 50 µL 
Tris buffer (100 mM NaCl, 5 mM MgCl2, and 50 mM Tris HCl at pH 8.0) were incubated 
overnight. 20 µL of digested sample was mixed with 700 µL Lanzetta reagent and then 
incubate for 20 min in the dark prior to measure the absorbance at 600 nm. Data was fitted 
again the calibration and the stock concentration back calculated. Measurements were 
carried out in duplicates or triplicates. 
8.5.2 Synthesis of transition state analogues 
8.5.2.1 Synthesis of the iminoribitol based transition state analogues 
5-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-L-lyxono lactone 
(5.8). The isopropylidene lactone 5.7 (5 g, 26.6 mmol), was dissolved 
in dry DMF (45 mL) cooled to 0oC followed by the addition of 
imidazole (2.7 g, 40 mmol) and  tert-butyldimethylsilyl chloride (6 g, 
40 mmol). The solution was allowed to warm up to room temperature (20oC). After 4 h, TLC 
analysis (PE/EtOAc, 4/1, v/v) indicated complete conversion of starting material (Rf 0.12) 
into a major product (Rf 0.52). The reaction mixture was concentrated. The residue was then 
purified by flash chromatography (EtOAc– PE, 1 : 6) to give the fully protected lactone 5.8 
(5.47 g, 68%) as a white crystalline solid, Crystallography: Single crystals of C14H26O5Si were 
grown by evaporation from Petroleum ether and ethyl acetate. A suitable crystal was 
selected and mounted on a nylon loop in perfluoronated oil on a SuperNova, Dual, Cu at 
zero, Atlas diffractometer. The crystal was kept at 120.01(10) K during data collection. Using 
Olex2, the structure was solved with the ShelXS structure solution program using direct 
methods and refined with the ShelXL refinement package using Least Squares 
minimisation.207–209 refinement parameters can be found in appendix IV. mp 90–91 ◦C Rf : 
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0.52 (Pe/EtOAc, 1/1, v/v): IR (ν): 462.1, 506.3, 723.8, 778.9, 843.4, 873.1, 917.1, 975.2, 
1034.0, 1092.6, 1126.5, 1176.1, 1225.5, 1265.3, 1774.6, 1784.4 cm-1): 1H NMR (400 MHz, 
CDCl3); δ 0.10 (s, 6H, 2x Me OTBDMS), 0.90 (s, 9H, t-Bu OTBDMS), 1.39 (s, 3H, Me iso-prop), 
1.46 (s, 3H, Me iso-prop), 3.96 (ddd, J = 6.7, 6.2 Hz, 2H, H5), 4.52 (dt, J = 6.6, 2.7 Hz, 1 H, H4), 
4.77 - 4.87 (m, 2H, H2, H3); 13C NMR (101 MHz, CDCl3); δ -5.38 (Me OTBDMS), -5.21 (Me 
OTBDMS), 18.45 (Cq, t-Bu OTBDMS), 25.93 (Me, t-Bu OTBDMS), 26.02 (Me iso-prop), 26.92 
(Me iso-prop), 61.02 (C5), 75.89, 76.19 (C2, C3), 79.53 (C4), 114.20 (Cq, iso-prop), 173.86 
(C1). HRMS(ESI) m/z calcld. for [C16H35O9S2Si]+: 303.1622, obsd.: 303.1619. Crystal Data for 
C14H26O5Si (M =302.44 g/mol): monoclinic, space group P21 (no. 4), a = 5.95513(12) Å, b = 
10.14114(19) Å, c = 13.3855(3) Å, β = 98.4789(19)°, V = 799.54(3) Å3, Z = 2, T = 120.01(10) K, 
μ(Cu Kα) = 1.442 mm-1, Dcalc = 1.256 g/cm3, 7139 reflections measured (13.376° ≤ 2Θ ≤ 
147.52°), 3067 unique (Rint = 0.0193, Rsigma = 0.0195) which were used in all calculations. The 
final R1 was 0.0253 (I > 2σ(I)) and wR2 was 0.0690 (all data). 
 
5-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-L-lyxol (5.6).  
Protected lactone 5.8 (3.9g, 12.9 mmol) was dissolved in MeOH 
(24 mL), cooled to 0oC and sodium borohydride (535 mg, 14.2 
mmol). The solution was allowed to warm up to rt. After 7 hours TLC analysis (PE/EtOAc, 
2/1, v/v) showed residual starting material as well as a major product (Rf 0.23). More 
sodium borohydride (530 mg, 14.2 mmol) was added at OoC. After a further 16 h, TLC 
showed complete consumption of starting material. The reaction was quenched by the 
addition of water, diluted with EtOAc and the organic phase washed with H2O (2x), and 
brine (1x), dried over MgSO4 filtered and concentrated in vacuo. The crude reaction mixture 
was used without further purification in the next reaction (3.87 g, 12.6). Rf : 0.23 (Pe/EtOAc, 
2/1, v/v): IR (ν): 474.8, 511.0, 556.9, 617.8, 668.6, 722.2, 746.1, 772.2, 836.8, 894.9, 1045.6, 
1059.5, 1081.5, 1105.6, 1133.6, 1168.9, 1212.5, 1257.2, 3229.4 cm-1): 1H NMR (400 MHz, 
CD3OD); δ 0.00 (s, 3H, Me OTBDMS), 0.01 (s, 3H, Me OTBDMS), 0.83 (s, 9H, t-Bu OTBDMS), 
1.23 (s, 3H, Me iso-prop), 1.39 (s, 3H, Me iso-prop), 3.57 - 3.60 (m, 2H, H1), 3.62 - 3.72 (m, 
3H, C1, H4),  4.10 - 4.16 (m, 1H, H3), 4.2 (dd, 1H, J = 2.8 Hz, J = 7.1 Hz, H3); 13C NMR (101 
MHz, CD3OD); δ -6.74 (Me OTBDMS), -6.67 (Me OTBDMS), 17.80 (Cq, t-Bu OTBDMS), 23.96 
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(Me iso-prop), 24.97 (Me, t-Bu OTBDMS), 25.95 (Me iso-prop), 60.82 (C5), 64.32 (C1), 69.13 
(C4), 75.73 (C3), 77.65 (C2), 107.78 (Cq, iso-prop); HRMS(ESI) m/z calcld. for [C14H27O5Si]+: 
307.1935, obsd.: 307.1934 
 
5-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-1,4-O-di-
methansulfonl-L-lyxol (5.9). To a cooled (0oC) solution of DMAP 
(402 mg, 3.3 mmol) in dry pyridine (30 mL), methanesulphonyl 
chloride (1.25 mL, 16.3 mmol) was added and left to stir for 10 
min upon which solids are formed. Diol 5.6 (2.1 g, 6.53 mmol)was co-evaporated 2x toluene 
and added to the reaction in CH2Cl2 (20 mL), the resulting mixture left to assume room 
temperature. After 15 hours TLC analysis (PE/EtOAc, 2/1, v/v) showed complete 
consumption of starting material and the formation of a higher running product (Rf 0.43). 
The reaction was diluted with CH2Cl2 and poored onto saturated aq. NaHCO3, the aqueous 
phase was washed with CH2Cl2 (3x). The combined organic layers was washed with brine 
(1x), dried over MgSO4 filtered and concentrated in vacuo. Purification by flash 
chromatography (silica gel, 4/12/1 PE/EtOAc) than gave dimesyl 5.9 in a 98% yield (3.0 g, 
6.5 mmol) as an amorphous white solid. Rf : 0.43 (Pe/EtOAc, 2/1, v/v): IR (ν): 528.3, 722.1, 
780.4, 780.4, 837.6, 966.6, 1081.3, 1124.9, 1177.8, 1221.8, 1256.7, cm-1): 1H NMR (400 MHz, 
CDCl3); δ 0.09 (s, 3H, Me OTBDMS), 0.10 (s, 3H, Me OTBDMS), 0.90 (s, 9H, t-Bu OTBDMS), 
1.38 (s, 3H, Me iso-prop), 1.51 (s, 3H, Me iso-prop), 3.07 (s, 3H, Me OMs), 3.11 (s, 3H, Me 
OMs), 3.83 (dd, J = 10.9, 6.1 Hz, 1H, H5b), 3.95 (dd, J=10.9, 5.4 Hz, 1H, H5a), 4.36 - 4.40 (m, 
2H, H1), 4.40 - 4.46 (m, 2H, H2,H3), 4.72-4.77 (m, 1H, H4); 13C NMR (101 MHz, CDCl3); δ -
5.38 (2x Me OTBDMS), 18.44 (Cq, t-Bu OTBDMS), 25.93 26.02 (Me iso-prop), 26.92 25.56 
(Me iso-prop), 25.98 (Me, t-Bu OTBDMS), 27.39 (Me iso-prop), 37.81 (Me OMs), 39.08 (Me 
OMs), 63.27 (C5), 68.05 (C1), 74.65, 75.55 (C2, C3), 79.09 (C4), 109.75 (Cq, iso-prop); 
HRMS(ESI) m/z calcld. for [C16H35O9S2Si]+: 463.1486, obsd.: 463.1485. 
 
N-benzyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-
isopropylidene-D-ribitol (5.5). Dimesyl 5.9 (3 g, 6.5 mmol) was taken 
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up in benzylamine (32 mL) and heated to 160oC with stirring. After 3 hour TLC analysis 
(PE/EtOAc, 2/1, v/v) showed complete consumption of starting material (Rf 0.43) and the 
reaction mixture cooled to room temperature. The reaction mixture was subjected to 
purification by flash chromatography (silica gel, CH2Cl2/PE, 1/1, v/v then PE/EtOAc, 10/1, 
v/v) to give protected iminosugar 5.5 in a 93% yield (2.29 g, 6.06 mmol) as a pale yellow oil. 
Rf : 0.90 (PE/EtOAc, 2/1, v/v), Rf : 0.30 (CH2Cl2/PE, 2/1, v/v): IR (ν): 698.2, 722.4, 776.2, 
837.6, 1058.6, 1107.4, 1159.8, 1209.5, 1254.5 cm-1): 1H NMR (400 MHz, CDCl3); δ 0.05 (s, 3H, 
Me OTBDMS), 0.06 (s, 3H, Me OTBDMS), 0.87 - 0.92 (s, 9H, t-Bu OTBDMS), 1.33 (s, 3H, Me 
iso-prop), 1.56 (s, 3H, Me iso-prop), 2.72 (dd, J=10.4, 2.8 Hz, 1H, H1b), 3.01 (dt, J=4.21, 2.15 
Hz, 1 H), 3.10 (dd, J=10.3, 5.6 Hz, 1H, H1a), 3.64 (dd, J=10.7, 4.2 Hz, 1H, H5b), 3.71 (d, J=13.5 
Hz, 1H, N-CH2 Bn), 3.77 (dd, J=10.7, 4.4 Hz, 1H, H5a), 4.01 (d, J=13.5 Hz, 1H, N-CH2 Bn), 4.55 
(dd, J=6.5, 2.1 Hz, 1H, H3), 4.65 (dd, J=6.2, 2.9 Hz, 1H, H2), 7.17 - 7.36 (m, 5H Harom Bn); 13C 
NMR (101 MHz, CDCl3); δ -5.36 (Me OTBDMS), -5.30 (Me OTBDMS), 18.32 (Cq t-Bu 
OTBDMS), 25.34 (Me iso-prop), 26.05 (Me t-Bu OTBDMS), 27.33 (Me iso-prop), 57.02 (CH2 
Bn), 59.41 (C1), 63.29 (C5), 69.06 (C4), 79.59 (C2), 83.46 (C3), 112.01 (Cq iso-prop), 126.97, 
128.38, 128.61, 139.60 (Carom Bn); HRMS(ESI) m/z calcld. for [C21H36NO3Si]+: 378.2459, 
obsd.: 378.2466. 
 
N-benzyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol (5.4). To a 
solution of protected iminosugar 5.5 (1.1 g, 2.9 mmol) in THF (30 mL), 
tetrabutylammonium fluoride trihydrate (1.4 g, 4.4 mmol) was added at 0oC. 
The reaction was left to assume room temperature. After 3 hours TLC 
analysis (PE/EtOAc, 2/1, v/v) showed complete consumption of starting material Rf (0.90) to 
a lower running product (Rf 0.20). Purification by flash chromatography (silica gel, 3/11/1 
PE/EtOAc) than gave alcohol 5.4 in a 99% yield (763.1 mg, 2.89 mmol) as a pale yellow oil. Rf 
: 0.20 (PE/EtOAc, 1/1, v/v): IR (ν): 515.1, 699.1, 741.1, 865.5, 1059.1, 1159.2, 1209.8, 1254.5, 
1604.0, 1812.9, 1882.7, 1951.8, 3445.0 cm-1): 1H NMR (400 MHz, CDCl3); δ  1.32 (s, 3H, Me 
iso-prop), 1.53 (s, 3H, Me iso-prop), 2.59 - 2.66 (m, 1H, H1b), 2.93 - 2.98 (m, 1H, H4), 3.15 - 
3.24 (m, 1H, H1a), 3.56 (dd, J=11.2, 3.7 Hz, 1H, H5b), 3.59 (d, J=12.8 Hz, 1H, N-CH2 Bn), 3.69 
(dd, J=11.2, 3.8 Hz, 1H, H1a), 3.97 (d, J= 13.0 Hz, 1H, N-CH2 Bn), 4.55 - 4.63 (m, 2H, H2,H3), 
7.23 - 7.36 (m, 5H, Bn Arom); 13C NMR (101 MHz, CDCl3); δ 25.05 (Me iso-prop), 27.44 (Me 
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iso-prop), 58.36 (N-CH2 Bn), 58.63 (C1), 59.62 (C5), 70.08 (C4), 78.64, 82.71 (C2,C3), 112.90 
(Cq iso-prop), 127.50, 128.64, 128.85, 138.58 (Carom Bn); HRMS(ESI) m/z calcld. for 
[C15H22NO3]+: 264.1594, obsd.: 264.1597. 
 
(2S,3R,4S)-1-benzyl-3,4-O-isopropylidine-2-carbaldehyde (5.18). To a 
solution of oxalyl chloride (261 µL, 3.04 mmol) in dry CH2Cl2 (15 mL) (-
78oC), dimethylsulfoxide (431 µL, 6.08 mmol) was added and left to stir 
for 60 min at -78oC. Alcohol 5.4 (198.8  g, 0.76 mmol,) was co-
evaporated three times with toluene and added dropwise in CH2Cl2 (15 mL) and kept at -
78oC. After 45 min. triethylamine (1.3 mL, 9.12 mmol) was added. The reaction was kept at -
78oC for an additional 2 hours and then allowed to warm up. When TLC analysis showed 
complete  consumption of starting material the reaction was diluted with CH2Cl2 saturated 
NaHCO3 was added and the aqueous layer extracted with CH2Cl2 (2x). The combined organic 
fractions were washed with Brine (1x), dried over MgSO4, filtered and concentrated. The 
crude was then taken up in toluene and triethylamine salts filtered off. Product formation 
was confirmed as the hydrate by HRMS(ESI) m/z calcld. for [C15H22NO4]+: 280.1543 obsd.: 
280.1543). The aldehyde 5.17 was used without further purification. diethyl (E)-2-
((2R,3R,4S)-1-benzyl-3,4-O-isopropylidine-pyrrolidin-2-yl)-vinylphosphonate (29). To a 
solution of tetraethyl methylenediphosphonate (245 µL, 0.99 mmol) in dry THF (25 mL) at -
78oC n-BuLi (0.73 mL, 1.42M in THF, 0.99 mmol) was added via the cold wall of the flask. The 
resulting mixture was allowed to warm up to 0oC. Aldehyde 5.17 was co-evaporated with 
toluene (3x) and added drupwise to the reaction. The reaction mixture was allowed to 
assume room temperature. After 14 hours t.l.c analysis (EtOAc), showed formation of a 
major product (Rf 0.42). The reaction was quenched with saturated aq. NH4Cl, diluted with 
CH2Cl2 and the aqueous layer was washed with CH2Cl2 (2x), the combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuo. Purification by flash 
chromatography (silica gel, PE/EtOAc 1/10/1) than gave vinyl phosphonate 5.18 in a 56% 
yield (167.6 mg, 0.42 mmol) over two steps as a yellow amorphous solid. Rf : 0.42 (EtOAc): IR 
(ν): 513.6, 722.1, 966.0, 1029.9, 1053.8, 1158.1, 1210.4, 1244.2 cm-1): 1H NMR (400 MHz, 
CDCl3); δ  1.30 (s, 3H, Me iso-prop), 1.33 (t, J= 7.09 Hz, 3H, Me OEt), 1.34 (t, J= 7.20 Hz, 3H, 
Me OEt), 1.53 (s, 3H, Me iso-prop), 2.58 (dd, J= 10.6, 3.6 Hz, 1H, H2b), 3.12 (dd, J= 10.6, 5.8 
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Hz, 1H, H2a), 3.32-3.36 (m, 1H, H5), 3.41 (d, J= 13.3 Hz, 1H, N-CH2a Bn), 3.86 (d, J= 13.3 Hz, 
1H, N-CH2b Bn), 4.00 - 4.16 (m, 4H, CH2 OEt), 4.41 (dd, J= 6.7, 3.8 Hz, 1H, H4), 4.66 (ddd, J= 
6.2, 3.8 Hz, 1H, H3), 5.97 (dd, J= 20.4, 17.2 Hz, 1H, H7), 6.72 (dd, J= 17.1, 7.8 Hz, 1H, H6), 
7.19 - 7.36 (m, 5H, Bn arom); 13C NMR (101 MHz, CDCl3); δ 16.51 (Me OEt), 16.58 (Me OEt), 
25.34 (Me iso-prop), 27.31 (Me iso-prop), 57.19 (CH2 Bn), 57.97 (C2), 61.93, 62.03 (CH2 OEt),  
71.97 (d, J= 22.1 Hz, 1C C5), 78.59 (C3), 84.91 (C4), 113.25 (Cq iso-prop), 120.7 (d, J= 186.9 
Hz, 1C, C7), 121.64, 127.31, 128.48, 128.66, 128.69, 138.32 (Carom Bn), 150.17, 150.22 (d, 
J= 5.3 Hz, 1C, C6). 31P NMR (162 MHz, CDCl3); δ 17.30 (s, 1P);  HRMS(ESI) m/z calcld. for 
[C20H31NO5P]+: 396.1934, obsd.: 396.1944. 
 
2-([2R,3R,4S]-3,4-dihydroxypyrrolidin-2-yl]ethyl phosphonic acid 
(5.2). To a solution of vinyl phosphonate 5.19 (75 mg, 0.19 mmol) in 
CH2Cl2,  bromotrimethylsylane (131 µL 1.0 mmol) was added. After 3 
hours TLC analysis (CH2Cl2/MeOH, 9/1, v/v) residual starting material as well as a major 
product (Rf 0.1). More bromotrimethylsylane (75 µL 0.5 mmol) was added and left for an 
additional 2 hours after which TLC analysis showed complete consumption of starting 
material. The reaction was the reaction was concentrated and product formation confirmed 
by HRMS(ESI) m/z calcld. for [C16H23NO5P]+: 340.1308, obsd.: 340.1308. The crude reaction 
mixture was dissolved in glacial acetic acid (2.5 mL), water (2,5 mL) was added and the 
resulting mixture was stirred at 70oC for 2 hours. Complete conversion was confirmed by 
NMR with loss of methyl peaks. The reaction was concentrated and used without further 
purification. The crude reaction mixture was dissolved in MeOH and hydrogen gas was 
bubbled through with a balloon for 15 min, 10 mg 10% palladium on carbon was then added 
and left to stir under balloon pressure. The reaction was stirred under balloon pressure for 
48 hours after which complete conversion was confirmed by HRMS. Purification by reverse 
phase HP20 then gave iminosugar 5.2 in 83% yield over three steps. 1H NMR (400 MHz, 
D2O); δ  1.79-1.82 (m, 2H), 1.92-2.17 (m, 2H), 3.31-3.34 (m, 1H), 3.52-3.56 (m, 2H), 4.09-4.12 
(m, 1H), 4.38 (bs, 1H);  HRMS(ESI) m/z calcld. for [C6H15NO5P]+: 212.0682, obsd.: 212.0686. 
N-benzyl-6-O-dibenzylphosphoryl-1,4-dideoxy-1,4-imino-2,3-O-
isopropylidene-D-ribitol (5.10). To a dried solution of 5.4 (107 mg, 
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0.38 mmol) in dichloromethane (7.0 mL), tetrazole (85 mg, 1.14 mmol) was added. The 
resulting suspension was left to stir for 10 min at room temperature before dibenzyl N,N-di-
isopropyl-phosphoramidite was added dropwise over 5 min after which most of the 
tetracole had dissolved. After 1.5 hours TLC analysis showed full conversion of starting 
material into a higher running product (Pe/EtOAc, 2/1, v/v, Rf 0.15). The reaction mixture 
was cooled down to -40 °C resulting in a cloudy solution. m-CPBA (131 mg, 0.76 mmol) was 
added in one portion and allowed to reach room temperature. After 2 hours TLC analysis 
(PE/EtOAc, 1/1, v/v) showed complete consumption of starting material Rf to a lower 
running product (Rf 0.50). Purification by flash chromatography (silica gel, 4/11/1 
PE/EtOAc) than gave protected phosphate 5.10 in a 42% yield (80 mg, 0.16 mmol) as a pale 
yellow oil. Rf : 0.20 (PE/EtOAc, 1/1, v/v): IR (ν): 492.9, 594.9, 695.5, 733.8, 860.8, 996.4, 
1156.8, 1210.5, 1256.1, 1379.3, 1455.0, 1496.4, 2935.8 cm-1: 1H NMR (400 MHz, CDCl3); δ  
1.25 (s, 3H, Me iso-prop) 1.45 (s, 3H, Me iso-prop), 2.57 (dd, J = 3.2 Hz, J = 10.4 Hz, 1H, H1b), 
2.95-2.99 (m, 2H, H1a, H4), 3.57 (d, J=13.2 Hz, 1H, N-CH2 Bn), 3.86 (d, J=13.2 Hz, 1H, N-CH2 
Bn), 3.98-4.01 (m, 2H, H5), 4.44-4.46 (m, 1H, H3), 4.50-4.54 (m, 1H, H2), 4.99-5.09 (m, 4H, O-
CH2 Bn), 7.18-7.21, 7.23-7.26, 7.35 (m, 15H, Bn Arom); 13C NMR (101 MHz, CDCl3); δ 23.72 
(Me iso-prop) 25.91 (Me iso-prop) 56.84 (N-CH2 Bn), 58.00 (C1), 66.09 (C5), 66.78 (C4), 
69.52, 69.58 (O-CH2 Bn), 78.53 (C2), 82.36 (C3), 112.30 (Cq iso-prop), 126.90, 127.02, 127.09, 
127.76, 127.82, 127.95, 128.31, 128.40, 128.46, 135.69, 135.75 (Carom Bn); HRMS(ESI) m/z 
calcld. for [C29H35NO6P]+: 524.2197, obsd.: 524.2220. 
 6-O-phosphoryl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 
(5.10). Protected phosphate 5.10 (14.0 mg, 0.028mmol) was taken op 
in methanol (3 mL) and acidified with concentrated HCl (0.2 mL). The 
resulting solution was left for 5 min and then concentrated to dryness by rotary 
evaporation. Additional methanol was added and the solvent again removed by rotary 
evaporation. TLC analysis of the reaction showed a single product (CH2Cl2/methanl, 95/5, 
v/v, Rf 0.3). Longer reaction times resulted in loss off one of the benzyl protecting groups 
(CH2Cl2/methanl, 95/5, v/v, Rf 0.15). Crude product was carried through without further 
purification. The 2,3-hydroxyl 5.10 was then taken up in ethanol (4 mL) 5 mg 10% palladium 
on carbon was added and hydrogen gas bubbled through the solution for 15 min and then 
sealed and left to stir for 6 hours. Purification by reverse phase chromatography (C18, H2O) 
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than gave the title compound 5.1 in 67% yield (4 mg, 0.019 mmol) as a pale yellow oil. IR (ν): 
932.9, 1048.5, 1633.3, 3256.6 cm-1: 1H NMR (400 MHz, D2O); δ  3.24 (dd, J=2.0 Hz, J=12.8 Hz, 
1H), 3.34-3.38 (m, 1H), 3.58-3.62 (m, 1H), 3.91-3.97 (m, 1H), 4.09-4.15 (m, 1H), 4.21-4.24 (m, 
1H), 4.26-4.28 (m, 1H); 13C NMR (101 MHz, CDCl3); δ 49.53, 60.78, 60.84, 69.47, 70.90; 31P 
NMR (162 MHz, CDCl3); δ 1.61 (s, 1P);   HRMS(ESI) m/z calcld. for [C12H19NO6P]+: 304.0945, 
obsd.: 304.0946. 
 
8.5.2.2 Synthesis of the cyclopentene transition state analogue 
2,3:5,6-di-O-isopropylidene-α-D-mannose (5.24). To a suspension of 
D-mannose 5.23 (10 g, 55.5 mmol) in dry acetone, H2SO4 (0.75 mL, 
13.9 mmol) was added followed by 2,2-dimethoxy propane (15 mL, 
122 mmol). The resulting mixture was stirred until TLC analysis 
showed complete conversion (Rf 0.40 PE/EtOAc, 1/1, v/v). Triethylamine (4.2 mL, 30 mmol) 
was added and the resulting mixture concentrated in vacuo. Purification by flash 
chromatography (silica gel, PE/EtOAc 5/12/1) than gave iso-propylidene 5.24 in a 79% 
yield (11.4 g, 43.7 mmol) as a white crystalline solid. Rf 0.40 (PE/EtOAc, 1/1, v/v): IR (ν): 
514.9, 722.2, 838.9, 975.8, 1062.5, 1166.6, 3431.0  cm-1): Rf : 0.42 (EtOAc): Rf 0.40 
(PE/EtOAc, 1/1, v/v): 1H NMR (400 MHz, CDCl3); δ 1.32, 1.37, 1.45, 146 (4x s, 3H, Me iso-
prop), 2.90 (bs, 1H, 1-OH), 4.04 (dd, J= 8.7, 5.0 Hz, 1H, H6b), 4.08 (dd, J= 8.7, 6.2 Hz, 1H, 
H6a), 4.18 (dd, J= 7.1, 3.6 Hz, 1H, H4), 4.40 (dd, J= 11.7, 6.2 Hz, 1H, H5), 4.61 (d, J= 5.9 Hz, 
1H, H2), 4.80 (dd, J= 5.9, 3.6 Hz, 1H, H3), 5.37 (s, 1H, H1); 13C NMR (101 MHz, CDCl3); δ 
24.63, 25.33, 26.00, 27.00 (4x Me iso-prop), 66.73 (C6), 73.40 (C5), 79.81 (C3), 80.51 (C4), 
85.64 (C2), 101.46 (C1), 109.24, 112.82 (2x Cq iso-prop); HRMS(ESI) m/z calcld. for 
[C12H20NaO6]+: 283.1152, obsd.: 283.1147. 
 
Benzoyl 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose (5.25). iso-
propylidene 5.24 (6.69 g, 25.7mmol) was co-evaporated with 
pyridine (1x) under a nitrogen atmosphere, dissolved in dry pyridine 
(65 mL) and cooled to 0oC. Benzoyl chloride (6 mL) was added drop 
wise over 2 min followed by p-dimethylaminopyridine (628 mg, 5.14 mmol), the resulting 
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reaction mixture was allowed to assume room temperature. After 2.5 hours t.l.c analysis 
(PE/EtOAc, 2/1, v/v) showed complete disappearance of starting material and the formation 
of a higher running product (Rf 0.53). The reaction was poured onto saturated aq. NaHCO3, 
diluted with EtOAc and the organic layers washed with saturated aq. NaHCO3 (2x), H2O (1x) 
and Brine (1x). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash chromatography (silica gel, PE/EtOAc 5/12/1) than gave benzoylated 
product 5.25 in a 86% yield (11.4 g, 43.7 mmol) as a white crystalline solid. Rf 0.53 
(PE/EtOAc, 2/1, v/v): IR (ν): 516.0, 720.4, 848.4, 969.9, 1035.7, 1072.0, 1084.1, 1208.3, 
1255.7, 1292.1, 1724.4 cm-1: 1H NMR (400 MHz, CDCl3); δ 1.375, 1.383, 1.46, 1.53 (4x s, 3H, 
Me iso-prop), 4.05 (dd, J= 8.9, 4.4 Hz, 1H, H6b), 4.09 - 4.16 (m, 2H, H4, H6a), 4.40 - 4.48 (m, 
1H, H5), 4.88 (d, J= 5.9 Hz, 1H, H2), 4.94 (dd, J= 5.8, 3.6 Hz, 1H, H3), 6.37 (s, 1H), 7.41 - 7.49 
(m, 2H, Harom O-Bz), 7.56 - 7.62 (m, 1H, Harom O-Bz), 7.99 - 8.04 (m, 2H, Harom O-Bz); 13C NMR 
(101 MHz, CDCl3); δ 24.85, 25.27, 26.13 27.12 (4x Me iso-prop), 67.03 (C6), 73.05 (C5), 79.55 
(C3), 82.76 (C4), 85.39 (C2), 101.68 (C1), 109.51, 113.50 (Cq iso-prop), 128.60 129.65 129.95, 
133.62 (Carom O-Bz), 165.06 (C=O, O-Bz); HRMS(ESI) m/z calcld. for [C19H24NaO7]+: 
387.1414, obsd.: 387.1413. 
 
Benzoyl 2,3-O-isopropylidene-α-D-lyxo-hex-5-enofuranose (5.22). 
Benzoyl 5.25 was dissolved in glacial acetic acid (32 mL), water (14 mL) 
was added and the resulting mixture was stirred at 55oC. After 75 min. 
TLC analysis (PE/EtOAc, 2/1, v/v) showed complete disappearance of starting material and 
the formation of a lower running product (Rf 0.53) and concentrated in vacuo. The crude 
was suspended in triethyl ortho formate (25 mL) and glacial acetic acid (0.4 mL, 0.7 mmol) 
was added and left until full conversion was observed by t.l.c analysis (Rf 0.76, PE/EtOAc, 
2/1, v/v). The solution was concentrated and heated to 170 oC in an open flask. Diphenyl 
acetic acid (212 mg, 0.06 mmol, 0.44 mol%) was added and after 4 hours all starting 
material had been transformed into a higher running product (Rf 0.55, PE/EtOAc, 4/1, v/v). 
The resulting brown oil was allowed to cool to room temperature. Purification by flash 
chromatography (silica gel, PE/EtOAc 7.5/1) gave homogenous title compound 5.22 in a 80% 
yield (3.2 g, 11.0 mmol). Rf 0.53 (PE/EtOAc, 2/1, v/v): 1H NMR (400 MHz, CDCl3); δ 1.36, 1.53 
(2x s, 3H, Me iso-prop), 4.62-4.66 (m, 1H), 4.82-4.86 (m, 1H), 4.87 - 4.90 (m, 1H), 5.36 (d, J= 
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10.3 Hz, 1H, H6-cis), 5.44 (d, J= 17.6 Hz, 1H, H6-trans), 6.01 (m, J=17.6, 10.3 Hz, 1H, H5), 6.42 
(s, 1H, H1), 7.40 - 7.49 (m, 2H, Harom O-Bz), 7.55 - 7.62 (m, 1H, Harom O-Bz), 8.00 - 8.04 (m, 2H, 
Harom O-Bz); 13C NMR (101 MHz, CDCl3); δ 25.22, 26.25 (2x Me iso-prop), 81.72, 81.80, 85.63 
(C2, C3, C4), 101.72 (C1), 119.29 (C6), 128.64, 129,39, 130.36 (Carom O-Bz), 132.16 (C5), 
133.92 (Carom O-Bz). HRMS(ESI) m/z calcld. for [C16H18NaO5]+: 313.1046, obsd.: 313.1040. 
 
2,3-O-isopropylidene-α-D-lyxo-hex-5-enofuranose (5.26). To a solution of 
alkene 5.22 in MeoH, t-BuOK was added until a pH of 12-14 and left to stir 
at room temperature. after 4.5 hour TLC analysis (PE/EtOAc, 1/1, v/v) 
showed complete disappearance of the starting material and formation of 
a lower running product (Rf 0.66). DOWEX H+ was added until neutral (pH 7) by pH paper 
and concentrated. Purification by flash chromatography (silica gel, PE/EtOAc 10/17.5/1) 
gave homogenous title compound 5.26 in a 95% yield (3.2 g, 11.0 mmol). Rf 0.66 (PE/EtOAc, 
1/1, v/v): IR (ν): 494.6, 515.2, 556.2, 717.9, 768.7, 823.0, 850.3, 877.4, 905.4, 842.3, 992.8, 
1014.8, 1039.5, 1069.0, 1161.7, 1210.1, 1237.46, 1377.8, 2943.0, 3468.3 cm-1; 1H NMR (400 
MHz, CDCl3); δ 1.32, 1.47 (2x s, 3H, Me iso-prop), 4.59 - 4.63 (m, 1H, H4), 4.64 (d, J=5.9 Hz, 
1H, H2), 4.73 (dd, J= 3.5 5.9 Hz, 1H, H3), 5.34 (d, J= 10.2 Hz, 1H, H6-cis), 5.41 (s, 1H, H1), 5.42 
(d, J= 17.2 Hz, 1H, H6-trans), 5.99 (ddd, J= 7.1, 10.5, 17.2 Hz, 1H, H5); 13C NMR (101 MHz, 
CDCl3); δ 25.03, 26.22 (2x Me iso-prop), 81.67, 81.70 (C3, C4), 85.95 (C2), 101.25 (C1), 
112.80 (Cq iso-prop), 119.36 (C6), 132.34 (C5). HRMS(ESI) m/z calcld. for [C9H14NaO4]+: 
209.0784, obsd.: 209.0788. 
 
 (3R,4S,5R)-3,4-O-isopropylidenehepta-1,6-diene-3,4,5-triol (5.21). To 
methyl triphenylphosphonium bromide (11.6 g, 32.5 mmol) in THF/HMPA 
(40 mL, 3/1, v/v), KOtBu (3.6 g, 32.5 mmol) was added at -15oC. The 
resulting solution was stirred for an additional hour at 0oC. A solution of lactol 5.26 (1.72 
mg, 9.34 mmol) in THF (2 mL) was added and the solution was allowed to warm to room 
temperature. After 14 hours all starting material had been converted into a slightly higher 
running product as indicated by t.l.c analysis (Rf 0.69, PE/EtOAc, 1/1, v/v). The reaction 
mixture was quenched with aq. sat. NH4Cl and extracted with Et2O. The ether layer was 
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dried (MgSO4), filtered and concentrated. Purification by flash chromatography (silica gel, 
PE/EtOAc 10/18/1) gave dialkene 5.21. Rf 0.69 (PE/EtOAc, 1/1, v/v): IR (ν): 513.2, 721.9, 
871.4, 928.4, 1043.5, 1216.7, 1243.1, 3475.7 cm-1): 1H NMR (400 MHz, CDCl3); δ 1.40, 1.54 
(2x s, 3H, Me iso-prop), 4.06-4.16 (m, 2H), 4.48-4.64 (m, 1H), 5.23 (d, J= 10.6 Hz, 1H), 5.30 
(d, J= 10.2 Hz, 1H), 5.37 (d, J= 17.2 Hz, 1H), 5.38 (d, J= 17.2 Hz, 1H), 5.85 (ddd, J= 5.1, 10.6, 
17.2 Hz, 1H), 6.02 (ddd, J= 8.2, 10.2, 17.2 Hz, 1H); 13C NMR (101 MHz, CDCl3); δ 25.16, 27.56 
(2x Me iso-prop), 70.77, 79.12, 80.82 (C3, C4, C5), 108.97 (Cq iso-prop), 117.19, 119.55 (C1, 
C6), 134.11, 136.93 (C2, C5). HRMS(ESI) m/z calcld. for [C10H16NaO3]+: 207.0992, obsd.: 
207.0986. 
 
 (3R,4S,5R)-3,4-O-Isopropylidene-cyclopentene-3,4,5-triol (5.20). Dialkene 
5.21 was dissolved in CH2Cl2 (25 mL), the solution was degassed by passing 
through a stream of argon for 15 min and 36 mg (0.5 mol%) of Grubbs’ 1st 
generation catalyst was added under an atmosphere of argon. After 5 hours TLC analysis 
revealed complete conversion (Rf 0.47, PE/EtOAc, 1/1, v/v). The reaction mixture was 
purified by flash chromatography (silica gel, PE/EtOAc 6/12/1) then gave cyclopentene 
5.20 in 52% yield over two steps (760 mg, 4.87 mmol) as a brown oil. Rf 0.47, (PE/EtOAc, 
1/1, v/v) IR (ν): 722.0, 865.5, 1039.4, 1159.5, 1209.8, 2933.9, 3390.2 cm-1): 1H NMR (400 
MHz, CDCl3); δ 1.34, 1.39 (2x s, 3H, Me iso-prop), 1.93 (bs., 1H, OH), 4.52 (d, J= 5.6 Hz, 1H), 
4.79 (bs, 1H), 5.28 (d, J= 5.6 Hz, 1H), 5.88 - 5.93 (m, 1H), 6.02-6.04 (m, 1H); 13C NMR (101 




3,4,5-triol (5.27). Alcohol 5.20 (317.4 mg, 2.03 mmol) was dissolved in THF (7 
mL) and cooled to 0 oC. Potassium hydride (165 mg, 4 mmol) was added and 
the resulting reaction mixture left for 10 min. Bu3-SnCH2I (0.66 mL, 2.2 mmol) 
was added and the solution was allowed to warm to rt. Stirring was continued for 60 min 
after which time TLC analysis (PE/EtOAc, 9/1, v/v) indicated consumption of all starting 
material and the formation of a higher running product (Rf 0.8). Water was added diluted 
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with  EtOAc, the organic phase was washed with H20 (2x), brine (1x), dried over MgSO4, 
filtered and concentrated. Purification by flash chromatography (silica gel, 4% EtOAc in PE) 
gave stannane ether 5.27 as a pale yellow oil. Rf 0.80 (PE/EtOAc, 9/1, v/v). 1H NMR (400 
MHz, CDCl3) δ: 0.86-0.91 (m, 9H, Me SnBu3), 1.22–1.34 (m, 6H, CH2 SnBu3), 1.36, 1.41 (2x s, 
Me iso-prop), 1.46-1.52 (m, 6H, CH2 SnBu3 3.69), 3.69 (d, J= 10.0 Hz, 1H, OCH2Sn), 3.88 (d, 
J=10.0 Hz, 1H, OCH2 Sn), 4.24 (s, 1H), 4.51 (d, J= 6.0 Hz, 1H), 5.19- 5.22 (m 1H), 5.88-5.91 (m, 
1H), 5.97-6.00 (m, 1H); 13C NMR (101 MHz, CDCl3); δ 9.17, 13.86 (SnBu3), 25.83, 27.48 (2x 
Me iso-prop), 27.42, 29.26 (SnBu3), 60.49 (OCH2Sn), 83.06, 84.43, 92.91 (C-3, C-4, C-5), 
111.71 (Cq iso-prop), 133.72, 134.11 (C-1, C-2).  
 (3S,4R,5R)-3,4-O-Isopropylidene-5-hydroxymethylcyclo-pentene-3,4-diol 
(5.19) 
Stannane ether 5.27 (473.3 mg, 1.03 mmol) was dissolved in THF (20 mL) 
and cooled to -78 oC. n-BuLi (1.1 mL, 1.42 M in THF, 1.6 mmol) was added 
dropwise via the cold wall of the flask. The solution was allowed to warm to rt. After 2 hours 
TLC analysis (PE/EtOAc, 2/1, v/v) showed formation of a lower running product (Rf 0.2). The 
solution was poured onto sat. aq. NH4Cl and extracted with EtOAc (2x). The combined 
organic layers were washed with brine (1x) dried over MgSO4, filtered and concentrated. 
Purification by flash chromatography (silica gel, PE/EtOAc 1/1) gave cyclopentene 5.19  as a 
clear oil in 95% yield (117 mg, 1.0 mmol). Rf 0.2 (PE/EtOAc, 2/1, v/v). IR (ν): 512.2, 738.8, 
859.8, 938.9, 1042.2, 1158.1, 1206.9, 1370.7, 2930.9, 3405.1 cm-1: 1H NMR (400 MHz, 
CDCl3): δ 1.36, 1.42 (2x s, 3H, Me iso-prop), 2.95-3.02 (m, 1H, H5), 3.56-3.61 (m, 1H, 
CH2OH), 3.72-3.78 (m, 1H, CH2OH), 4.59 (d, J= 6.0 Hz, 1H, H3), 5.12-5.17 (m, 1H, H-4), 5.73-
5.77 (m, 1H, H2), 5.91-5.96 (m, 1H, H1); 13C-NMR (100 MHz, CDCl3): δ 25.64, 27.46 (2x Me 
iso-prop), 54.81 (C5), 63.72 (CH2OH), 81.49 (C4), 85.16 (C3), 110.09 (Cq iso-prop), 132.9 (C2), 
133.5 (C1). HRMS(ESI) m/z calcld. for [C9H14NaO3]+: 193.0835, obsd.: 193.840 
 (3S,4R,5R)-3,4-O-Isopropylidene-5-(hydroxymethyl-O-phosphoryl)-
pentene-3,4-diol (5.28). Hydroxymethyl 5.19 (30 mg, 0.176 mmol) was 
dissolved in CH2Cl2 (1 mL) and cooled to 0 oC. triethyl amine (73 µL, 0.53 
mmol) was added followed by diphenyl phosphoryl chloride (43 µL, 0.21 
mmol) and allowed to reach rt, after 4 hours complete consumption of 
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starting material into a higher running product was observed by TLC analysis (PE/EtOAc, 1/1, 
v/v, Rf 0.60). The reaction was quenched with water. The organic layer was washed with 
water (1x), sat. aq. NaHCO3 (1x), dried over MgSO4, filtered and concentrated. Purification 
by flash chromatography (silica gel, PE/EtOAc 4/1) gave protected phosphate 5.19  as a clear 
oil in 84% yield (59 mg, 1.0 mmol). Rf 0.2 (PE/EtOAc, 2/1, v/v). IR (ν): 505.4, 688.4, 754.5, 
945.9, 1021.1, 1160.7, 1187.7, 1284.6, 1370.4, 1487.8, 1589.8, 1723.8 cm-1: 1H NMR (400 
MHz, CDCl3): δ 1.29, 1.38 (2x s, 3H, Me iso-prop), 3.09-3.13 (m, 1H, H5), 4.13-4.17 (m, 1H, 
CH2OH), 4.27-4.32 (m, 1H, CH2OH), 4.47 (d, J=6.0 Hz, 1H, H4), 4.97-4.99 (m, 1H, H-4), 5.65-
5.67 (m, 1H, H2), 5.83-5.85 (m, 1H, H1); 13C-NMR (100 MHz, CDCl3): δ 25.49, 27.26 (2x Me 
iso-prop), 52.63 (C5), 69.25 (CH2OH), 80.52 (C4), 84.85 (C3), 110.26 (Cq iso-prop), 119.99, 
120.00, 120.03, 120.06, 125.45, 128.77, 129.78, 129.80, 130.85 (Carom Bn), 131.64 (C1), 
133.95 (C2),132.44, 150.40, 150.49  (Carom Bn); 31P NMR (162 MHz, CDCl3); δ 12.09 (s, 1P); 
HRMS(ESI) m/z calcld. for [C21H24O6P]+: 403.1305, obsd.: 403.1335 
 
 (3S,4R,5R)-5-(hydroxymethyl-O-diphenylphosphoryl)-cyclo-pentene-
3,4-diol (5.29). Protected phosphate 5.28 (31.5 mg, 0.078 mmol) was 
taken op in methanol (2 mL) and acidified with concentrated HCl (0.2 
mL). The resulting solution was left for 1 min and then concentrated to 
dryness by rotary evaporation. TLC analysis of the reaction showed complete consumption 
of starting material and a major product (CH2Cl2/MeOH, 95/5, v/v, Rf 0.5). Purification by 
flash chromatography (silica gel, CH2Cl2/MeOH 100/0  90/10) gave 2,3-hydroxy 5.29  as a 
clear oil in 70% yield (20 mg, 0.05 mmol). (CH2Cl2/MeOH, 95/5, v/v, Rf 0.5) IR (ν): 505.4, 
688.4, 754.5, 945.9, 1021.1, 1160.7, 1187.7, 1284.6, 1370.4, 1487.8, 1589.8, 1723.8, 2930.4 
cm-1: 1H NMR (400 MHz, CDCl3): δ 2.72 (bs, 2H, OH-2, OH-3), 2.96-2.97 (m, 1H, H5), 3.97-
4.00 (m, 1H, H4), 4.24-4.35 (m, 2H, CH2OH), 4.48-4.49 (m, 1H, H4), 5.79-5.81 (m, 1H, H1), 
5.85-5.88 (m, 1H, H2); 13C-NMR (100 MHz, CDCl3): δ 52.34 (d, J=6.8 Hz, C5), 69.22(d, J=6.1 
Hz, CH2OH), 72.85 (C4), 74.68 (C3), 120.00, 120.06, 125.52, 129.84 (C Ph), 133.61, 133.70 
(C1, C2), 150.34, 150.42 (Carom Ph); 31P NMR (162 MHz, CDCl3); δ 12.00 (s, 1P);. HRMS(ESI) 




(5.3). Diol 5.29 (13.2 mg, 0.036 mmol) was taken op in THF (2 mL) and 
cooled down to -78 °C. A flow of ammonium gas was blown over the 
flask until approximately 10 mL was collected. Sodium metal cut clean 
of oxydised surface (5-10 mg cubes) were added until a dark blue colour 
persisted. This was maintained for 45 min after which MeOH was added (3 mL) and the 
ammonia blown off under a flow of nitrogen. The reaction was then neutralised with 
DOWEX® resin, the resin filtered off and was washed with methanol, and methanol was 
removed on a rotary evaporator. Purification by reverse phase chromatography (C18, H2O) 
gave cyclopentene phosphate 5.3 as a clear oil in 55% yield (4.2 mg, 0.02 mmol). IR (ν): 
795.0, 960.8, 1087.1, 1333.6, 1428.9, 1675.7, 3157.5 cm-1: 1H NMR (400 MHz, D2O): δ 2.77-
2.78 (m, 1H, H5), 3.79-3.94 (m, 1H, CH2OH), 4.44 (d, J= 5.2 Hz, 1H, H4), 5.78-5.85 (m, 1H, H-
3), 7.05-7.08 (m, 1H), 7.24-7.28 (m, 1H)(H1, H2). HRMS(ESI) m/z calcld. for [C6H12O6P]+: 
211.0366, obsd.:211.0370 
8.5.3 Inhibition study of transition state analogues 
The cyclopentene phosphate, iminoribitol phosphate and iminoribitol phosphonate were 
tested for inhibition again the ATP-PRTase enzyme from M. tuberculosis and C. jejuni. The 
compounds were tested under competitive conditions ranging from 0 to 500 µM of 
transition state analogue. The inhibition was tested under varying PRPP concentrations (1 to 
3 times Km, 50-150 µM for the M. tuberculosis ATP-PRTase enzyme and 11-33 µM for the C. 
jejuni ATP-PRTase enzyme) the ATP concentrations was kept constant at 3 times Km (750 
µM M. tuberculosis ATP-PRTase and 500 µM C. jejuni ATP-PRTase enzyme). The reactions 
were preincubated for at least two minutes prior to initiation with PRPP. 
Data obtained from the kinetic assays where processed using Prism 6.0 and the standard 
calculations for a competitive inhibitor were used to find inhibition constants.  
Concentration of the phosphate containing analogues were established by cleaving the 
phosphate with alkaline phosphatase followed by assessment of the released inorganic 
phosphate by lenzetta assay (section 8.5.1). The concentration for the iminoribitol 
phosphonate was found by 31P NMR with phosphoric acid as the internal standard.  
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8.6 Experimental procedures for chapter 6 
8.6.1 Purification of C. jejuni core mutant 
Expression and purification of C. jejuni ATP-PRTase core mutant was carried out according to 
established procedures by Dr G. H. mittlestäd.67 The constructuct contained a GST tag. The 
H33 and H35 allowed partial purification by HiTrap column prior to further purification by 
GST column chromatography. C. jejuni ATP-PRTase core mutant/pDEST15/E. coli Bl21* (DE3) 
cell cultures were grown in autoclaved LB (Lennox LB) at 20 g/L containing the appropriate 
concentration of Ampicillin. Pre-cultures in LB (Lennox LB) media containing Ampicillin 
(Section 8.1.21) were inoculated using a single culture grown from a glycerol stock and 
grown overnight with shaking (180 rpm) at 37 °C. Approximately 25 mL of pre-culture per 
litre of cell culture were used to inoculate growths (OD600 of 0.1 AU). Cells were grown at 37 
°C until mid-logarithmic phase (OD600 of 0.4–0.6 AU). The protein expression was induced by 
addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.5 mM final concentration), and 
growth was continued for 4 hours. Cells were harvested by centrifugation (14,000 g for 15 
min at 4 °C) and the cell pellet was flash-frozen in liquid nitrogen and stored at −80 °C. The 
cell pellet was resuspended in low imidazole buffer (50 mM Na2HPO4, 500 mM NaCl, 5 mM 
MgCl2 and 20 mM imidazole at pH 8.5), lysed for 3x 5min 80 %, spun down for 30 min at 
40,000 g. The supernatant was filtered and loaded onto a 5 mL GE Healthcare His trap HP 
column. Protein which bound to the column was eluted with high imidazole buffer (50 mM 
Na2HPO4, 500 mM NaCl, 5 mM MgCl2 and 500 mM imidazole at pH 8.5) and fractions 
containing enzyme determined by SDS-page gel electrophoresis were pooled together. The 
pooled fractions were buffer exchanged by spin concentrator into phosphate buffered 
seline (PBS) at pH 7.3. The target protein was then loaded onto a 5 mL GE Healthcare GST 
HP column and eluted with 10 mM glutathione in a 50 mM Tris buffer at pH 8.0. Fractions 
containing the C. jejuni ATP-PRTase core mutant enzyme were pooled together and buffer 
exchanged back into PBS buffer by spin concentrator and treated with TEV protease at a 1% 
mol/mol concentration at 37 °C for one hour and then at at 4°C overnight. TEV treated 
enzyme was run through a 5 mL GE Healthcare GST HP column and the flow through was 
collected, concentrated and buffer exchanged into Tris buffer (100mM NaCl, 5mM MgCl2, 
and 50 mM Tris at pH 8.0 before loading onto a 26/60 size exclusion column preequilibrated 
with Tris buffer. Fractions containing C. jejuni ATP-PRTase core mutant as detected by sds-
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page gel electrophoresis were concentrated to 15-20 mg/mL, flash-frozen in liquid N2 and 
stored at -80 °C. 4 litres of culture would yield approximately 20-30 mg of protein per 
purification. 
8.6.2 Protein stability assay 
Enzyme stability was monitored by the rate of conversion of PRPP and ATP into PRATP and 
PPi. Because NMR requires the longest experimental time, conditions similar to these 
samples were chosen for the stability assay (Protein concentration 15 µM, Tris 10 mM, NaCl 
30 mM, MgCl2 1 mM and D2O 10% at pH 8.5). The sample was kept at room temperature for 
the duration of the activity assay. The rate of conversion was measured after the sample 
was made up (day 0) and monitored with 24 hours interval for 6 days, a reduced conversion 
rate compared to this initial value (day 0) was considered a sign of degradation of the 
enzyme (Figure 8.3). On day one no reduction in the conversion rate was observed, after 
day two a 7% loss in conversion was observed and over the course of the next 4 days this 
progressed with a total loss of 1/3 of the activity over that time. These results show that 
stability of the protein will not be a problem for the required experiment time. 
  
 
Figure  8.3. The graph displays the rate of conversion in (U mg-1) of PRPP (0.3 mM) and ATP (2.5 mM) into 























8.6.3 STD-NMR sample preparation 
The STD-NMR spectra were acquired by Dr Herbert Wong from Callaghan Inovation on a 
DRX 500 spectrometer (Bruker) operating at 500MHz and 25 °C. Samples consisted of 5 mM 
MgCl2, 100 mM NaCl, 15% (v/v) D2O and 10 mM Tris (HCl) at pH 8.0. Ligands were added to 
a concentration of 2mM from 100mM stock made up in D2O or DMSO-D6 depending on 
solubility. DPFGSE water suppression was applied to all experiments. A 1H-Proton and STD-
NMR spectrum was taken in absence of enzyme. C. jejuni wt ATP-PRTase Enzyme was then 
added to a finial concentration of 15 µM. A second STD-NMR spectrum was then taken and 
compared to reference spectra. The STD pulse program followed the standard provided 
scheme with the topspin software package and with optimisation of the pre-acquisition 
time from 5s to 3s, a protein saturation time of 2 seconds and the on-resonance set to 11 or 
-1ppm. Spectra were collected with 200-512 scans. 
8.6.4 Differential scanning fluorimetry 
Differential scanning fluorimetry was carried out on an iCycler iQ5 Multicolour Real-Time 
PCR Detection System (Bio-Rad). The melting temperature of protein in presence of natural 
and non-natural ligands was established following a modified method by Ericsson et al.210 A 
typical run was set up measuring the temperature from 20 °C to 80 °C at 0.2 °C increments 
with a 20s dwell time. SYPRO orange dye 250X (Invitrogen) was used to visualise the melting 
profile.  
Samples were measured in three replicates and one blank. Samples and dye were prepared 
on ice. A typical sample was set up by the addition of 5 µL of 250 times SYPRO orange dye to 
100 µL of buffer (100 mM NaCl, 5mM MgCl2 and 50 mM Tris at pH 8.0), which included the 
appropriate ligand or other additive. Of this stock 21 µL was added to the blank well and 4 
µL of Buffer was added. To the remaining sample stock 16 µL of protein (0.5 – 1 mg/mL) was 
added, and 25 µL dispensed into the three replicate wells 
For the analysis of the data an Excel spreadsheet with custom VBA-scripted macro created 
by Dr T. Allison was used to display melting profiles. The melting temperature were 
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Kinetic isotope effect data for M. tuberculosis ATP-PRTase 
[1′-3H]  [1′-14C]  [1-15N] 
KIE 1 1.225  KIE 1 1.027  KIE 1 1.023 
KIE 2 1.245  KIE 2 1.033  KIE 2 1.026 
KIE 3 1.217  KIE 3 1.024  KIE 3 1.023 
KIE 4 1.283  KIE 4 1.026  KIE 4 1.032 
KIE 5 1.249  KIE 5 1.027  KIE 5 1.025 
KIE 6 1.259  KIE 6 1.028  KIE 6 1.021 
KIE 7 1.265  KIE 7 1.027  KIE 7 1.022 
KIE 8 1.259  KIE 8 1.030  KIE 8 1.029 
      KIE 9 1.027 
      KIE 10 1.021 
      KIE 11 1.027 
      KIE 12 1.018 
 
       
Average 1.250  Average 1.028  Average 1.024 
Stdev 0.021  Stdev 0.003  Stdev 0.004 
SEM 0.008  SEM 0.001  SEM 0.001 
 
[6-15N]  [5′-3H] 
KIE 1 1.011  KIE 1 1.014 
KIE 2 1.016  KIE 2 1.022 
KIE 3 1.014  KIE 3 1.020 
KIE 4 1.020  KIE 4 1.021 
KIE 5 1.010  KIE 5 1.014 
KIE 6 1.011  KIE 6 1.017 
KIE 7 1.009  KIE 7 1.011 
KIE 8 1.010  KIE 8 1.018 
     
Average 1.012  Average 1.017 
Stdev 0.004  Stdev 0.004 





Kinetic isotope effect data for C. jejuni ATP-PRTase 
[1′-3H]  [1′-14C]  [1-15N] 
KIE 1 1.224  KIE 1 1.029  KIE 1 1.027 
KIE 2 1.224  KIE 2 1.035  KIE 2 1.028 
KIE 3 1.208  KIE 3 1.037  KIE 3 1.030 
KIE 4 1.217  KIE 4 1.035  KIE 4 1.031 
KIE 5 1.210  KIE 5 1.023  KIE 5 1.029 
KIE 6 1.209  KIE 6 1.027  KIE 6 1.028 
KIE 7 1.208  KIE 7 1.019  KIE 7 1.024 
KIE 8 1.209  KIE 8 1.025  KIE 8 1.025 
KIE 9 1.205       
KIE 10 1.208       
        
Average 1.212  Average 1.029  Average 1.028 
Stdev 0.007  Stdev 0.007  Stdev 0.002 
SEM 0.002  SEM 0.002  SEM 0.001 
 
[6-15N]  [5′-3H] 
KIE 1 0.977  KIE 1 1.002 
KIE 2 0.987  KIE 2 1.002 
KIE 3 1.000  KIE 3 1.006 
KIE 4 1.003  KIE 4 1.006 
KIE 5 1.001  KIE 5 1.000 
KIE 6 1.000  KIE 6 1.003 
KIE 7 1.001  KIE 7 1.000 
KIE 8 0.999  KIE 8 1.004 
     
Average 0.996  Average 1.002 
Stdev 0.009  Stdev 0.002 





Kinetic isotope effect data for L. lactis ATP-PRTase 
[1′-3H]  [1′-14C]  [1-15N] 
KIE 1 1.127  KIE 1 1.030  KIE 1 0.981 
KIE 2 1.158  KIE 2 1.029  KIE 2 0.985 
KIE 3 1.167  KIE 3 1.026  KIE 3 0.994 
KIE 4 1.147  KIE 4 1.030  KIE 4 0.998 
KIE 5 1.132  KIE 5 1.037  KIE 5 0.999 
KIE 6 1.178  KIE 6 1.032  KIE 6 1.003 
KIE 7 1.158  KIE 7 1.028  KIE 7 0.999 
KIE 8 1.151  KIE 8 1.032  KIE 8 1.003 
KIE 9 1.140       
KIE 10 1.113       
        
Average 1.147  Average 1.031  Average 0.995 
Stdev 0.020  Stdev 0.003  Stdev 0.008 
SEM 0.006  SEM 0.001  SEM 0.003 
 
[6-15N]  [5′-3H] 
KIE 1 1.006  KIE 1 1.012 
KIE 2 1.007  KIE 2 1.008 
KIE 3 1.006  KIE 3 1.013 
KIE 4 1.004  KIE 4 1.010 
KIE 5 1.002  KIE 5 1.003 
KIE 6 1.003  KIE 6 1.008 
KIE 7 1.002  KIE 7 1.009 
KIE 8 1.008  KIE 8 1.006 
     
Average 1.005  Average 1.007 
Stdev 0.002  Stdev 0.003 







In red is the reference spectrum. In blue the STD-NMR spectrum in absence of enzyme, no unspecific excitation 
is observed in the absence of the C. jejuni ATP-PRTase enzyme.  
 
In red is the reference spectrum. In blue the STD-NMR spectrum in presence of the C. jejuni ATP-PRTase 




Crystal information for 5-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-L-lyxono lactone 5.8 
Crystal data and structure refinement for 5.8.  
Identification code  GJM1a  
Empirical formula  C14H26O5Si  
Formula weight  302.44  
Temperature/K  120.01(10)  
Crystal system  monoclinic  
Space group  P21  
a/Å  5.95513(12)  
b/Å  10.14114(19)  
c/Å  13.3855(3)  
α/°  90  
β/°  98.4789(19)  
γ/°  90  
Volume/Å3  799.54(3)  
Z  2  
ρcalcg/cm
3  1.256  
μ/mm-1  1.442  
F(000)  328.0  
Crystal size/mm3  0.4068 × 0.3699 × 0.2228  
Radiation  Cu Kα (λ = 1.5418)  
2Θ range for data collection/°  13.376 to 147.52  
Index ranges  -7 ≤ h ≤ 7, -12 ≤ k ≤ 11, -16 ≤ l ≤ 12  
Reflections collected  7139  
Independent reflections  3067 [Rint = 0.0193, Rsigma = 0.0195]  
Data/restraints/parameters  3067/1/188  
Goodness-of-fit on F2  1.034  
Final R indexes [I>=2σ (I)]  R1 = 0.0253, wR2 = 0.0689  
Final R indexes [all data]  R1 = 0.0255, wR2 = 0.0690  
Largest diff. peak/hole / e Å-3  0.25/-0.17  
Flack parameter 0.01(3) 
 
 
 
